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ABSTRACT 
 
SECRETION OF MALARIA TRANSMISSION-BLOCKING 
PROTEINS FROM PARATRANSGENIC BACTERIA 
 
 
 
By 
Nicholas James Bongio 
May 2015 
 
Dissertation supervised by Dr. David Lampe 
Malaria is a debilitating and deadly disease that afflicts over 200 million people 
and kills over 600 thousand each year. Due to quickly evolving drug resistance and lack 
of an affordable vaccine, novel interventions are needed to fight the Plasmodium 
parasites that cause malaria. Targeting Plasmodium inside their mosquito hosts is one 
approach that could complement other preventative and medicinal interventions by 
reducing the ability of the mosquitoes to transmit the disease to humans. The research 
presented here uses paratransgenesis, the genetic modification of symbiotic bacteria 
within the mosquito midgut, to provide antimalarial protein to the mosquito and to 
interfere with the life cycle of Plasmodium within the insect host.  
This research has produced three new antimalarial paratransgenic tools. The first 
tool is a set of new antimalarial effector proteins that were constructed by converting 
 v 
anti-Plasmodium mouse antibodies into single-chain variable fragment (scFv) versions 
for expression by bacteria. These antibodies bind to Plasmodium surface proteins and 
interfere with critical steps in the parasite life cycle. The second tool is a modified 
bacterial species, Pantoea agglomerans, which was engineered to secrete diverse 
antimalarial proteins via the hemolysin secretion pathway. Modified P. agglomerans 
were fed to mosquitoes and were capable of inhibiting the invasion of Plasmodium within 
the midgut. The third tool is another modified bacterial species, Asaia sp. SF2.1. Native 
Type II secretion signals were discovered that enable the creation of paratransgenic 
strains of these bacteria. Modified strains of Asaia sp. SF2.1 were also demonstrated to 
interfere with the invasion of Plasmodium within the mosquito. 
These tools have laid the groundwork for the future use of paratransgenic bacteria 
to combat malaria in the wild. Asaia sp. SF2.1 bacteria, in particular, are capable of 
spreading throughout mosquito populations, so they provide their own drive mechanism 
to establish themselves within the mosquito vectors of malaria. While further 
modifications will be required to make these bacteria ready for field use, the findings of 
this research provide proof of concept that the bacteria are suitable for eventual use in 
malaria transmission-blocking interventions. 
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Chapter 1 
The problem of human malaria 
 
MALARIA: THE DISEASE 
 In 2012, there were approximately 207 million cases of human malaria, and the 
disease was estimated to have caused 627,000 deaths worldwide, the majority of these 
deaths being among children under 5 years old in sub-Saharan Africa (WHO 2013). 
Currently, there are 104 countries and territories where malaria is considered endemic, 
meaning that 3.4 billion people are at risk of becoming infected with malaria every day 
(WHO 2013). 
 Malaria is one of the deadliest infectious diseases on earth, and accordingly, a 
great deal of research focuses on its prevention and treatment. The two main areas of 
research to combat the virulent Plasmodium parasite, which causes malaria, have 
concentrated on the synthesis of antimalarial drugs to target the parasite in the human 
host, and on the manufacture of insecticides to eliminate or to reduce the mosquito vector 
populations (Karunamoorthi 2014, Ansari 2013). Despite decades of research providing 
new drugs and interventions, malaria is still a large problem in many developing nations 
across the world. This is due to the fact that Plasmodium rapidly evolves resistance to 
new drugs, and the drugs themselves are expensive to produce and distribute in the 
quantities necessary to cure the millions of cases that occur every year (Poirot 2013, 
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Sibley 2014). Reaching infected individuals in impoverished nations is extraordinarily 
difficult. 
 The malaria parasite has been coevolving with humans throughout history (Cox 
2010), and was described as early as the year 2700 BC, when the symptoms of malaria 
were described in the “Nei Ching,” a medical text edited by Emperor Huang Ti of China. 
The malaria parasite was identified in humans as long ago as 1323 BC in ancient Egypt, 
and Plasmodium was identified by molecular means in the autopsy of King 
Tutankhamun, and was hypothesized to be one cause of his death (Timmann 2010). 
Malaria was given its current name by the contraction of the Italian words mala aria 
meaning “bad air,” because prior to the discovery of the mosquito vector, it was believed 
that breathing foul vapors from swamps caused the disease. In 1880, the malaria parasite 
was discovered by Alphonse Laveran (Cox 2010), and in 1897, the function of the 
mosquito vector in transmission was identified in avian malaria by Ronald Ross (Ross 
1898). 
 Due to centuries of parasite-host coevolution, Plasmodium has become adept at 
avoiding the human immune system. Within the human blood stream, for instance, the 
parasite undergoes antigenic shifting which allows it to evade detection by the host's 
adaptive immune system. A prime example of antigenic shifting is the Plasmodium 
falciparum erythrocyte membrane protein 1. This protein is encoded by 60 unique var 
genes, each of which produces a different protein that is displayed on the surface of host 
erythrocytes. Through a developmentally-regulated process, the parasite randomly selects 
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one of these proteins to display upon invasion of a cell, so the host's immune system will 
not recognize the new antigen presented (Chen 1998).  
 Not only has Plasmodium adapted to evade the human immune system, but also  
the human population has experienced genetic changes which impart resistance against 
the parasite (Kwiatkowski 2005, Allison 2009). Many human genetic mutations have 
been identified that provide resistance against infection, including alterations in 
membrane proteins of red blood cells, alterations in enzymes of red blood cells, and 
mutations in the hemoglobin genes responsible for oxygen transport (Williams 2006, 
Lopez 2010). For example, sickle cell disease is a result of a hemoglobin gene mutation 
which interferes with Plasmodium within infected erythrocytes (Beutler 1955, Bunn 
2013). Though the sickle cell phenotype has a protective effect against Plasmodium, it 
also has a serious health cost for the host and can cause fatal organ failure (Powars 1990). 
Such adaptations provide important perspective on the evolutionary cost of malaria on 
humans; the cost is so great that we have evolved resistance mechanisms to the disease, 
many of which are deleterious mutations on their own (Lopez 2010). 
 
ANTIMALARIAL EFFORTS 
 Since malaria has plagued mankind throughout history, many interventions have 
been attempted to curb the devastation it causes. The first medicines used to treat malaria 
were derived from plants. These medicines include quinine, which is naturally found in 
the bark of trees in the Cinchona genus, and artemisinin, which is produced by Artemisia 
annua or sweet wormwood. Modern science has allowed us to produce artemisinin 
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artificially by expressing the gene in yeast, and variants of these medicines have also 
been synthesized in laboratories (Dhingra 1999). There is a constant need for new 
medicines since the parasite has been steadily evolving resistance to each new drug used 
(Enayati 2009). Typically, these drugs are used in combination in an attempt to curtail the 
development of resistant strains and still quickly eliminate infections (Fairhurst 2012). 
 Vaccines against malaria have demonstrated some effectiveness (Seder 2013); 
however, these require attenuated sporozoite stage parasites, and production of the 
necessary large quantities of the sporozoites is time and cost prohibitive. Probably the 
most effective interventions to prevent transmission of the disease have been in vector 
control, including bed nets, window screens, and insecticides that either physically 
separate people from the mosquito or eliminate the vector population. These simple 
treatments can lead to a great reduction in transmission of malaria, but supplying them to 
millions of individuals in impoverished nations is difficult to orchestrate and can be 
expensive (Sabot 2010). 
 
THE BIOLOGY AND LIFE CYCLE OF PLASMODIUM 
 There are five species of Plasmodium that cause human malaria. These are 
Plasmodium falciparum, P. malariae, P. vivax, P. knowlesi, and P. ovale. Among these 
species, P. falciparum is the most deadly. Plasmodium are protozoan parasites in the 
phylum Apicomplexa. Apicomplexans have a plastid organelle called an apicoplast, which 
is believed to have evolved from the endosymbiosis of algae. The apicoplast is important 
for the production of a large number of proteins for Plasmodium, and it is involved in the 
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invasion of host cells (Kalanon 2010). Apicomplexans use two structures to invade host 
tissues: (1) an apical complex, which is cone-shaped structure composed of spirally- 
arranged microtubules, and (2) the rhoptry, which is a secretory complex for invasion-
related enzymes and proteases. Plasmodium use these structures at many points in its life 
cycle to invade diverse tissues of each host it infects. 
 Plasmodium have a complex life cycle requiring both an Anopheles mosquito and 
a human host (Ghosh 2000) (Figure 1.1). The parasite enters into the bloodstream of the 
human host when an infected female mosquito injects saliva while taking a blood meal. 
The saliva contains the sporozoite form of Plasmodium, which travel through the blood 
stream into the liver where they invade Kuppfer cells. In the case of P. vivax, P. 
malariae, and P. ovale, it is common for some of the infected cells to go into a dormant 
state called the hypnozoite, or “sleeping parasite,” and to delay the transformation into 
blood stage parasites for months or years. The sporozoite-infected cell then forms a 
schizont, which is a rapidly growing and dividing cell that produces tens of thousands of 
blood-stage merozoites. The schizont bursts open to release the merozoites into the blood 
stream. Merozoites infect red blood cells where they reproduce asexually, bursting open 
and releasing more merozoites every 1-3 days, perpetuating the cycle. This cyclical 
invasion and rupturing of red blood cells is what causes most of the disease symptoms of 
malaria, such as anemia and fever. The periodicity of these cycles of asexual 
reproduction and fever are synchronized and have a specific frequency for the different 
species of Plasmodium that can be tertian, occurring every two days, or quartan, 
occurring every three days (Garcia 2001). A small percentage of the trophozoites, or 
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newly infected red blood cells, will produce male or female gametes instead of producing 
merozoites. These infected cells remain dormant while in the blood stream. They can 
then be taken up by an uninfected Anopheles mosquito during a blood meal. 
 Once ingested in a blood meal, Plasmodium-infected red blood cells burst open 
and the released gametes undergo sexual reproduction in the mosquito midgut (Figure 
1.1 part C). Their activity is triggered by the change in pH, the decrease in temperature, 
and the exposure to xanthurenic acid produced by the mosquito (Billker 1998). Within 24 
hours, the male and female gametes fuse to form a zygote which transforms into an 
ookinete, a motile form of Plasmodium. The ookinete actively invades and passes 
through the midgut epithelium of the mosquito. On the outer surface of the midgut and 
under the basement membrane, the ookinete forms an oocyst in which it divides to 
produce thousands of sporozoites. These oocysts burst open when mature, releasing their 
sporozoites into the hemolymph of the mosquito, which can travel to and invade the 
salivary glands, ready to be injected into the next human host. 
 Fertilization within the mosquito host and subsequent invasion of the mosquito 
midgut present the greatest bottlenecks to Plasmodium transmission (Su 2007). This 
critical life stage has, therefore, been targeted for transmission-blocking experiments in 
attempts to stop the development of the parasite before the anopheline host is infected. 
Fertilization is complex and requires multiple protein interactions between male and 
female gametocytes. Blocking the proteins involved with neutralizing antibodies can 
prevent successful fertilization, hence arresting development. For example, antibodies 
that bind to Pfs48/45, a protein on the surface of the female macrogametocyte required 
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for interaction with the male gametocyte, and Pfs230, a large protein on the surface of 
male gametocytes involved in the formation of exflagellation centers necessary for 
fertilization, have been shown to interfere with the life cycle of P. falciparum 
(Outchkourov 2008, Eksi 2006). 
 Other proteins can be targeted to block ookinete invasion. These include the 
Plasmodium and Anopheles proteins that the parasite uses to attach to and to penetrate the 
midgut epithelial cells. One of these proteins is Pfs25, a P. falciparum surface protein 
that is necessary for parasite binding to the midgut epithelium. Antibodies have been 
produced that will block invasion of mosquito tissues by interfering with the function of 
Pfs25 (Saxena 2007) and have been used for transmission-blocking interventions by 
masking the Pfs25-binding domains necessary for invasion. Similarly, the SM1 peptide 
blocks the anopheline receptor of the enolase binding protein of ookinetes and the use of 
the lectin, Jacalin, that binds to anopheline aminopeptidase N, yet another target of 
ookinete binding (Ghosh 2001, Dinglasan 2007). A final example of a target is 
Plasmodium chitinase, an enzyme which is necessary for degrading the peritrophic matrix 
of the mosquito to allow the ookinete to reach the midgut epithelium and invade (Tsai 
2001).  
 
TRANSMISSION-BLOCKING EFFECTOR PROTEINS 
 Passage through the peritrophic matrix and midgut epithelium is one of the major 
bottlenecks in the life cycle of the parasite, making it a prospective target for 
transmission-blocking therapies. In field-caught anopheline malaria vectors, there are 
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typically only between 0 - 5 oocysts per midgut (Gouagna 1998). An intervention at this 
life stage of Plasmodium development targets the parasite when it is especially 
vulnerable, and previous antimalarial techniques have not yet exploited this avenue. 
 Antibodies have been used in the treatment of multiple diseases and have proven 
effective in providing immunity in some cases of malaria. Furthermore, multiple 
antibodies have been shown to be capable of blocking transmission through the midgut 
(Barr 1991, Outchkourov 2008, Quakyi 1987). These antibodies have been expressed 
from hybridoma cell lines and subsequently fed to mosquitoes mixed into an infective 
blood meal to demonstrate their activity artificially (Barr 1991, Roeffen 1995, Roeffen 
2001). An anti-chitinase single-chain antibody (scFv) has also been demonstrated to 
block transmission (Li 2005). Plasmodium chitinase is an important factor for the parasite 
to make its way through the midgut peritrophic matrix. A different scFv was generated 
which targets Pbs21, a surface protein on ookinetes of Plasmodium berghei, a rodent 
malaria that has been widely used for transmission-blocking experiments in the lab 
(Yoshida 1999). This scFv expressed by a baculovirus expression system blocked 93% of 
oocyst development in the mosquito (Yoshida 1999). 
 Proteinase inhibitors have been demonstrated to prevent transmission by 
disrupting various parts of the parasite's reproductive cycle in the midgut (Rupp 2008). 
There are multiple protease inhibitors that can be used to block transmission, because the 
parasite requires different proteinases to break through the mosquito's defenses. For 
example, ankyrin, a 10 amino acid peptide, has been shown to prevent exit of the parasite 
from erythrocytes by blocking the protease function of Falcipain-2 (Dhawan 2003). It 
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should be relatively simple to secrete this small peptide from bacteria; however, the 
fitness cost associated with the protease inhibitors may be significant for the mosquito 
host. Such inhibition could interfere with blood meal digestion, and without a blood meal, 
female mosquitoes would be unable to produce eggs and to propagate the species. 
 Various antimicrobial peptides from arthropods have also been demonstrated to 
have anti-Plasmodium properties. Gomesin is an antimicrobial peptide isolated from the 
spider Acanthoscurria gomesiana (Silva 2000). It has displayed the ability to inhibit 
exflagellation and ookinete formation (Moreira 2007). Scorpine is a potent antimalarial 
and antibacterial agent from Pandinus imperator scorpion venom that causes membrane 
disruption and cell lysis across a range of microbial species (Corzo 2001, Conde 2000). If 
either of these proteins can be expressed from bacteria in the mosquito midgut, then it 
would provide a powerful inhibitory effect on both gametes and ookinetes. The scorpine 
protein is rather small, too, at only 8,350 Da, and this should be easy to produce 
heterologously, if a suitable host bacterium which is itself resistant to the antibacterial 
mechanism can be found. It has been expressed from transgenic strains of the fungus 
Metarhizium anisopliae and been demonstrated to disrupt Plasmodium development in 
vivo (Fang 2011). 
 The goal of using effectors to block transmission in the mosquito midgut is to 
prevent the parasite from ever reaching the human host. After all, malaria is a disease of 
poverty, primarily affecting the poorest regions in the world where the population has 
limited access to health care or preventative measures (Sabot 2010). Transmission-
blocking effectors are a cheap and renewable source of disease prevention and can lessen 
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the heavy medical and financial burden caused by the production and delivery of 
conventional medicines and vaccines. 
 
THE MOSQUITO VECTORS OF HUMAN MALARIA 
 Globally, the Plasmodium parasites that cause human malaria are vectored by 
over 100 species of anopheline mosquitoes, with 30 to 40 of these species effecting the 
bulk of transmission (Raghavendra 2011). These mosquitoes live on all continents except 
Antarctica and have been known historically to transmit malaria worldwide. Although the 
disease has been eliminated in many regions of the world including North America, most 
of Europe, Australia, and northern Asia, the vector mosquitoes still inhabit these places 
and the reintroduction of malaria remains a threat (Cohen 2012). Female anopheline 
mosquitoes spread the Plasmodium parasite during blood meals which are essential for 
their reproductive cycle. When taking the blood meal, an infected female mosquito can 
inject sporozoites into an uninfected human host; while an uninfected female mosquito 
can itself become infected by taking a blood meal from a human with a blood-stage 
infection. 
 A female Anopheles mosquito requires a blood meal from a mammalian host in 
order to produce eggs. Upwards of 200 eggs per female are laid in fresh water, and the 
eggs undergo four life stages: egg, larva, pupa, and adult. The egg, larva, and pupa stages 
are all aquatic, and ambient temperature determines the speed of progression from egg to 
adult, which can be anywhere from 5 to 14 days. It takes 10 to 18 days after the female 
mosquito feeds on an infected human for sporozoites to develop and to reach the salivary 
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glands. After this time, the mosquito can take a blood meal from another human host and 
inject sporozoites to continue the cycle of infection. These growth and survival 
requirements for malaria transmission are important determinants in the prevalence of 
malaria in a given geographic region. During a drought, malaria transmission can 
decrease drastically in an area which typically has hyperendemic malaria transmission, as 
was observed in Southern Zambia between 2004 and 2005 (Kent 2007). 
 The anopheline host is not immune to the effects of malaria infection. 
Plasmodium can decrease host life expectancy depending on both the intensity of 
infection as well as on the age of the mosquito when it becomes infected (Dawes 2009). 
Anopheles mosquitoes have evolved resistance mechanisms against the malaria parasite 
to lessen this burden. The mosquito can produce an immune response that can be 
modulated by the midgut microbiome and that can interfere with Plasmodium 
development (Cirimotich 2011). Anopheline mosquitoes also have a natural immune 
response that causes melanization of oocysts. Melanization occurs when the mosquito's 
immune system encapsulates foreign objects in order to isolate and to destroy them. 
Despite these adaptations to combat infection, anopheline mosquitoes remain viable 
vectors for Plasmodium. 
 
MOSQUITO MICROBIOTA 
 Anopheline mosquitoes have a diverse community of microbes inhabiting their 
midguts (Rani 2009, Wang 2011). The bacteria of the midgut have been shown to change 
from the larva life stage to the adult, presumably by the shedding of the meconium, or 
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lining of the midgut, during the transformation (Moll 2001). During the larval stage of 
life, the mosquito microbiota consist largely of photosynthetic Cyanobacteria (Wang 
2011). The shedding of the meconium after emergence partially sterilizes the midgut of 
the larva. The midgut will be repopulated with new species when the adult mosquito 
feeds on plant nectar that contains bacteria. The reestablished population of the adult 
mosquito midgut is very different and consists primarily of Proteobacteria and 
Bacteroidetes with the predominant taxa being Enterobacteriaceae and 
Flavobacteriaceae (Wang 2011). Pantoea agglomerans (previously known as 
Enterobacter agglomerans), a Gram-negative, γ-proteobacterium, is a particular midgut 
symbiont of interest (Gavini 1989). Pantoea agglomerans is a common bacterium found 
in the midgut of Anopheles and Aedes mosquitoes, and it is easily cultured and 
manipulated in the lab (Moro 2013, Straif 1998). 
 Other important anopheline midgut symbionts include the Asaia sp. bacteria. 
Asaia are Gram-negative, α-proteobacteria which been isolated from flower nectar 
(Yamada 2000, Chouaia 2010).  Asaia represent a large proportion of the midgut 
bacterial population, in some isolates encompassing 60% of all bacteria as identified by 
454 sequencing (Boissiere 2012). Asaia has been identified in all species of Anopheles 
mosquitoes, and it seems to be an integral part of the host's midgut microbiome and 
necessary for the health of the mosquito host (Mitraka 2013). In addition, Asaia 
contribute to overall health during larval development (Mitraka 2013). Asaia bacteria 
within the midgut of anopheline mosquito larvae increase the transcription of certain host 
genes that allow the larvae to develop more rapidly (Mitraka 2013). These aspects of 
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Asaia's microbial ecology make this bacterium a prime candidate for paratransgenesis 
(Favia 2007, Damiani 2010). 
 
TRANSGENESIS AND PARATRANSGENESIS 
 Previous transmission-blocking approaches in mosquitoes have used direct 
transgenesis of the anopheline mosquito host of Plasmodium to make the insect produce 
antimalarial proteins (Ito 2002). Ito et al. used the piggyBac transposon system to insert 
the gene encoding the SM1 peptide that inhibits P. berghei invasion of the midgut 
epithelium. This gene was inserted under control of the Anopheles gambiae 
carboxypeptidase promoter, which is highly activated by a blood meal in the mosquito 
(Ito 2002). The results found by Ito et al. showed that transgenic mosquitoes produced in 
this way would have greatly enhanced resistance to infection by P. berghei malaria. A 
study of the fitness of transgenic mosquitoes expressing antimalarial effector genes 
determined that lab-reared transgenic mosquitoes that were fed infected blood had a 
fitness advantage over wild type mosquitoes fed the same infected blood (Marrelli 2006). 
Marrelli et al. concluded that the fitness advantage perceived in the lab setting would not 
translate to the field due to the much lower infection rate of wild mosquitoes (Taye 
2006). Some other mechanism would be required to cause a transgene to spread through 
the wild mosquito population and become established permanently. 
 Gene drive mechanisms have been proposed that can cause a gene to be selected 
for in a population; these mechanisms use naturally occurring selfish genetic elements 
that can increase in frequency within a population (Sinkins 2006). Transposons could be 
 14 
used to drive genes through mosquito populations and deliver the genes necessary to 
make the population refractory to infection; Arensburger et al. identified an active 
transposon called Herves in Anopheles gambiae, the primary vector of P. falciparum that 
could be used to drive antimalarial genes into a population (Arensburger 2005). An 
approach such as this would not harm the mosquito population but make them less 
suitable hosts for Plasmodium. Another mechanism that forces a gene to increase in 
frequency is underdominance; mosquitoes that contain a set of genes on different 
chromosomes that each encode a toxin gene and a trans-acting repressor for the toxin 
gene on the opposite chromosome would necessitate that offspring have a copy of each to 
survive, or they will produce the toxin and die. Any gene can be inserted into a construct 
such as this, and it will be selected for along with it (Davis 2001). This setup will allow 
the transgenic mosquitoes to mate with one another and produce homozygous offspring, 
but if they mate with wild mosquitoes, the offspring will die therefore increasing the 
transgenic genotype over time. A caveat to this approach is necessity of an antibiotic 
resistance gene, which would likely never gain approval for release in the wild. 
 Some other mechanisms seek to decrease the population of the vector mosquito 
by delivering dominant lethal genes into the population by a technique called the release 
of insects carrying a dominant lethal (RIDL); an example of this is the dominant 
flightless female gene which is only expressed in female mosquitoes (Marinotti 2013). 
Males with the flightless gene are not affected, therefore they can be raised and released 
into the wild to mate, and any female offspring they produce will be flightless and die 
causing a population crash (Marinotti 2013). The generation of transgenic mosquitoes for 
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malaria control is time intensive, and replacing the natural population of vector 
mosquitoes in the wild has an additional obstacle associated with it, driving the gene into 
multiple populations. Malaria is not transmitted by a single mosquito species, and there 
are over 100 species that can carry Plasmodium (Raghavendra 2011). Even within a 
single vector species, there can be distinct sexually-isolated molecular types that do not 
interbreed, as is the case with the Anopheles gambiae molecular forms (Favia 1997). For 
these reasons, transgenic mosquitoes would be extremely difficult to utilize in field 
applications and to guarantee that all modes of transmission have been targeted. 
 A simpler, alternative approach to generating transgenic mosquitoes would be to 
produce paratransgenic bacteria, which are capable both of inhabiting the midgut of 
diverse mosquito species and of rapidly spreading among wild mosquito populations 
(Wang 2013). Paratransgenesis is the modification of symbiotic microorganisms residing 
within a host in order to alter that host's phenotype (Durvasula 2008). A ubiquitous 
anopheline midgut symbiont would present a single target for modification and be much 
easier to utilize than the numerous species of mosquito hosts (Wang 2013). Furthermore, 
if this paratransgenic bacterial strain expressed a protein that targets all five malaria-
causing Plasmodium species, then that single paratransgenic strain could be utilized 
worldwide against any species of Plasmodium and in any anopheline vector. 
 Paratransgenesis has previously been used to combat human diseases. The first 
demonstration of this technique was the use of paratransgenic Rhodococcus rhodnii in the 
triatomine bug, Rhodnius prolixus, to combat Chagas disease (Durvasula 1997). R. 
rhodnii were modified to secrete Cecropin A, an antimicrobial peptide that is lethal to 
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Trypanosoma cruzi, the parasite that causes Chagas disease (Hurwitz 2011). Durvasula et 
al. reported reduction or elimination of T. cruzi in R. prolixus bugs that had been 
inoculated with the paratransgenic bacteria. They further identified a mechanism to 
spread bacteria to R. prolixus in the wild by allowing the insect to ingest the bacteria 
mixed in with artificial feces, simulating their natural route of coprophagous symbiote 
acquisition (Durvasula 1997).   
 Five other notable studies have also used paratransgenesis to fight disease. One 
study worked to combat African sleeping sickness by utilizing the tsetse fly symbiont, 
Sodalis glossinidius. S. glossinidius was modified to secrete nanobodies which target the 
variant surface glycoprotein of Trypanosoma bruci, the cause of African sleeping 
sickness, by using the pelB secretion signal (De Vooght 2012). A second study targeted 
HIV by using modified Lactobacillus jensenii to secrete functional human CD4 
glycoprotein, which inhibits HIV entry into host T-cells (Chang 2003). A third study 
targeted malaria by engineering modified Pantoea agglomerans to secrete the 
antimalarial peptide SM1, the anti-Pbs21 single chain antibody, and the PLA2 enzyme 
into the midgut of the Anopheles host of Plasmodium. This was accomplished via two 
secretion pathways, by using the pelB leader peptide and the hemolysin secretion system 
(Bisi 2011). Two additional studies also targeted malaria: an Anopheles densonucleovirus 
was discovered and modified to produce green fluorescent protein within the Anopheles  
host to demonstrate its potential for delivery of antimalarial effectors (Ren 2008); and the 
fungus Metarhizium anisopliae, a natural pathogen of mosquitoes, was modified to 
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produce the antimalarial peptide SM1 and the antimicrobial scorpine and proved capable 
of reducing sporozoite counts by 98% (Fang 2012). 
 These previous studies have been proofs of concept of using paratransgenic 
organisms to reduce disease transmission. In order to create strains of paratransgenic 
bacteria that can be applied in the real world, however, certain hurdles must be overcome 
to ensure the organism is suitable for release. A paratransgenic organism intended to 
combat malaria must be prevalent across anopheline species and must have a suitable 
microbial ecology that allows it to remain in the mosquito population for the long term. 
One such species, Asaia sp. SF2.1, has already been isolated (Favia 2007). This Gram-
negative, acetic acid bacterium is associated with many tissues of the mosquito body; it 
can be found inhabiting the reproductive organs, the salivary glands, and the midgut 
(Favia 2007). All three of these organs are important for paratransgenic malaria 
intervention. Asaia sp. SF2.1 has also been demonstrated to be transmitted from female 
mosquitoes to their progeny by a process termed "egg smearing," in which the mother 
paints bacteria on the surface of eggs, and the bacteria passed on survive until adulthood 
(Favia 2007, Damiani 2008). These bacteria can also be passed from male to female 
during copulation since they inhabit the reproductive organs of the mosquito host 
(Damiani 2008).  
 
PROTEIN SECRETION FROM GRAM-NEGATIVE BACTERIA 
 A challenge of creating paratransgenic bacteria is the identification of a protein 
secretion system, which will allow the bacteria to deliver effector proteins into the 
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mosquito midgut environment. Effectors must be secreted in order to make contact with 
Plasmodium and interfere with its development. One way to accomplish this is by fusing 
an effector protein to a signal sequence that directs it for export through a preexisting 
secretion system of the host bacteria.  
 Gram-negative bacteria possess diverse protein transport systems which have 
evolved to move proteins across two lipid membranes and through the protective 
peptidoglycan layer surrounding their cells. Protein production by the ribosome takes 
place in the cytosol of the bacterial cell. Proteins that are needed in the periplasm, that are 
inserted into either membrane, that are part of the protective peptidoglycan layer, or that 
are exported from the cell must be translocated through either one or two cell membranes 
depending on their localization. There are currently nine recognized secretion systems 
that have been identified in Gram-negative bacteria to accomplish this; however, the 
Type I and Type II secretion pathways are the most useful for the secretion of 
heterologous proteins (Mergulhao 2005). 
 Type I secretion involves the export of folded proteins directly from the cytosol to 
the environment. This is accomplished by a secretory complex consisting of three 
proteins that form a channel linking the outer and inner membranes of the cell, allowing 
proteins to pass through the channel without stopping in the periplasm. These proteins 
include an ABC protein within the inner membrane, which facilitates protein recognition 
and initiates transport, a membrane fusion protein that spans the inner and outer 
membrane, providing a channel for direct secretion, and an outer membrane protein that 
allows passage of the translocated protein through the outer membrane (Kudva 2013). 
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 The first identified Type I secretion system was the hemolysin secretion system of 
E. coli. This system is used by some pathogenic E. coli strains to secrete the alpha-
hemolysin toxin, a 107 kDa protein. This protein inserts into the membrane of a host cell, 
causing membrane disruption and cell lysis. The hemolysin secretion complex consists of 
three proteins, HemolysinB (HlyB), HemolysinD (HlyD), and TolC, which mediate the 
export of the HemolysinA (HlyA) toxin (Figure 1.2). The HlyB protein forms the inner 
membrane pore which recognizes and initiates secretion of HlyA. The C-terminal portion 
of the HlyA protein interacts with HlyB to direct it for secretion (Zhang 1993). HlyB is 
part of the family of ATP-binding cassette (ABC) transporters, and it couples ATP 
hydrolysis with protein export. HlyD is the membrane fusion protein in the hemolysin 
secretion apparatus; it forms a trimer that connects HlyB in the inner membrane to TolC 
in the outer membrane to facilitate direct transfer of the secreted protein (Gentschev 
2002). The TolC protein also forms a trimer to produce the outer membrane pore through 
which directed HlyA exits the cell. TolC is a general pore complex found across a wide 
range of Gram-negative bacteria, and it is not specific to this secretion complex (Wiener 
2000). 
 The hemolysin secretion system has previously been adapted for the secretion of 
heterologous proteins. It has been used in E. coli to secrete scFv antibodies and to allow 
the formation of disulphide bonds during transport through the periplasm (Fernandez 
2001). Part of the HlyA gene encoding the C-terminal domain that directs secretion was 
fused to an scFv gene to create a fusion protein, and the scFv proteins exported by the 
Type I hemolysin system were found to form disulphide bonds while traversing the 
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periplasm (Fernandez 2001). This is useful for the secretion of effector scFvs, since these 
proteins require disulphide bridges between cysteine residues to maintain protein 
conformation and function (Schouten 2002). Hemolysin secretion has been utilized to 
secrete active scFv and other effector proteins that inhibit Plasmodium, as well. The 
phospholipase A2 enzyme and an anti-Pbs21 scFv, both antimalarial effectors, were 
successfully secreted in Pantoea agglomerans via fusion to the HlyA C-terminal domain 
(Bisi 2011). More recent experiments have demonstrated the activity of these effectors 
and others as secreted by P. agglomerans in vivo against P. berghei and P. falciparum 
within the midgut of Anopheles mosquitoes (Wang 2012). Interestingly, the HlyA 
secretion system has also been used on an industrial scale for the production and 
extracellular accumulation of molecules such as polyhydroxyalkanoates, which are non-
proteinaceous polymers (Rahman 2013). These results demonstrate the flexiblity of the 
secretion system for its potential use with a wide range of effector molecules. 
 In contrast to Type I secretion, Type II secretion pathways do not directly export 
proteins through a channel between membranes. These secretion pathways use specific 
translocases within the inner membrane to move proteins into the periplasm before they 
are exported by a separate mechanism. Two inner membrane transporters handle the 
majority of membrane traffic in Gram-negative bacteria (Figure 1.2): (1) the general 
secretory (Sec) translocon, which secretes the majority of exported proteins and cytosolic 
membrane-inserted proteins (Natale 2008), and (2) the twin-arginine translocation (Tat) 
channel, which transports specific proteins that are incompatible with the Sec pathway, 
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such as assembled protein complexes and individual proteins that require folding to take 
place in the cytosol (Lee 2006). 
 Type II secretion by the Sec-dependent pathway is a common mechanism found 
in all bacteria and is coupled with ATP hydrolysis. This secretion pathway is also 
essential, unlike the TolC-dependant pathway which can be disrupted without causing 
lethality (Forestal 2006). The Sec translocon transports proteins across the cytosolic 
membrane in the general secretion pathway and is responsible for the majority of protein 
secretion in bacteria. The translocon is composed of secYEG heterotetramers which form 
a transmembrane hydrophilic pore that regulates and facilitates protein transport (Saier 
2006). Proteins are directed to this pore complex by leader sequences that consist of a 
positively charged N-terminal domain, a hydrophobic middle region, and a polar C-
terminal domain followed by a signal peptidase cleavage site. There are many variations 
of the signal peptide, and those that are very hydrophobic are recognized by the signal 
recognition particle (SRP) protein to be directed to the Sec pore complex (Zhou 2014). 
 The Type II PelB leader sequence from the pectate lyase gene of Erwinia 
carotovora, a Gram-negative plant pathogen, has been demonstrated to be able to direct 
secretion of heterologous proteins by a Sec-dependent pathway in E. coli and P. 
agglomerans (Bisi 2011). The PelB leader has also been used successfully with scFv 
antibody secretion, and it is the leader used in the Tomlinson I + J human scFv library for 
the selection of scFvs binding to antigens in a selective screen (Winter 1994). This leader 
peptide has great potential for use in targeted interventions due to the possibility of using 
specific antigen binding scFvs against pathogens. 
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 Type II Tat-dependent protein secretion requires a complex of three proteins in 
the inner membrane: TatA, TatB, and TatC which function together to recognize and 
transport proteins with specific N-terminal signal sequences. These signal sequences are 
similar to those recognized by the Sec pathway, with a positively charged N-terminal 
domain, a hydrophobic middle domain, and a polar C-terminal domain; however, they 
have a much longer N-terminal domain which contains a pair of conserved arginine 
residues, thus giving the system its name. Proteins secreted by this pathway are fully 
folded in the cytosol before passage through the Tat translocon. Protein transport via the 
Tat pathway does not require ATP hydrolysis, but rather it is driven by the proton motive 
force (Saier 2006). The Tat secretion pathway has been used for the large scale 
production of recombinant proteins, as demonstrated by the use of the TorA signal 
peptide and TatAdAc system of Bacillus subtilis in E. coli to secrete GFP into culture 
medium (Albiniak 2013) and the use of the B. subtilis TatAyAc to secrete methyl 
parathion hydrolase directed by the YwbN signal peptide (Liu 2014). 
  The research described here focused both on discovering protein secretion signals 
for use in Asaia sp. bacteria and on using these secretion signals to transport antimalarial 
effectors outside the cell for direct delivery into the mosquito midgut. 
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Figure 1.1. The Plasmodium life cycle. The Plasmodium life cycle is complex, and 
requires two hosts, both a human and a mosquito. When a human is bitten by an infected 
mosquito seeking a blood meal, it injects sporozoites into the blood stream which invade 
liver cells (Part A). Within the liver cells, the sporozites divide and produce blood-stage 
parasites called merozoites. These are released into the bloodstream, where they invade 
red blood cells and continue to reproduce asexually (Part B). These cells burst open 
releasing more mereozoites and perpetuating the cycle. A small fraction of these 
asexually reproducing cells instead make gametes that remain dormant until a new 
mosquito takes them up in a blood meal (Part C). Male and female gametocytes from the 
ingested blood meal fertilize within the midgut and develop into an invasive ookinete that 
is capable of penetrating the midgut epithelium of the host. 
(public domain Figure provided by CDC – DPDx/ Alexander J. da Silva, PhD, Melanie 
Moser) 
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Figure 1.2. Secretion systems of Gram-negative bacteria. Type I secretion systems, 
such as the hemolysin secretion pathway, transport folded proteins through both 
membranes without stopping in the periplasm. The hemolysin secretion system 
recognizes the C-terminal domain of hemolysin A to direct proteins for export. Type II 
secretion systems translocate unfolded (Sec) or folded (Tat) proteins into the periplasm, 
after which they are exported fully from the cell. Type II secretion systems export 
proteins that are recognized by short N-terminal peptide leader sequences that are cleaved 
off in the periplasm prior to the protein exiting the cell. 
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Chapter 2 
Production of single-chain variable fragment antibodies and 
secretion from bacteria 
 
ABSTRACT 
 To date, at least 30 antimalarial effector peptides and proteins have been 
discovered or produced that interfere with the transmission of malaria. Such effector 
proteins are capable of interfering with the development of the Plasmodium parasite 
within the mosquito host. For example, three single-chain antibodies produced by 
hybridoma cell lines are known to bind Plasmodium falciparum gamete or ookinete 
surface proteins and to cause a disruption of fertilization or invasion of host tissues within 
the mosquito midgut (Barr 1991, Roeffen 1995, 2001). In this study, antibody variable 
regions from these three hybridoma lines were converted into single-chain antibody 
(scFv) format that can be expressed from bacteria (Fernandez 2000).  
 These three scFv proteins are designed to bind to P. falciparum surface proteins 
Pfs25, Pfs48/45, and Pfs230 (Barr 1991, Roeffen 1995, 2001). As described in this work, 
scFv genes were cloned in-frame with various secretion signals from Escherichia coli, 
Gluconobacter oxydans, and Gluconacetobacter diazotrophicus, and expression plasmids 
with these gene constructs were transformed into Pantoea agglomerans and Asaia SF2.1. 
The bacteria expressing these secretion constructs displayed unhealthy phenotypes and 
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had growth defects. Therefore, the scFv effector genes require a novel secretion system to 
allow export of the proteins from the bacteria without causing these growth defects. 
 
BACKGROUND 
 Previously, most experiments involving P. falciparum transmission-blocking 
proteins have observed transmission-blocking effects by feeding purified protein to 
mosquitoes along with an infective blood meal (Barr 1991, Roeffen 1995, 2001). While 
this technique has led to the identification of many useful midgut transmission-blocking 
molecules, no method has been devised to adequately deliver the protein to wild 
mosquitoes in the field. 
 Alternatively, transgenic mosquitoes expressing antimalarial proteins can be 
produced to inhibit P. falciparum invasion (Riehle 2007). This technique, however, 
imposes a large metabolic load on the mosquito, and replacement of the natural mosquito 
population with these transgenic mosquitoes cannot be easily achieved. Gene drive 
mechanisms have been proposed to spread the transmission-blocking genes into wild 
populations (Huang 2007, Akbari 2013); but this approach may require an extended 
period of time, and the parasite would likely evolve resistance to the effector molecule, 
therefore necessitating that the entire process be repeated using a new drive mechanism. 
Genetic manipulation of the mosquito itself may get more complicated over time, since 
new transmission blocking genes must be incorporated into the genome. 
 Effectors capable of being secreted from bacteria can be designed which will both 
remain in the mosquito without direct intervention and continue to inhibit the parasite 
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from generation to generation. Rather than feeding an effector molecule to mosquitoes in 
the lab or creating transgenic mosquitoes that produce the effector, bacteria will be fed to 
mosquitoes in the wild and persist in the population, thus providing an unlimited supply 
of the transmission-blocking effector. In addition to the ease of deploying such bacteria, 
they could also be genetically modified to contain different effector proteins and be re-
released if the parasite ever evolves resistance to the current strain. The experiments in 
this chapter demonstrate the cloning of anti-Plasmodium falciparum single-chain 
antibodies and their attempted expression from bacterial vectors, as well as their 
subsequent secretion utilizing a number of cloned secretion signals. 
 
Anti-Plasmodium falciparum antibodies 
 P. falciparum proteins Pfs25, Pfs48/45, and Pfs230 exist on the surface of 
gametocytes and ookinetes and are necessary for transmission through the midgut 
epithelium of the mosquito host (Rener 1983). These surface proteins are necessary for 
the parasite to either bring the male and female gametocytes together or to invade the 
midgut epithelium. Antibodies or other effector proteins which prevent the function of 
these surface proteins can inhibit the different stages of host reproduction or invasion.   
 Mouse-derived monoclonal antibodies have been proven to block transmission 
when produced by hybridoma cells and directly fed to mosquitoes with an infective blood 
meal (Barr 1991, Roeffen 1995, 2001). The three hybridoma lines that produce these 
antibodies are MRA-315, MRA-316, and MRA-878 from the MR4 Malaria Research 
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Center (www.mr4.org). These antibodies target Plasmodium proteins Pfs25, Pfs48/45, 
and Pfs230, respectively (Barr 1991, Rener 1983, Quakyi 1987). 
 Previous use of these monoclonal antibodies has demonstrated inhibition via 
purified antibody protein fed to mosquitoes in infective blood meals (Barr 1991, Saxena 
2007, Eksi 2006). All of these antibodies target specific proteins that are only expressed 
or displayed on the surface of the gamete, zygote, or ookinete stages of the Plasmodium 
life cycle. Since these proteins are not exposed to the human immune system, they do not 
normally produce an immune response in the host. Injection of these proteins as a 
vaccine, however, can produce transmission-blocking immunity in a person (Carter 
2001). A person vaccinated in this way produces IgG antibodies against the Plasmodium 
surface proteins, and these antibodies are able to bind to the parasite only after they are 
taken up during a mosquito blood meal. This immunity prevents Plasmodium from 
infecting mosquitoes that feed on the vaccinated individual. 
 Among transmission-blocking candidates, Pfs25 is the most widely utilized due to 
its small size, which makes it easier to express heterologously for vaccine production. 
Monoclonal antibodies against this protein have long been known to block transmission 
of P. falciparum (Barr 1991). Pfs25 is a 25 kDa protein expressed at the surface of zygote 
and ookinete forms of P. falciparum as they develop in the host mosquito's midgut (Barr 
1991). Pfs25 plays an important role in attachment of the parasite to the mosquito; it 
interacts with the midgut basement membrane to attach the parasite to the surface. This 
binding is an essential step in the transformation from ookinete to oocyst (Saxena 2007). 
This protein has been expressed in a variety of organisms for use in transmission-
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blocking vaccines and in the production of monoclonal antibodies, including the yeast 
Pichia pastoris and eukaryotic green microalgae Chlamydomonas reinhardtii (Barr 1991, 
Gregory 2012). 
 Pfs48/45 is a protein expressed on the surface of female macrogametes, and it 
plays an important role in parasite fertilization (Outchkourov 2008). The MRA316 
hybridoma line produces monoclonal antibodies against this surface protein which are 
known to inhibit P. falciparum transmission in vivo by preventing fertilization and zygote 
formation (Rener 1983). 
 Pfs230 is a protein expressed at the surface of the male gametocyte, and it 
mediates the binding of the exflagellating male gamete to human red blood cells. The 
function of this binding is to create an exflagellation center, a cluster consisting of 
parasite gametes and host erythrocytes which is needed for proper fertilization and 
ookinete formation (Eksi 2006). Transmission-blocking activity of monoclonal antibodies 
against specific domains of this 230kDa protein have been shown (Quakyi 1987). 
Unfortunately, the whole protein is too large to express in bacteria, and only fragments of 
it have been produced and used separately for use in immunizations. Active monoclonal 
antibodies against the Pfs230 antibody are produced by the MRA878 hybridoma line 
(Quakyi 1987). 
 
Prokaryotic expression of scFv antibodies 
 Hybridoma lines that produce monoclonal antibodies of a know function can be 
powerful tools in the lab and in medicine. The IgG proteins that are produced by the cell 
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line can be purified and used as molecular detection tools or as treatment for specific 
disease such as non-Hodgkin lymphoma which can be treated with Rituximab, a 
monoclonal antibody that targets B-cells for destruction (Maloney 1997). For large-scale 
production of antibodies, useful IgG proteins can be converted into a single-chain 
variable fragment (scFv) format that is suitable for expression in bacteria and that can be 
cheaply produced (Bayly 2002). The basic scFv format antibody retains only the antigen-
binding variable regions from the heavy and light chain proteins of the IgG complex 
which have been recombined into a single protein as shown in Figure 2.1 B. The scFv 
protein is capable of being secreted from bacteria (Better 1988). Given that there are 
antimalarial antibodies that can block transmission of Plasmodium, this technique could 
be used to make paratransgenic bacteria that produce scFv proteins engineered from those 
antibodies and that could secrete the proteins directly into the mosquito midgut. 
 
Selecting suitable bacteria for paratransgenesis 
 Effector secretion constructs were produced in expression vectors capable of 
replicating in E. coli, Pantoea agglomerans, and Asaia bogorensis. E. coli was selected 
because it is an easy-to-use host strain, which is useful for manipulation of plasmids and 
for laboratory testing of expression effectiveness P. agglomerans and A. bogorensis are 
both good candidates for paratransgenic approaches to malaria control, as both commonly 
inhabit the mosquito midgut (Lindh 2005, Favia 2007). The Gram-negative, α-
proteobacteria A. bogorensis is a particularly good candidate for transmission blocking, 
as it transfers vertically from mother to progeny, so it would produce a longer-lasting 
 31 
effect in the mosquito population (Favia 2008). Asaia was detected in Anopheles 
stephensi salivary glands, which is rather unusual; most microbes that compose an 
organism's microbiome inhabit the digestive tract. It may be possible to take advantage of 
this fact and to secrete proteins in the salivary glands which may prevent passage of P. 
falciparum sporozoites into the salivary glands or interfere with invasion of the human 
host. 
 Transformation of An. stephensi mosquitoes with transgenic Asaia has already 
been shown to work by Favia et al., by feeding a GFP-expressing strain of Asaia to An. 
stephensi (Favia 2007). Fluorescent bacteria were detected in a large portion of fed 
mosquitoes, and bacteria were stably detected throughout the mosquitoes lifespan (Favia 
2007). 
 
Molecular tools for bacterial protein expression 
 The origin of replication of plasmid pBBR1, originally from a cryptic Bordetella 
bronchiseptica plasmid, has been demonstrated to replicate in a wide range of Gram-
negative bacteria (Kovach 1995). pBBR1MCS-2, a plasmid containing this replication 
origin, was created as a cloning platform for the expression of genes in these diverse 
bacteria (Kovach 1995). Previously, similar plasmids with the pBBR1 replication origin 
have been modified for the cloning and expression of fluorescent proteins in Asaia sp. 
bacteria (Favia 2007). The pBBR1MCS-2 plasmid contains a kanamycin selective 
marker, the neomycin phosphotransferase II gene (nptII). This is very useful because 
kanamycin is one of the few antibiotics that Asaia is known to be susceptible to. This 
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plasmid contains the lacZ alpha gene with a multiple cloning site (MCS) for blue-white 
screening. This was modified to contain an MCS compatible with the genes that have 
been inserted and to allow the promoter to be easily changed. The lac promoter is not 
known to function in Asaia, but the nptII promoter does function. This is a constitutive 
promoter that has been demonstrated to have a high level of protein expression in 
transformed Asaia (Favia 2007). The expression of heterologous proteins can have a high 
fitness cost to bacteria with a constitutive promoter. Therefore, it may be necessary to 
change this promoter to an inducible promoter that is controllable in Asaia, or to a weaker 
constitutive promoter if the bacteria cannot survive. 
 
Combining scFv effectors 
 The activity of an scFv effector gene can be amplified by combining two scFv 
binding domains in one protein (Figure 2.1 D). The resulting fusion protein, or diabody, 
is produced from heavy and light chain immunoglobulins with a short, inflexible linker 
peptide between the two. These proteins do not fold to join the two antigen-binding 
domains together, as in a standard scFv; instead, the heavy and light chains dimerize and 
form one protein complex with two binding sites. The result is that the two antigen-
binding domains end up facing directly opposite from one another. A diabody has the 
advantage of increasing the avidity of the protein for its antigen (Fernandez 2004). 
 Some antibodies, such as MRA-316 and MRA-315, act by binding and 
neutralizing the active site of the antigen; while other antibodies require complement 
protein binding to target the pathogen for an immune response. The MRA-878 antibody, 
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which binds Pfs230, interferes with transmission by complement-mediated cell lysis 
(Healer 1997, Read 1994). This antibody interacts with complement proteins in human 
serum, so it requires either a human antibody constant region to interact with complement 
or some alternative. This problem can be solved by designing diabodies with one binding 
domain for the Pfs230 antigen and one for human IgG. This technique has been explored 
in the lab of Dr. Greg Winter in which bispecific diabodies were produced (Kontermann 
1997). Their complement-recruiting antibody domain effectively binds human C1q, a 
subunit of the C1 complex of the classical complement pathway, and produces efficient 
cell lysis. For non-complement-mediated antibodies, their transmission-blocking activity 
may also be increased by the addition of a complement-binding domain. This would 
target them for immune response in addition to their normal neutralizing activity. 
 An alternative to adding a C1q-binding scFv domain is adding a human constant 
domain to the construct. Such di-diabodies have previously been created: they consist of 
two diabodies with immunoglobulin G CH3 constant domains associated with them (Lu 
2003). The resulting molecule is tetravalent and has the normal complement-binding 
domain of a human antibody (Figure 2.2). Constructs like these could be very useful for 
future antimalarial research. Divalent diabodies could be produced with two different 
anti-Plasmodium binding domains combined in the same structure, and this approach 
should exhibit both a greater avidity, due to its four binding domains,as well as an 
increased affinity for Plasmodium, due to the binding of two different antigens. 
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Secretion of single-chain variable fragment antibodies 
 No single secretion system has been proven to work for all protein constructs, and 
attaining a working secretion system for any given protein requires a trial-and-error 
approach (Choi 2004). It is not known which secretion systems will function in Asaia. 
Some secretion systems move proteins by translocating the denatured amino acid chain 
linearly though the general secretion (Sec pathway) pore complex, while others 
translocate fully folded protein directly into the periplasm through the twin-arginine 
translocase (Tat pathway). Since these systems require the protein to fold in different 
environments, specifically the cytosol or the periplasmic space, the proteins exported by 
these pathways may behave differently. 
 A common secretion signal used in scFv secretion is the pelB signal (Winter 
MRC laboratory). The pelB signal directs proteins through a Type II secretion pathway 
which exports protein using the Sec pore complex into the periplasm, where it can refold 
and form disulphide bonds in the oxidizing environment of the periplasmic space before 
export from the cell by poorly understood mechanisms (Saier 2006). The pelB signal 
peptide has been demonstrated to export fully functional scFv molecules from 
recombinant bacterial strains (Bisi 2011). 
 
MATERIALS AND METHODS 
Media and antibiotics 
 Top10 F' E. coli cells were used for cloning and plasmid propagation. The Top10 
F' cells were cultured in standard Luria Bertani (LB) broth (10 g Tryptone, 5 g NaCl, 5 g 
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yeast extract, in a final volume of 1 L distilled water) or LB agar (LB broth plus 15 g/L 
agar). For selection of plasmids with kanamycin, media was supplemented with 30 μg/ml 
kanamycin; likewise, gentamycin was used at 50 μg/ml, and ampicillin was used at 100 
μg/ml. All E. coli cultures were grown at 37 °C, with agitation for liquid broth cultures. 
Pantoea agglomerans was cultured in the same media as E. coli. 
 Asaia sp. bacteria were cultured in Mannitol broth (5 g yeast extract, 3 g peptone, 
25 g mannitol, in a final volume of 1 L distilled water) or Mannitol agar (Mannitol broth 
plus 15 g agar). Media was adjusted to pH 6.5 before sterilization. For selection of 
plasmids with kanamycin, media was supplemented with 120 μg/ml kanamycin. All 
Asaia cultures were grown at 30 °C, with agitation for liquid broth cultures. 
 
Growth of hybridoma cell lines 
 The hybridoma lines which produce transmission-blocking antibodies were 
obtained from MR4 Malaria Research Institute (MR4, ATCC, Manassas, VA). They were 
obtained through the MR4 as part of the BEI Resources Repository, NIAID, NIH, 
deposited by LH Miller, A Saul. Cells were grown in vented T-flasks in a 5% CO2 
incubator at 37 °C. Growth media used was Advanced MEM media (Gibco, Thermo 
Fisher Scientific, Waltham, MA #12492) with 10% heat-inactivated fetal bovine serum 
(ATCC, Manassas, VA 30-2021), 0.2% sodium bicarbonate, 100 U/ml penicillin, 0.1 
mg/ml streptomycin, 10 μl of 1M L-glutamine, and 50 μM 2-mercaptoethanol. Cells were 
passed when near confluency at a 1:3 rate into new T-flasks. Cells were stored by adding 
100 μl of sterile DMSO to 900 μl of resuspended confluent cell culture and by slow 
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freezing using a Nalgene cryo freezing container (Nalgene, Rochester, NY #5100-0001) 
that cools at 1 °C per min in a -80 °C freezer. Cells were placed in liquid nitrogen for 
long term-storage. 
 
Hybridoma line RNA extraction and reverse-transcription 
 A total of 5x106 cells were harvested from each hybridoma line, and RNA was 
extracted with TRI Reagent using the company protocol for animal cells (Molecular 
Research Center Inc., Cincinnati, OH http://mrcgene.com/?s=tri+reagent). This whole-
cell RNA was purified on a poly-dT column that isolated only the mRNA present in the 
samples by binding their polyA tails (polyA mRNA Isolation Kit, New England Biolabs, 
Ipswich, MA, #S1560S, https://www.neb.com/protocols/1/01/01/isolation-of-mrna-
s1560). This step eliminated the large amounts of ribosomal RNA present in whole-cell 
RNA extracts. The purified mRNA was reverse transcribed with a cDNA synthesis kit 
following the standard protocol (Fermentas, Thermo Fisher Scientific, Waltham, MA 
#K1611, http://www.thermoscientificbio.com/uploadedFiles/Resources/coa_k1611.pdf). 
 
Amplification of H and L chain variable regions from hybridoma cDNA 
 Three sets of degenerate primers designed for mouse antibody variable regions 
were used to amplify the antigen-binding domains of the heavy and light chain of each 
antibody via PCR (Barbas 2001). The protocols laid out in this text were followed, except 
with reduced volumes for each reaction of 25 μl. The goal was not to create a phage 
display library but to simply isolate the unique clone that is produced by each hybridoma 
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line. PCR was performed using Phusion polymerase (New England Biolabs, Ipswich, 
MA, #M0530). The PCR primers in these reactions were identical to the published 
primers, with one modification which was the addition of a NotI restriction digestion site 
to five of the primers (Table 2.2). The resulting fragments were size-separated on 1% 
agarose gel, extracted using a Zymoclean Gel DNA Recovery Kit (Zymo Research, 
Irvine, CA #D4002), and used as templates in an overlap extension PCR (Figure 2.3). 
This PCR reaction connected the antibody gene fragments by a DNA sequence encoding 
a flexible linker, which should allow the heavy and light chain protein fragments to fold 
into their proper orientation and align their binding domains as in a standard antibody. 
These constructs were created in two forms, with both long and short linkers between the 
domains (Figure 2.4). 
 The proteins produced with these different linkers assemble into alternative 
formats. Those with a long linker will be able to fold back on themselves, aligning the 
heavy and light chain variable domains, and produce a single antibody binding domain 
(Figure 2.1). Those with a short linker will be more rigid, and will require two copies of 
the protein which will dimerize, forming a diabody. This is a divalent antibody fragment 
which has two antibody binding domains, increasing its avidity. 
 
Cloning svFv genes into expression vectors 
 Each overlap extension PCR product was cloned into the pDB48 plasmid (Bisi 
2011) by restriction digestion and ligation. The PCR products and pDB48 plasmid were 
digested to completion with the AscI and PacI restriction enzymes, and the plasmid was 
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treated with calf intestinal phophatase. The PCR products were ligated into the linearized 
plasmid using T4 DNA ligase at 16 °C overnight. The ligated DNA was transformed into 
Top10 F' E. coli cells and selected on LB media containing 50 μg/ml gentamycin. These 
insertions placed the scFv genes in-frame with the pelB leader sequence at the N-terminal 
end and with the 6-His and Myc epitope tags at the C-terminal end. Clones isolated from 
this selection were verified by sequencing to ensure that no mutations were introduced. 
Gene design is shown in Figure 2.5. 
 
TA cloning antibody variable fragments and sequencing 
 The PCR products produced using degenerate primers to amplify the variable 
regions of each antibody and overlap PCR were TA cloned into the pCR2.1-TOPO vector 
using a standard kit and protocol (Invitrogen Thermo Fisher Scientific, Waltham, MA 
#45-0641). The cloning reactions were selected in Top10 F' E. coli on LB media 
supplemented with 100 μg/ml ampicillin and 100 μg/ml X-gal. 
 The TA cloned antibody variable region fragments were sequenced using the 
vector primers in the pCR2.1-TOPO plasmid, M13 forward (-20) and M13 reverse. 
Sequences were aligned using the DNASTAR program SeqMan to assemble the full gene 
fragments. 
 
Gene optimization for prokaryotic expression 
 Some genes can be inserted in bacterial expression vectors and heterologous 
production can be achieved without any further alteration of the sequence. Since the scFv  
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constructs produced in that way did not express and secrete functional antibodies, the 
scFv gene sequences were modified to allow them to translate more efficiently in the 
heterologous hosts, E. coli, P. agglomerans, and A. bogorensis.  
 To increase efficiency of a gene expressed in a heterologous host, the codons that 
determine the amino acid sequence were changed to better suit the codon usage of the 
heterologous host. The gene sequence of the hybridoma antibody genes were optimized 
for expression by changing the nucleotide sequence of each codon to the most commonly 
used codon for that amino acid in E. coli. This was achieved by selecting the codon usage 
table for E. coli into the Graphical Codon Usage Analyzer (http://gcua.schoedl.de) and by 
using the gene analyzer to change the codons of each gene sequence to the most 
frequently-used codons from the E. coli usage table. scFv gene sequences are shown in 
Figures 2.6 through 2.9. 
 The anti-Pfs48/45 scFv gene was codon harmonized. Codon harmonization is the 
process of calculating the percent usage of each particular codon in the gene's original 
species and changing the codons in the harmonized gene to a matching percent usage 
codon in the heterologous host species (Angov 2008, Figure 2.10). This allows a protein 
to be translated at the same rate of speed as if it had naturally occurred. Translation speed 
can have an effect on protein folding, as regions of slow translation have been 
demonstrated to permit the ribosome to pause, thus allowing a portion of the protein to 
fold prior to continuing (Thanaraj 1996). A fully optimized gene will be translated at the 
fastest rate possible by the ribosome; therefore it could miss critical pauses where the 
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nascent protein may need time to stop and achieve the correct conformation before 
translation resumes. The codon-harmonized anti-Pfs48/45 is shown in Figure 2.11. 
 Allowing the ribosome to translate a heterologous protein at the same rate as it 
would in the native organism should prevent the product from misfolding. This can 
potentially reduce degradation of the protein, prevent aggregation, and increase 
solubility. Misfolded protein can have a large impact on the bacteria which express it, and 
this burden can cause growth inhibition (Rosano 2009, Kudla 2009). This is an important 
consideration for a paratransgenic expression construct, because the bacteria must 
reliably compete against wild type bacteria in the mosquito midgut while still producing 
enough scFv protein to be effective during an infective blood meal. 
 
mRNA 5' UTR structure 
 The 5'-UTR folding free energy of the mRNA molecule was taken into account 
while optimizing and harmonizing the gene sequences. Both the UTR and part of the 
open reading frame (ORF) directly following it can have an impact on translation 
initiation of a gene transcript (Kozak 2005). The Shine-Delgarno sequence on an mRNA 
transcript may become obscured if there is a complementary sequence capable of forming 
a hairpin with it, preventing the ribosome from binding the RNA and locating the start 
codon. Probable hairpin-forming structures were identified by entering sequences into the 
mFold webserver RNA secondary structure predictor (SUNY Albany, Albany, NY 
http://mfold.rit.albany.edu/?q=mfold). The hairpin structure of the MRA316 anti-
Pfs48/45 RNA is shown in Figure 2.12, and it has a ΔG of -49.60 kcal/mol. The 
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coding sequence was altered accordingly to remove the hairpin-forming sequence while 
retaining the encoded amino acid sequence (Figure 2.13). A hairpin at the 5' end of the 
mRNA can cause a significant decrease in the amount of protein produced, with a 
significant drop-off occurring when the free energy of a hairpin reaches -8 kcal/mol or 
lower (Kudla 2009). Codons in the beginning of the ORF for the optimized antibody 
genes were adjusted to eliminate potential hairpins that could decrease protein translation. 
 
Expression plasmid construction and molecular cloning 
 The expression vector used to express protein in multiple host bacteria was 
constructed using the backbone of pBBR1MCS-2, a broad-host range plasmid containing 
an origin of replication originally isolated in Bordetella and has been proven to function 
in Asaia (Kovach 1995). Other features on the plasmid include a mobilization element for 
conjugal transfer and the lacZ alpha gene containing a multiple cloning site (MCS). The 
plasmid has the kanamycin resistance marker, neomycin phosphotransferase,  which is 
useful for selection since it is one of the few antibiotics that Asaia are susceptible to. 
 The lacZα gene of pBBR1MCS-2 (Figure 2.14) was replaced by bacterial 
recombination with a new cloning site that I designed (Figure 2.15). Primers were 
designed to amplify the ampicillin resistance gene (bla) encoding beta-lactamase and 
extend this to have a translational enhancer preceding the ORF, an NdeI restriction site at 
the beginning of the gene, and five other unique restriction sites following the gene. The 
primers included 40 nucleotides of homology to the pBBR1MCS-2 plasmid on each end 
of the amplified product which are required for recombination the primers are listed in 
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Table 2.2 as “pBBR rec F” and “pBBR rec R”. The bla gene was amplified by PCR from 
pSC189 (Chiang 2002) using these primers and purified by gel-extraction using a Zymo 
kit (Zymo Research, Irvine, CA #D4002). The pBBR1MCS-2 plasmid was purified from 
E. coli using a Qiagen miniprep kit (Qiagen, Germantown, MD, #27104). The 
pBBR1MCS-2 plasmid was linearized by digestion with the EcoRI and BamHI 
restriction enzymes to completion. 
 Fifty ng of the linear plasmid and 50 ng of the PCR product were co-transformed 
into MG1655 E. coli cells, which were incubated in non-selective LB media for 1.5 h at 
37 °C to allow for the bacteria to recombine the two DNA fragments. This culture was 
plated on selective LB media containing ampicillin. The resulting colonies from this 
selection contained the new plasmid named pNB20 (Figure 2.16), which now had a 
specific set of restriction sites with which to modify the expression cassette. 
 The pNB20 plasmid was further modified by changing the promoter region for 
beta-lactamase to the neomycin phosphotransferase promoter (PnptII). This promoter is 
constitutively active and has high activity in Asaia sp. as demonstrated by its effective 
use expressing green fluorescent protein (Favia 2007). The PnptII region of pHM2-GFP 
(Favia 2007) was amplified by standard PCR using primers that add NsiI and NdeI 
restriction sites to the ends of the amplicon (primers “PnptII F NsiI” and “PnptII R 
NdeI”). This PCR product and pNB20 were each digested to completion with the NsiI 
and NdeI restriction enzymes, and the plasmid was treated with calf intestinal 
phophatase. The PCR product was ligated into the linearized plasmid using T4 DNA 
ligase at 16 °C overnight. The ligated DNA was transformed into Top10 F' E. coli cells 
 43 
and selected on LB media containing ampicillin and kanamycin. Clones isolated from 
this selection were verified by sequencing to ensure there were no mutations introduced. 
The new plasmid created was named pNB51 (Figure 2.17). 
 
Vector construction 
 The anti-Pfs25 scFv was initially synthesized with an optimized pelB leader 
sequence at the N-terminal end followed by an AscI restriction digest site and with 6-His 
and Myc epitope tags at the C-terminal end of the gene for western blot detection. This 
gene was further flanked with restriction enzyme sites NdeI and BamHI at the N- and C-
terminal ends, respectively. The plasmid bearing the synthesized gene and the plasmid 
pNB20 were digested using the NdeI and BamHI restriction enzymes, and the antibody 
gene was then ligated into pNB20 3' to the lac promoter. This plasmid was called pNB39 
(Table 2.1), and it was used for further cloning of antibody effectors. 
 Other optimized or harmonized antibody scFv genes were digested from plasmid 
DNA using the AscI and EcoRI restriction digest sites and ligated into the pNB39 
plasmid in-frame with the PelB leader to replace the anti-Pbs25 scFv gene. The resulting 
plasmids were called pNB37 (anti-Pfs48/45 scFv) and pNB38 (anti-Pfs230 scFv) (Figure 
2.18). An anti-BSA scFv gene from pDB51 (Bisi 2011) was also cloned into pNB39 by 
PCR amplification using primers “BSA F AscI” and “BSA R EcoRI” and by directionally 
cloning into the same site. The anti-BSA plasmid was called pNB55. 
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Insertion of GFP into secretion plasmids 
 The GFP gene was amplified from pHM2GFP and inserted into pNB20 to both 
test for the expression activity of the promoters in Asaia, as well as to observe protein 
activity. gfp was amplified using standard PCR with the primers “GFP F NdeI” and “GFP 
R EcoRI.” These PCR products along with purified plasmids pNB20 and pNB51 were 
digested using the NdeI and EcoRI restriction enzymes, and the plasmid was treated with 
calf intestinal phophatase. The PCR products were ligated into the linearized plasmid 
using T4 DNA ligase at 16 °C overnight. The ligated DNA was then transformed into 
Top10 F' E. coli cells and selected on LB media containing 30 μg/ml kanamycin. The 
produced plasmids were called pNB49 (with lac promoter) and pNB50 (with nptII 
promoter). Clones isolated from this selection were verified by sequencing to ensure 
there were no mutations introduced, and confirmed under fluorescence microscopy to 
verify expression of the gfp gene. These plasmids were subsequently purified and 
introduced into Asaia bogorensis competent cells. Fluorescence activity of the GFP 
protein produced in Asaia was visualized under excitation conditions with 395 nm light. 
 
Cloning secretion signals from acetic acid bacteria 
 Since the Asaia genome was not yet sequenced, signal peptides from two related 
species of acetic acid bacteria were tested for activity in Asaia. Proteins identified as 
secreted in the psortdb database (http://db.psort.org) from Gluconobacter oxydans and 
Gluconacetobacter diazotrophicus were selected, and their secretion signals were 
identified by processing the amino acid sequences using the SignalP4.1 software 
 45 
(www.cbs.dtu.dk/services/SignalP) artificial neural network Hidden Markov models 
(Nielsen 1997). This program is capable of machine learning and pattern recognition, 
therefore it utilizes a database of secreted proteins and identifies unknown proteins by 
their homologous sequence to the database. Primers were designed to amplify only the 
signal peptide gene sequence of these proteins, and to add NdeI and AscI restriction sites 
to the 5' and 3' ends of the product, respectively (Table 2.2). 
 Routine PCR was performed using genomic DNA from Gluconobacter oxydans 
or Gluconacetobacter diazotrophicus as template and an individual set of primers for a 
given gene. Each of these amplified products was inserted into plasmid pNB39 by 
restriction digestion and ligation exactly as described previously, replacing the PelB 
secretion signal with each of these newly identified signals. Thirteen unique secretion 
signals were cloned in this way and are listed in Table 2.4, and the plasmids are listed in 
Table 2.1 as pNB44 through pNB76. 
 
Western blot to detect scFv proteins expressed from inducible promoters 
 E. coli, P. agglomerans, and A. bogorensis with scFv expression plasmids were 
grown to an OD600 of 1.0. Protein production was induced in E. coli by adding 0.5 mM 
IPTG to strains that expressed genes under control of the lac promoter, and the culture 
was grown for 12 h. Cultures of each strain containing no plasmid were grown for 
negative controls, and E. coli expressing the plasmid pDB49 which produces an anti-
bovine serum albumin (anti-BSA) scFv protein were induced as a positive control. To 
separate the pellet and supernatant fractions, 100 μl of the cell cultures were pelleted at 
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8,000g for 2 min. The pellet was resuspended in 100 μl of 3X Laemmli sample buffer 
(BioRad) with 2-mercaptoethanol, and 75 μl of the supernatant was mixed with 25 μl of 
Laemmli buffer. These samples were boiled for 8 min to denature the proteins, and 8 μl 
of the ColormarkPlus Prestained Protein Ladder (New England Biolabs), 20 μl of each 
supernatant protein sample, and 5 μl of each pellet protein sample were loaded into the 
wells of a 5% stacking and 10% separating polyacrylamide gel. Proteins were separated 
by electrophoresis, transferred onto a 0.45 μm pore size PVDF membrane in a BioRad 
transfer apparatus using Tris-Glycine transfer buffer (25mM Tris, 150mM glycine, 10% 
methanol) at 95 V for 75 minutes. The PVDF membrane was blocked for 18 h with 1% 
BSA TBS-Tween 20 (TBS-T) (50mM Tris-CL, 150 mM NaCl, 0.1% Tween 20, 1% w/v 
fraction V BSA, pH 7.5) with agitation at 4 °C. Next, the blocking solution was replaced 
with the primary antibody, a mouse anti-myc antibody (Invitrogen 45-0603) 1:5000 in 
blocking buffer, and incubated at 4 °C for 24 h with agitation. The primary antibody 
solution was removed, and the blot was washed four times in TBS-T for 15 min each 
time. Following washes, the secondary antibody, goat anti-mouse HRP (BioRad 170-
5046), was applied and the blot was incubated for 1 h at room temperature. The wash 
steps were repeated, 2 ml of Supersignal West Femto Maximum Sensitivity Substrate 
(Thermo Scientific # 34095) was added to the blot and incubated for 5 min. The blot was 
exposed to X-ray film (Thermo Scientific 34090) for multiple time exposures ranging 
from 10 sec to 10 min and then developed using an automatic developer. 
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Northern blot to detect transcription of scFv genes 
 Digoxigenin-labeled probes were created using the DIG High Prime DNA 
Labeling and Detection Starter Kit I (Roche 11745832910). First, each gene to be 
identified in the northern blot was amplified by PCR, including the anti-BSA scFv, anti-
Pfs25 scFv, anti-Pfs48/45 scFv, and anti-Pfs230 scFv. Three μg of each template PCR 
product were mixed with the DIG High Prime reagent and incubated at 37 °C for 20 h. 
Labeling efficiency of each probe was determined by serial dilution of the probes and a 
control DIG-labeled control DNA. These were spotted onto a piece of nitrocellulose 
membrane, and detected using NBT/BCIP. Spot intensity was compared to that of the 
control labeled DNA, and each probe was diluted to the same working concentration as 
per the DIG labeling kit instructions. 
 E. coli Top10 F' cells with expression plasmids as well as control E. coli with no 
plasmid were grown at 37 °C to a OD600 of 1.0. Duplicates of each strain tested were 
prepared from these cultures, and one of each was induced by the addition of 0.5 mM 
IPTG. Cultures were then grown for 1 h at 37 °C. RNA was extracted from each sample 
using TRI Reagent using the MRC protocol for bacterial cells 
(http://mrcgene.com/?s=tri+reagent). The samples were size separated on a 1% agarose 
gel with 0.4% formaldehyde. The bands were transferred to a nitrocellulose membrane by 
capillary action using the Turboblotter following standard protocols (Whatman 
Schleicher & Schuell). The RNA was UV-crosslinked to the wet membrane using a UV 
transilluminator for 1 min with 254 nm light. The full Whatman Turboblotter protocol 
can be found at: (https://www.gelifesciences.com/gehcls_images/ 
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GELS/Related%20Content/Files/1389873234232/litdoc29088931_20140116215520.pdf) 
 The membrane was probed with the previously prepared DIG-labeled DNA and 
hybridized at 44 °C in a Fisherbrand rotisserie hybridization oven following the DIG 
labeling kit protocols. Detection of labeled RNA was performed as written in the Roche 
kit instruction manual. The DIG labeling kit manual can be found at:  
(http://lifescience.roche.com/wcsstore/RASCatalogAssetStore/Articles/05353149001_08.
08.pdf) 
 
RESULTS 
Antibody variable region cloning 
 Three hybridoma lines that produce antibodies against surface proteins Pfs25, 
Pfs48/45, and Pfs230 of P. falciparum gametes and ookinetes were obtained from the 
MR4 depository, and cDNA was produced from each. Another hybridoma line that 
produces antibodies against human IgG (ATCC CRL-1757) was also obtained for 
incorporation into divalent diabodies with Pfs230; the proposed diabodies are expected to 
allow binding of the anti-Plasmodium scFv to the parasite and to allow the connected 
anti-complement scFv to initiate a complement cascade that will destroy the ookinete. 
The gene sequences of each antibody's binding domains were identified by PCR 
amplification of the variable region of the heavy and light chains from the cDNA. These 
variable regions were recombined into single-chain variable fragment (scFv) format 
suitable for expression in prokaryotes (Figure 2.1) These gene constructs include a long, 
flexible linker sequence connecting the two antigen binding domain that allows the 
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protein to align the domains and retain the function of the original antibody protein 
complex (Winter, Tomlinson Library). 
 
Antibody variable region sequencing and manipulation 
 The scFv format genes of these antibodies were cloned using the TA system into 
the pCR2.1-TOPO vector and sequenced using standard M13 vector primers. The full 
sequence of each antibody was obtained this way (Figures 2.6-2.9), allowing for the 
modification of the scFv gene in order to enhance its activity in bacterial hosts. Some 
scFv genes cloned directly from mammalian cells can be produced in bacteria; however, 
the codon usage of eukaryotes and prokaryotes differ greatly, and optimization for the 
expressing organism can have a large impact on protein production (Hannig 1998). The 
coding sequences of these genes were altered in two ways. Each of the scFv genes was 
optimized for the codon usage of E. coli, using only the most common amino acids from 
that host. The only deviation from this optimization was in changes to specific amino 
acids that were identified to cause potential RNA hairpin structures that interfere with 
translation initiation (Hall 1982). 
 A second version of the anti-Pfs48/45 antibody was also generated, by comparing 
the codon usage of the original gene sequence to the codon frequency in the mouse and 
by selecting codons at each site for bacterial expression that match the codon usage 
frequency in E. coli. This is called a harmonized gene sequence, and it can possibly aid 
the folding of proteins thereby increasing the efficiency of production by harmoniously 
replicating the translation speed of the original host (Roy 2009). This allows a nascent 
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protein to slow translation when necessary to allow portions of the protein to fold before 
translation continues (Angov 2008). 
 
Expression of single-chain variable fragment antibodies in bacterial host organisms 
 The scFv genes were cloned into expression vectors under control of the lac and 
nptII promoters. These constructs fused the scFv gene to the pelB leader sequence from 
the Erwinia carotovora pectate lyase gene, which has been successfully used by others to 
secrete scFv proteins from E. coli. The C-terminal end of these genes also contained 6-
His and Myc epitope tags. These plasmids were transformed into E. coli, P. agglomerans, 
and A. bogorensis to assess protein production and secretion. 
 Protein production was not apparent in any of the bacterial strains produced, as 
shown by a lack of protein of the predicted size by both Coomassie and western blot 
(Figure 2.19). A control strain of E. coli expressing an anti-BSA scFv from either 
plasmid pDB51 or pDB49 was used as a positive control for western blot detection, and 
that protein was detected normally. 
 
Transcription of gene constructs in E. coli 
 Due to a lack of protein production from expressing strains, a northern blot was 
conducted to determine if the problem was related to transcription. RNA was prepared 
from different expression constructs, and mRNA transcripts of the scFv gene sequences 
were identified using a digoxigenin labeling reaction. All strains that contained plasmids 
expressing scFv genes produced mRNA of the correct predicted size (Figure 2.20). 
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Activity of lac and nptII promoters in Asaia 
 Expression plasmids were constructed with the pBBR origin of replication, 
kanamycin resistance marker, and the gfp gene either under the control of the lac 
promoter or the nptII promoter (Figures 2.21 and 2.22). These gene constructs did not 
have any modifications such as secretion signals or tags, and the promoters were identical 
to previous expression constructs. The plasmids were transformed into Asaia, and strains 
expressing each were viewed under a fluorescence microscope. The lac promoter 
produced a very faint amount of fluorescence, whereas the nptII promoter produced a 
strong signal (Figure 2.23). 
 
Testing secretion signals from species related to Asaia 
 Secretion signals were tested from two close relatives of Asaia bogorensis in the 
family Acetobacteraceae: Gluconobacter oxydans and Gluconacetobacter diazotrophicus 
since the Asaia genome was not yet sequenced. Thirteen genes from these species were 
selected from a list of known secreted proteins on the psortdb database (db.psort.org), and 
their secretion signals were identified using the SignalP4.1 algorithms 
(www.cbs.dtu.dk/services/SignalP). The leader peptides for the thirteen genes were 
amplified from genomic DNA and cloned into scFv expression plasmids in-frame with 
both the anti-BSA scFv and the anti-Pfs25 scFv. The complete list of genes from which 
secretion signals were cloned and their amino acid sequence are listed in Table 2.4. 
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 These plasmids were transformed into Asaia competent cells, and protein 
production was assessed by western blot (Figures 2.24 and 2.-25). Despite the use of 
secretion signals from closely-related species, no protein production was detected. 
 
DISCUSSION 
 Malaria remains a significant cause of human mortality and morbidity in the 
world, and new techniques to combat the disease are necessary to supplement current 
interventions. In this work, new effector molecules, which can potentially be secreted by 
paratransgenic bacteria living within anopheline mosquito hosts, were generated. These 
proteins are single-chain variable fragment (scFv) antibodies that should be capable of 
binding to surface proteins of Plasmodium falciparum and interfering with the parasite's 
development. The genes for these scFv effectors were tested for protein expression and 
secretion from E. coli and from two mosquito midgut symbionts, Asaia bogorensis and 
Pantoea agglomerans. 
 
Novel scFv effector molecules 
 Heavy and light chain variable binding domain regions for three antimalarial 
antibodies known to interfere with P. falciparum within the mosquito midgut were cloned 
from hybridoma lines and sequenced. These variable region genes were recombined into 
genes designed to produce single-chain variable fragment antibodies within heterologous 
hosts. Such molecules only contain the binding domain of the heavy and light antibody 
chains and are much smaller than a standard antibody. They have a great potential for use 
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as antimalarial effector molecules to combat P. falciparum, the most deadly species of 
Plasmodium in humans. Furthermore, the activity of these effector molecules would be 
restricted to targeting only the parasite of interest and should not interfere with any other 
aspects of the microbiota, as could be the case with some other more general 
antimicrobial effectors, like scorpine, that kill a wide range of microorganisms 
(Carballer-Lejarazu 2008). 
 
Difficulties in scFv expression and secretion 
 Despite multiple attempts to express and to secrete these scFv proteins in E. coli, 
A. bogorensis, and P. agglomerans, no success was achieved. The genes proved to be 
properly transcribed in the heterologous hosts; however, no protein was detected by 
either Coomassie-stained protein gels or by western blot targeting the Myc epitope tag of 
the protein. There can be issues involved with protein expression at multiple points in the 
process, during translation, protein folding, or secretion. Not all promoters will function 
in all bacteria: the lac promoter is known to function in E. coli and P. agglomerans, but 
no protein was produced even from IPTG-induced cells. Indeed, transcription does not 
seem to be a problem with these constructs, as evidenced by the northern blot which 
shows full length products from each construct tested. 
 There could be a problem during translation of the proteins, although that would 
be unlikely to cause a complete lack of protein considering that multiple gene 
combinations were attempted, including different effectors and different N-terminal 
signal sequences. Incorrect protein folding is a common problem in heterologously 
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expressed proteins, especially for scFv antibodies (Maeng 2011). Single-chain antibody 
fragments are less stable than natural antibodies, and stability engineering is a concern 
(Worn 2001). These proteins require the formation of disulphide bonds in the periplasm 
to retain their correct structure. The PelB secretion signal has been used extensively for 
the export of scFv molecules from bacterial cells (Mergulhao 2005), and it utilizes the 
general secretory (Sec) pathway which translocates the protein into the periplasm before 
it leaves the cell entirely. Typically, this is a beneficial pathway for scFv secretion, 
because the protein can form disulphide bonds in the oxidizing environment while it 
passes through the periplasm (Popplewell 2005). The Sec translocon transfers proteins in 
an unfolded conformation that requires proteins to refold within the periplasm and this 
fact may prevent the proteins designed in this study from folding properly and hence be 
degraded by cellular proteases (Dalbey 2012). 
 Visual analysis of transformed bacterial colonies containing these plasmids 
showed unusual phenotypes such as a raised morphology and greater transparency than in 
wild type cells. These phenotypes could be indicative of problems with the membrane of 
the cell caused by incorrect translocation and “clogging” of the membrane, causing the 
cells to rupture or activate some sort of stress response. The GFP expression plasmids 
used in Asaia were proven to function quite well with the nptII promoter and only 
slightly with the lac promoter; therefore, the negative results from expression plasmids 
utilizing the nptII promoter to express either GFP or scFv genes with secretion signals 
indicates that the problem lies in the secretion system used to translocate these proteins. 
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They are likely being transcribed and translated but are degraded by cellular proteases 
due to problems at the cell membrane.  
 
Conclusions 
 Single-chain variants of mouse monoclonal antibodies have been cloned and 
sequenced successfully; however, the proteins were not expressed properly by any 
bacteria transformed with diverse expression plasmids utilizing different secretion 
signals, promoters, and gene variants. Secretion in Gram-negative bacteria involves many 
different pathways that translocate proteins by very different mechanisms. These scFv 
genes likely require a different secretion signal or mechanism to successfully export the 
protein safely, without detriment to the bacteria. The PelB leader sequence secretes 
proteins using the general secretory (Sec) pathway of prokaryotes. This pathway 
translocates proteins into the periplasm post-translationally, where they must refold. 
Twelve of the cloned leader peptides from G. oxydans and G. diazotrophicus were Sec-
dependent, and one was Tat-dependent. Constructs with any of these signals failed to 
produce detectable protein. It is possible that a native secretion signal from Asaia would 
allow the proteins to be translated and exported from the cell correctly. Unfortunately, the 
Asaia genome was not sequenced at the time of these experiments, only genomes from 
related species were available. The scFv gene constructs cloned were retained for future 
use after a new secretion system is identified that functions well in Asaia. 
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Figure 2.1. Forms of antibodies. From left to right: a natural IgG antibody, a single 
chain antibody utilizing only the antigen binding domains from IgG, a diabody with two 
IgG binding domains back-to-back, and a single chain antibody fused with a folding 
chaperone. Both the scFv and diabody can be expressed in prokaryotes, and they can also 
accomodate added fusion proteins, like the Skp molecular chaperone depicted here. Skp 
is a trimeric periplasmic protein chaperone of Gram-negative bacteria which can increase 
the avidity of a scFv molecule by increasing the number of binding domains in a single 
protein complex and by aiding in the correct folding of the protein in the periplasm 
(Wang and Xiang 2013). Antimicrobial peptides, such as the Shiva1 antimicrobial, can 
also be fused to the scFv to complement its function by creating a single protein that acts 
against Plasmodium in two different ways (Wang 2013). 
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Figure 2.2. Di-diabody. The structure of a di-diabody, which consists of two diabodies 
held together by CH3 constant domains. This molecule has a greater avidity than standard 
scFv constructs that contain just a single binding domain and provides complement-
fixing functionality by the natural CH3 domain interaction. 
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Figure 2.3. Overlap extension PCR. The heavy and light chain variable regions of each 
antibody were separately amplified from cDNA using degenerate primer sets (primers ab 
and cd, above). Primers b and c share a region of homology. This allows the two products 
(products AB and CD) to act as primers for the opposite strand in a new PCR reaction in 
which both products are included as templates and external primers (primers a and d) are 
used. 
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A.   B.  
Figure 2.4. Antibody variable region PCR and overlap extension PCR. A.) One 
percent agarose gel showing separation of light and heavy chain antibody variable 
fragments amplified from MRA315, anti-Pfs25 antibody, one of the three anti-
Plasmodium hybridomas. These are the PCR products later used in sequencing reactions 
to obtain sequence and to run overlap-extension PCR. The lanes are: 1.) kappa variable 
region (Vk) short linker, 2.) Vk long linker, 3.) lambda variable region (Vl) short linker, 
4.) Vl long linker, and 5.) heavy chain variable region (Vh). Separate primer sets were 
used to amplify the Vk and Vl antibodies, and since each hybridoma line will only 
produce a single light chain that will be either Kappa or Lambda. B.) The successful 
overlap extension PCR of the fragments from Part A. 1.) scFv with a short linker 
sequence, and 2.) scFv with a long linker sequence. These products consist of single-
chain antibody genes, which were gel-purified and inserted into an expression vector to 
attempt expression of the un-modified gene construct. Similar products were amplified 
from MRA 316, anti-Pfs48/45 and MRA878, anti-Pfs230. 
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Figure 2.5. Single-chain antibody construct. This is the first open reading frame (ORF) 
design for each scFv construct as cloned in pDB48. There are multiple restriction sites 
built into the gene construct for the ease of switching scFv or other protein effectors in 
and out. These are located on either side of the PelB leader, and the C-terminal tag region 
so either the entire ORF can be moved or the specific protein between them can be 
replaced. Later, these gene constructs were modified to include different promoters and 
leader peptides (Figure 2.14). 
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Pfs48/45 hair     1 CCAACCTGCTGAGCTCGACGTTGTGTTAACACAGTCTCCTGCTTCCTTAGCTGTATCTCT  60  
                    CCA CC GC GAGCTCGACGTTGTGTTAACACAGTCTCCTGCTTCCTTAGCTGTATCTCT      
Pfs48/45 orig     1 CCAGCCGGCCGAGCTCGACGTTGTGTTAACACAGTCTCCTGCTTCCTTAGCTGTATCTCT  60  
 
Figure 2.6. Nucleotide sequence of the 5' end of anti-Pfs48/45 scFv hairpin fix. This 
is the nucleotide sequence of the 5' end of the anti-Pfs48/45 scFv that was modified to 
prevent the formation of possible translation-blocking RNA hairpins. Pfs48/45 hair = 
modified gene sequence. Pfs48/45 orig = original gene sequence. 
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Pfs25 opt      1 ATGAAATATCTGCTGCCGACCGCCGCTGCTGGACTGCTGCTGCTGGCTGCTCAACCTGCT  60  
                 ATGAAATATCTGCTGCCGACCGCCGCTGCTGGACTGCTGCTGCTGGCTGCTCAACCTGCT      
Pfs25 orig     1 ATGAAATATCTGCTGCCGACCGCCGCTGCTGGACTGCTGCTGCTGGCTGCTCAACCTGCT  60  
 
Pfs25 opt     61 ATGGCCGGCGCGCCTCCTTCTTCGATGTTCGCCTCTCTGGGTGACCGTGTATCCCTGTCT 120  
                 ATGGCCGGCGCGCC CC TC TC ATGTT GCCTCTCTGGG GAC G GT    CT TCT      
Pfs25 orig    61 ATGGCCGGCGCGCCACCATCGTCCATGTTTGCCTCTCTGGGAGACAGAGTCAGTCTCTCT 120  
 
Pfs25 opt    121 TGCCGTGCTTCTCAGGACATTCGTGGGAATCTGGATTGGTTCCAACAAAAACCGGGGGGT 180  
                 TG CG GCT  TCAGGACATT G GG AAT T GA TGGTT CA CA AAACC GG GG       
Pfs25 orig   121 TGTCGGGCTAGTCAGGACATTAGAGGTAATTTAGACTGGTTTCAGCAGAAACCAGGTGGA 180  
 
Pfs25 opt    181 ACGATTAAACTGCTGATCTATTCGACCTCTAACCTAAATTCTGGTGTTCCGAGCCGCTTT 240  
                 AC ATTAAACT CTGATCTA TC AC TC AA  TAAATTCTGGTGT CC     G TT       
Pfs25 orig   181 ACTATTAAACTCCTGATCTACTCCACATCCAATTTAAATTCTGGTGTCCCATCAAGGTTC 240  
 
Pfs25 opt    241 AGTGGATCTGGTTCTGGTAGCGACTATTCTCTGACCATCTCTTCACTGGAGAGCGAGGAC 300  
                 AGTGG   TGG TCTGG    GA TATTCTCT ACCATC      CT GAG   GA GA       
Pfs25 orig   241 AGTGGCAGTGGGTCTGGGTCAGATTATTCTCTCACCATCAGCAGCCTAGAGTCTGAAGAT 300  
 
Pfs25 opt    301 CTGGGGGATTATTATTGTCTGCAACGCAACGCTTATCCGCTGACCTTTGGTAGTGGTACA 360  
                  TGGG GA TATTA TGTCT CA CG AA GC TATCC CT AC TT GG    GG ACA      
Pfs25 orig   301 TTGGGAGACTATTACTGTCTACAGCGTAATGCGTATCCTCTCACGTTCGGGTCGGGGACA 360  
 
Pfs25 opt    361 AAACTGGAAATCAAAAGCTCCGGTGGTGGAGGAAGTGGCGGGGGAGGCGGAGGTTCTTCT 420  
                 AA  TGGAAAT AAA  CTC GGTGG GG GG    GGCGG GG GG GG GGTTC TCT      
Pfs25 orig   361 AAGTTGGAAATAAAATCCTCTGGTGGCGGTGGCTCGGGCGGTGGTGGGGGTGGTTCCTCT 420  
 
Pfs25 opt    421 CGTTCAAGCCTGGAAGTTCAACTGGTGGAATCTGGTGGTGGTCTGGTTCAACCGGGTGGT 480  
                  G TC   CCT GA GT CAACTGGTGGA TCTGG GG GG  T GT CA CC GG GG       
Pfs25 orig   421 AGATCTTCCCTCGAGGTGCAACTGGTGGAGTCTGGAGGAGGCTTAGTGCAGCCTGGAGGG 480  
 
Pfs25 opt    481 TCACAGAAACTGAGCTGTGCTGCTAGTGGTTTCACCTTTAGCGATTATGGTATGGCGTGG 540  
                 TC CAGAAACT   CTGTGC GC   TGG TTCAC TT AG GA TA GG ATGGCGTGG      
Pfs25 orig   481 TCCCAGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTGACTACGGAATGGCGTGG 540  
 
Pfs25 opt    541 TTTCGTCAGGCCCCTGGAAAAGGCCCTGAATGGGTGGCGTTTATCAACAATCTGGCCTAT 600  
                 TTTCG CAGGC CC GG AA GG CCTGA TGGGT GC TT AT AA AAT TGGC TAT      
Pfs25 orig   541 TTTCGACAGGCTCCAGGGAAGGGGCCTGAGTGGGTAGCATTCATTAATAATTTGGCATAT 600  
 
Pfs25 opt    601 AGCATCTATTATGCCGACACCGTTACTGGTCGTTTTACGATCTCTCGTGAGAATGCCAAA 660  
                 AG ATCTA TATGC GACAC GT AC GG CG TT AC ATCTCT G GAGAATGCCAA       
Pfs25 orig   601 AGTATCTACTATGCAGACACTGTGACGGGCCGATTCACCATCTCTAGAGAGAATGCCAAG 660  
 
Pfs25 opt    661 AACACCCTGTATCTGGAGATGTCTAGCCTGCGTTCCGAGGATACTACGATGTATTATTGT 720  
                 AACACCCTGTA CTGGA ATG   AG CTG G TC GAGGA AC AC ATGTA TA TGT      
Pfs25 orig   661 AACACCCTGTACCTGGAAATGAGCAGTCTGAGGTCTGAGGACACAACCATGTACTACTGT 720  
 
Pfs25 opt    721 GCCCGTGGTAACCTGTATTATGGGCTGGACTATTGGGGTCAAGGGACAACACTGACTGTT 780  
                 GC  G GG AA CT TA TA GG CT GACTA TGGGG CAAGG AC AC CT AC GT       
Pfs25 orig   721 GCAAGGGGGAATCTTTACTACGGTCTAGACTACTGGGGCCAAGGCACCACTCTCACAGTC 780  
 
Pfs25 opt    781 AGTAGCGCCAAAACAACACCGCCTAGCGTCTATCCGCTGGCTGCGGCCGCACACCATCAT 840  
                       GCCAAAAC ACACC CC    GTCTATCC CTGGC GCGGCCGCACACCATCAT      
Pfs25 orig   781 TCCTCAGCCAAAACGACACCCCCATCTGTCTATCCACTGGCCGCGGCCGCACACCATCAT 840  
 
Pfs25 opt    841 CATCATCATGGCGCCGCTGAACAGAAACTGATCTCGGAGGAAGATCTGAACGGAGCTGCC 900  
                 CATCATCATGGCGCCGCTGAACAGAAACTGATCTCGGAGGAAGATCTGAACGGAGCTGCC      
Pfs25 orig   841 CATCATCATGGCGCCGCTGAACAGAAACTGATCTCGGAGGAAGATCTGAACGGAGCTGCC 900  
 
Pfs25 opt    901 TAA 903  
                 TAA      
Pfs25 orig   901 TAA 903 
Figure 2.7. Nucleotide sequence of the anti-Pfs25 scFv. This is the nucleotide sequence 
of the scFv designed from sequence data of the MRA315 hybridoma line (MR4, 
Manassas, VA). Pfs25 orig = original sequence. Pfs25 opt = optimized gene. 
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Pfs48/45 opt      1 GGCGCGCCACAACCTGCTGAACTGGACATCGTGCTGACCCAATCGCCTGCTTCCCTGGCC  60  
                    GGCGCGCC CA CC GC GA CT GAC T GTG T AC CA TC CCTGCTTCC T GC       
Pfs48/45 orig     1 GGCGCGCCCCAGCCGGCCGAGCTCGACGTTGTGTTAACACAGTCTCCTGCTTCCTTAGCT  60  
 
Pfs48/45 opt     61 GTATCACTGGGACAACGTGCTACCATCTCTTATCGTGCCTCCAAAAGCGTTTCTACGAGT 120  
                    GTATC CTGGG CA  G GC ACCATCTC TA  G GCC  CAAAAG GT   TAC   T      
Pfs48/45 orig    61 GTATCTCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCT 120  
 
Pfs48/45 opt    121 GGTTATTCCTATATGCACTGGAACCAACAAAAACCGGGACAGCCTCCTCGTCTGCTGATT 180  
                    GG TAT   TATATGCACTGGAACCAACA AAACC GGACAGCC CC  G CT CT AT       
Pfs48/45 orig   121 GGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCCAGACTCCTCATC 180  
 
Pfs48/45 opt    181 TATCTGGTGTCGAACCTGGAAAGTGGTGTGCCTGCCCGTTTCTCCGGATCTGGATCTGGG 240  
                    TATCT GT TC AACCT GAA  TGG GT CCTGCC G TTC   GG   TGG TCTGGG      
Pfs48/45 orig   181 TATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGG 240  
 
Pfs48/45 opt    241 ACTGATTTTACCCTGAACATTCACCCTGTGGAAGAGGAAGATGCCGCCACCTATTATTGC 300  
                    AC GA TT ACCCT AACAT CA CCTGTGGA GAGGA GATGC GC ACCTATTA TG       
Pfs48/45 orig   241 ACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGT 300  
 
Pfs48/45 opt    301 CAACACATTCGTGAGCTGACACGCTCTGAAGCTGGTACAAAACTGGAGATCAAAAGCTCT 360  
                    CA CACATT G GAGCT ACACG TC G AG  GG AC AAACTGGA ATCAAA  CTCT      
Pfs48/45 orig   301 CAGCACATTAGGGAGCTTACACGTTC-GGAGGGGGGACCAAACTGGAAATCAAATCCTCT 359  
 
Pfs48/45 opt    361 GGTGGTGGTGGAAGTGGTGGTGGTGGAGGTGGTTCTTCTCGTTCTAGCCTGGAAGTCATG 420  
                    GGTGG GGTGG    GG GGTGGTGG GGTGGTTC TCT G TCT  CCT GA GT ATG      
Pfs48/45 orig   360 GGTGGCGGTGGCTCGGGCGGTGGTGGGGGTGGTTCCTCTAGATCTTCCCTCGAGGTGATG 419  
 
Pfs48/45 opt    421 CTGGTCGAATCTGGTCCTGACCTGGTTAAACCTGGTGCTTCCGTGAAAATTTCCTGTAAA 480  
                    CTGGT GA TCTGG CCTGACCTGGT AA CCTGG GCTTC GTGAA AT TCCTG AA       
Pfs48/45 orig   420 CTGGTGGAGTCTGGACCTGACCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAG 479  
 
Pfs48/45 opt    481 GCGAGCGGGTATTCCTTCATCAACTATTATATGCACTGGGTTAAACAGAGCCACGGCAAA 540  
                    GC    GG TATTC TTCAT AA TA TATATGCACTGGGT AA CAGAGCCA GG AA       
Pfs48/45 orig   480 GCTTCTGGTTATTCATTCATTAATTACTATATGCACTGGGTGAAGCAGAGCCATGGAAAG 539  
 
Pfs48/45 opt    541 TCACTGGAATGGATTGGTCGTGTTAATCCTCAGAATGGCGGTACACGTGACAATCAGAAA 600  
                       CT GA TGGATTGG CG GTTAATCCTCAGAATGG GGTAC  G GACAA CAGAAA      
Pfs48/45 orig   540 AGCCTTGAGTGGATTGGACGAGTTAATCCTCAGAATGGTGGTACTAGGGACAACCAGAAA 599  
 
Pfs48/45 opt    601 TTCAAAGGCAAAGCCATCTTTACGGTGGACAAATCGTTCAATACAGCGTATATGGAACTG 660  
                    TTCAA GGCAA GCCAT TTTAC GT GACAA TC TTCAA ACAGC TATATGGAACT       
Pfs48/45 orig   600 TTCAAGGGCAAGGCCATATTTACTGTAGACAAGTCATTCAACACAGCCTATATGGAACTA 659  
 
Pfs48/45 opt    661 CGTTCACTGACCTCGGAGGACTCTGCTGTGTATTATTGTGCCCGTGAAGTCCACTATGAT 720  
                    CG    CTGAC TC GAGGACTCTGC GT TATTA TGTGC CG GA GT CA TA GA       
Pfs48/45 orig   660 CGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTGCACGAGAGGTTCATTACGAC 719  
 
Pfs48/45 opt    721 GAGGCGCTGGATTATTGGGGTCAAGGCACCTCTGTAACCGTTTCTAGCGCCAAAACAACA 780  
                    GAGGC  TGGA TA TGGGGTCAAGG ACCTC GT ACCGT TC    GCCAAAACAACA      
Pfs48/45 orig   720 GAGGCTTTGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACAACA 779  
 
Pfs48/45 opt    781 CCGCCTAGCGTTACAAGTGCGGCCGC 806  
                    CC CC    GT AC AGTGCGGCCGC      
Pfs48/45 orig   780 CCCCCATCTGTCACTAGTGCGGCCGC 805   
 
Figure 2.8. Nucleotide sequence of the anti-Pfs48/45 scFv. This is the nucleotide 
sequence of the scFv designed from sequence data of the MRA316 hybridoma line (MR4 
Manassas, VA). Pfs48/45 orig = original gene sequence. Pfs48/45 opt = optimized gene 
sequence. 
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Pfs48/45 harm     1 GGCGCGCCCCAGCCCGCGGAACTTGATATCGTCCTAACGCAGTCACCGGCGAGCCTAGCA  60  
                    GGCGCGCCCCAGCC GC GA CT GA  T GT  TAAC CAGTC CC GC   C TAGC       
Pfs48/45 orig     1 GGCGCGCCCCAGCCGGCCGAGCTCGACGTTGTGTTAACACAGTCTCCTGCTTCCTTAGCT  60  
 
Pfs48/45 harm    61 GTATCACTGGGTCAGCGCGCGACCATTTCCTATCGCGCGAGCAAGAGTGTCAGTACGTCA 120  
                    GTATC CTGGG CAG G GC ACCAT TC TA  G GC AGCAA AGTGTCAGTAC TC       
Pfs48/45 orig    61 GTATCTCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCT 120  
 
Pfs48/45 harm   121 GGCTACAGTTACATGCATTGGAATCAACAGAAGCCTGGTCAGCCTCCGCGCCTTCTTATT 180  
                    GGCTA AGTTA ATGCA TGGAA CAACAGAA CC GG CAGCC CC  G CT CT AT       
Pfs48/45 orig   121 GGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCCAGACTCCTCATC 180  
 
Pfs48/45 harm   181 TACTTGGTAAGCAATTTAGAGAGCGGGGTCCCGGCGCGCTTTAGTGGCAGTGGGTCAGGG 240  
                    TA  T GTA  CAA  TAGA    GGGGTCCC GC  G TT AGTGGCAGTGGGTC GGG      
Pfs48/45 orig   181 TATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGG 240  
 
Pfs48/45 harm   241 ACGGATTTTACCCTTAATATTCACCCGGTGGAAGAAGAAGACGCGGCAACCTACTATTGT 300  
                    AC GA TT ACCCT AA AT CA CC GTGGA GA GA GA GC GCAACCTA TA TGT      
Pfs48/45 orig   241 ACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGT 300  
 
Pfs48/45 harm   301 CAGCACATTCGTGAGCTGACACGCTCTGAAGCGGGTACTAAACTGGAGATCAAAAGCTCT 360  
                    CAGCACATT G GAGCT ACACG TC G AG GGG AC AAACTGGA ATCAAA  CTCT      
Pfs48/45 orig   301 CAGCACATTAGGGAGCTTACACGTTC-GGAGGGGGGACCAAACTGGAAATCAAATCCTCT 359  
 
Pfs48/45 harm   361 GGTGGTGGTGGAAGTGGCGGGGGTGGTGGTGGATCATCTCGTTCTAGCCTGGAGGTGATG 420  
                    GGTGG GGTGG    GGCGG GGTGG GGTGG TC TCT G TCT  CCT GAGGTGATG      
Pfs48/45 orig   360 GGTGGCGGTGGCTCGGGCGGTGGTGGGGGTGGTTCCTCTAGATCTTCCCTCGAGGTGATG 419  
 
Pfs48/45 harm   421 CTGGTTGAATCTGGTCCTGATCTGGTGAAACCGGGGGCGTCCGTGAAAATAAGCTGCAAA 480  
                    CTGGT GA TCTGG CCTGA CTGGTGAA CC GGGGC TC GTGAA ATA  CTGCAA       
Pfs48/45 orig   420 CTGGTGGAGTCTGGACCTGACCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAG 479  
 
Pfs48/45 harm   481 GCGTCAGGGTACTCCTTTATCAACTATTACATGCATTGGGTGAAACAGAGCCACGGTAAA 540  
                    GC TC GG TA TC TT AT AA TA TA ATGCA TGGGTGAA CAGAGCCA GG AA       
Pfs48/45 orig   480 GCTTCTGGTTATTCATTCATTAATTACTATATGCACTGGGTGAAGCAGAGCCATGGAAAG 539  
 
Pfs48/45 harm   541 AGCTTAGAATGGATCGGTCGAGTAAACCCGCAGAACGGGGGGACGCGCGATAATCAGAAG 600  
                    AGC T GA TGGAT GG CGAGT AA CC CAGAA GG GG AC  G GA AA CAGAA       
Pfs48/45 orig   540 AGCCTTGAGTGGATTGGACGAGTTAATCCTCAGAATGGTGGTACTAGGGACAACCAGAAA 599  
 
Pfs48/45 harm   601 TTTAAAGGCAAAGCGATATTCACGGTAGATAAATCGTTTAATACGGCGTACATGGAGCTA 660  
                    TT AA GGCAA GC ATATT AC GTAGA AA TC TT AA AC GC TA ATGGA CTA      
Pfs48/45 orig   600 TTCAAGGGCAAGGCCATATTTACTGTAGACAAGTCATTCAACACAGCCTATATGGAACTA 659  
 
Pfs48/45 harm   661 CGGAGCCTGACGTCAGAAGATTCAGCTGTCTACTATTGTGCACGAGAAGTACACTATGAT 720  
                    CG AGCCTGAC TC GA GA TC GC GTCTA TA TGTGCACGAGA GT CA TA GA       
Pfs48/45 orig   660 CGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTGCACGAGAGGTTCATTACGAC 719  
 
Pfs48/45 harm   721 GAAGCGTTGGATTATTGGGGGCAAGGTACCTCCGTCACCGTCAGCTCCGCGAAGACGACG 780  
                    GA GC TTGGA TA TGGGG CAAGG ACCTC GTCACCGTC  CTC GC AA AC AC       
Pfs48/45 orig   720 GAGGCTTTGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACAACA 779  
 
Pfs48/45 harm   781 CCGCCTTCAGTCACGAGTGCGGCCGC 806  
                    CC CC TC GTCAC AGTGCGGCCGC      
Pfs48/45 orig   780 CCCCCATCTGTCACTAGTGCGGCCGC 805   
 
Figure 2.9. Nucleotide sequence of the codon-harmonized anti-Pfs48/45 scFv. This is 
the nucleotide sequence of the scFv designed from sequence data of the MRA316 
hybridoma line (MR4 Manassas, VA). Pfs48/45 orig = original gene sequence. Pfs48/45 
harm  = codon harmonized gene sequence. 
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Pfs230 opt      1 GGCGCGCCACAACCGGCTGAACTGGATATCGTTATGACCCAGAGCCACAAATTCATGAGT  60  
                  GGCGCGCC CA CCGGC GA CT GA AT GT ATGACCCAG   CACAAATTCATG         
Pfs230 orig     1 GGCGCGCCCCAGCCGGCCGAGCTCGACATTGTGATGACCCAGTCTCACAAATTCATGTCC  60  
 
Pfs230 opt     61 ACCAGCGTCCGTGACCGTGTTAGTATCACGTGTAAAGCGTCCCAGGACGTGGGAACAGCG 120  
                  AC    GT  G GAC G GT AG ATCAC TG AA GC    CAGGA GTGGG AC GC       
Pfs230 orig    61 ACATCAGTAAGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGGGTACTGCT 120  
 
Pfs230 opt    121 GTAGCATGGTATCAGCAAAAACCGGGACAGTCACCGAAACTGCTGATCTATTGGGCATCA 180  
                  GTAGC TGGTATCA CA AAACC GG CA TC CC AAACT CTGAT TA TGGGCATC       
Pfs230 orig   121 GTAGCCTGGTATCAACAGAAACCAGGTCAATCTCCTAAACTACTGATTTACTGGGCATCC 180  
 
Pfs230 opt    181 ACACGCCATACTGGTGTGCCGGACCGTTTCACCGGATCTGGAAGCGGAACCGATTTTACC 240  
                  AC CG CA ACTGG GT CC GA CG TTCAC GG   TGGA   GG AC GATTT AC       
Pfs230 orig   181 ACCCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTTCACT 240  
 
Pfs230 opt    241 CTGACGATTTCTAACGTTCAAAGCGAGGACCTGGCCGATTATTTCTGCCAACAGTATAGC 300  
                  CT AC ATT   AA GT CA    GA GAC TGGC GATTATTTCTG CA CA TATAGC      
Pfs230 orig   241 CTCACCATTAGCAATGTGCAGTCTGAAGACTTGGCAGATTATTTCTGTCAGCAATATAGC 300  
 
Pfs230 opt    301 ATCTATCCTCCGCTGACCTTTGGAGCAGGCACAAAACTGGAGCTGAAACACATCCGTGAA 360  
                  ATCTATCCTCCGCT AC TT GG GC GG AC AA CTGGAGCTGAAACACAT CGTGA       
Pfs230 orig   301 ATCTATCCTCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAACACATTCGTGAG 360  
 
Pfs230 opt    361 CTGACCCGTTCTGAAGCAGGCACGAAACTGGAGATTAAAAGCTCGGGTGGTGGAGGTTCG 420  
                  CTGAC CG TCTGAAGC GG AC AAACTGGAGAT AAAAGCTC GGTGGTGG GG          
Pfs230 orig   361 CTGACACGCTCTGAAGCGGGTACTAAACTGGAGATCAAAAGCTCTGGTGGTGGTGGAAGT 420  
 
Pfs230 opt    421 GGAGGCGGGGGAGGTGGTTCTTCTCGTTCTAGCCTGGAGGTGATGCTGGTAGAATCTGGT 480  
                  GG GG GG GG GGTGG TC TCTCGTTCTAGCCTGGAGGTGATGCTGGT GAATCTGGT      
Pfs230 orig   421 GGCGGGGGTGGTGGTGGATCATCTCGTTCTAGCCTGGAGGTGATGCTGGTTGAATCTGGT 480  
 
Pfs230 opt    481 CCTGGTGGTAGCAGTCGTTCTAGTCTGGAAGTCAAACTGGTGGAAAGCGGCGGTGGTCTG 540  
                  CCTGGTGGT  C  T G TCT   CT GA GT AA CTGGTGGA    GG GG GG  T       
Pfs230 orig   481 CCTGGTGGTTCCTCTAGATCTTCCCTCGAGGTGAAGCTGGTGGAGTCTGGGGGAGGCTTA 540  
 
Pfs230 opt    541 GTCCAACCTGGCGGTTCTCTGAAACTGAGTTGTGCTGCCTCTGGTTTCACTTTTAGCAAC 600  
                  GT CA CCTGG GG TC CTGAAACT    TGTGC GCCTCTGG TTCACTTT AG AAC      
Pfs230 orig   541 GTGCAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAAC 600  
 
Pfs230 opt    601 TATTATATGAGCTGGGTTCGCCAGACGCCTGAAAAACGCCTGGAATGGGTTGCCTATATC 660  
                  TATTA ATG   TGGGTTCGCCAGAC CC GA AA  G CTGGA TGGGT GC TA AT       
Pfs230 orig   601 TATTACATGTCTTGGGTTCGCCAGACTCCAGAGAAGAGGCTGGAGTGGGTCGCATACATT 660  
 
Pfs230 opt    661 TCAAGCGGCGGTGGAAGCACTTATTATCCTGACAGCGTCAAAGGCCGTTTTACCATTAGC 720  
                     AG GG GGTGG AGCAC TA TATCC GACAG GT AA GG CG TT ACCAT   C      
Pfs230 orig   661 AGTAGTGGTGGTGGTAGCACCTACTATCCAGACAGTGTGAAGGGTCGATTCACCATCTCC 720  
 
Pfs230 opt    721 CGTGACAATGCCAAAAACACGCTGTATCTGCAGATGTCTAGCCTGAAAAGCGAGGACACA 780  
                   G GACAATGCCAA AACAC CTGTA CTGCA ATG   AG CTGAA    GAGGACACA      
Pfs230 orig   721 AGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCAGTCTGAAGTCTGAGGACACA 780  
 
Pfs230 opt    781 GCCATGTATTATTGTACCCGCCAAGAATGGTCACCATGGTTCGCTTATTGGGGTCAAGGA 840  
                  GCCATGTATTA TGTAC  G CA GAATGGTC CC TGGTT GCTTA TGGGG CAAGG       
Pfs230 orig   781 GCCATGTATTACTGTACAAGACAGGAATGGTCCCCCTGGTTTGCTTACTGGGGCCAAGGG 840  
 
Pfs230 opt    841 ACCCTGGTTACAGTTTCTGCTGCCAAAACCACACCTCCGTCTGTTACAAGTGCGGCCGC 899  
                  AC CTGGT AC GT TCTGC GCCAAAAC ACACC CC TCTGT AC AGTGCGGCCGC      
Pfs230 orig   841 ACTCTGGTCACTGTCTCTGCAGCCAAAACAACACCCCCATCTGTCACTAGTGCGGCCGC 899  
 
Figure 2.10. Nucleotide sequence of the anti-Pfs230 scFv. This is the nucleotide sequence 
of the scFv designed from sequence data of the MRA878 hybridoma line (MR4 Manassas, 
VA). Pfs230 orig = original gene sequence. Pfs230 opt = optimized gene sequence. 
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comp opt      1 GGTGGGGGTGGTTCTATTGTTATGACACAGAGCCCGGCAACGCTGAGTGTAACGCCTGGT  60  
                               ATTGT ATGAC CAGAGCCCGGC AC CTGAG GT AC CC GG       
comp orig     1 ---------------ATTGTGATGACCCAGAGCCCGGCGACCCTGAGCGTGACCCCGGGC  45  
 
comp opt     61 GATAGTGTTAGCCTGAGCTGTCGTGCTTCTCAATCAATCGGGAATAATCTGCACTGGTAT 120  
                GATAG GT AGCCTGAGCTG CG GC    CA    AT GG AA AA CTGCA TGGTAT      
comp orig    46 GATAGCGTGAGCCTGAGCTGCCGCGCGAGCCAGAGCATTGGCAACAACCTGCATTGGTAT 105  
 
comp opt    121 CAGCAAAAAAGCCATGAAAGCCCTCGTCTGCTGATCAAATATGCCAGCCAGTCCATTAGC 180  
                CAGCA AAAAGCCATGAAAGCCC CG CTGCTGAT AAATATGC AGCCAG  CATTAGC      
comp orig   106 CAGCAGAAAAGCCATGAAAGCCCGCGCCTGCTGATTAAATATGCGAGCCAGAGCATTAGC 165  
 
comp opt    181 GGCATTCCTAGCCGTTTTAGTGGCAGTGGTAGTGGTACGGATTTTACCCTGATTATCAAC 240  
                GGCATTCC AGCCG TTTAG GGCAG GG AG GG AC GATTTTACCCTGATTAT AAC      
comp orig   166 GGCATTCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGATTATTAAC 225  
 
comp opt    241 AGCGTGGAAACCGAAGATTTCGGCATGTATTTCTGCCAACAGACCAACATTTGGCCGTAT 300  
                AGCGTGGAAACCGAAGATTT GGCATGTATTT TGCCA CAGACCAACATTTGGCCGTAT      
comp orig   226 AGCGTGGAAACCGAAGATTTTGGCATGTATTTTTGCCAGCAGACCAACATTTGGCCGTAT 285  
 
comp opt    301 ACCTTTGGTGGAGGGACAAAACTGGAGATTAAA------GGTGGTGGCGGTTCTGGTGGT 354  
                ACCTTTGG GG GG AC AAACTGGA ATTAAA      GG GG GGCGG    GG GG       
comp orig   286 ACCTTTGGCGGCGGCACCAAACTGGAAATTAAAAGCAGCGGCGGCGGCGGCAGCGGCGGC 345  
 
comp opt    355 GGTGGA-TCTGGAGGAG-----GCGGTTCTGAAGTTCAGCTGCAGCAAAGTGGAGCCGAG 408  
                GG GG   C G AG AG     GC G    GAAGT CAGCTGCAGCA AG GG GC GA       
comp orig   346 GGCGGCGGCGGCAGCAGCCGCAGCAGCCTGGAAGTGCAGCTGCAGCAGAGCGGCGCGGAA 405  
 
comp opt    409 CTGGTTCGTTCTGGAGCATCAGTTCGCCTGAGTTGTACAGCAAGCGGCTTCAACATCAAA 468  
                CTGGT CG    GG GC    GT CGCCTGAG TG AC GC AGCGGCTT AACAT AAA      
comp orig   406 CTGGTGCGCAGCGGCGCGAGCGTGCGCCTGAGCTGCACCGCGAGCGGCTTTAACATTAAA 465  
 
comp opt    469 GACTATTATATCCATTGGGTGAAACAGCGCCCTGAGCAAGGCCTGGAGTGGATCGGGTGG 528  
                GA TATTATAT CATTGGGTGAAACAGCGCCC GA CA GGCCTGGA TGGAT GG TGG      
comp orig   466 GATTATTATATTCATTGGGTGAAACAGCGCCCGGAACAGGGCCTGGAATGGATTGGCTGG 525  
 
comp opt    529 ATCGACCCTGAAGATGGCGACACCGAATATGCCCCAAAATTCCAAGACAAAGCGACCATG 588  
                AT GA CC GAAGATGGCGA ACCGAATATGC CC AAATT CA GA AAAGCGACCATG      
comp orig   526 ATTGATCCGGAAGATGGCGATACCGAATATGCGCCGAAATTTCAGGATAAAGCGACCATG 585  
 
comp opt    589 ACGGCGGATACAAGCTCTAATACTGCTTATCTGCAACTGCGTCGTCTGACAAGCGAGGAT 648  
                AC GCGGATAC AGC   AA AC GC TATCTGCA CTGCG CG CTGAC AGCGA GAT      
comp orig   586 ACCGCGGATACCAGCAGCAACACCGCGTATCTGCAGCTGCGCCGCCTGACCAGCGAAGAT 645  
 
comp opt    649 ACAGCGGTCTATTATTGTAACACGTGGCGTGGCTATGGAAACTATGACAGCATGGACTAT 708  
                AC GCGGT TATTATTG AACAC TGGCG GGCTATGG AACTATGA AGCATGGA TAT      
comp orig   646 ACCGCGGTGTATTATTGCAACACCTGGCGCGGCTATGGCAACTATGATAGCATGGATTAT 705  
 
comp opt    709 TGGGGTCAGGGAACCTCTGTTACCGTGTCTAGCGCCAAAACAACACCTCCGTCAGTGACT 768  
                TGGGG CAGGG ACC   GT ACCGTG   AGCGC AAAAC AC CC CCG   GTGAC       
comp orig   706 TGGGGCCAGGGCACCAGCGTGACCGTGAGCAGCGCGAAAACCACCCCGCCGAGCGTGACC 765  
 
comp opt    769 AGTGGCGGGGGAGGCTCA 786  
                AG                      
comp orig   766 AGC--------------- 768   
 
Figure 2.11. Nucleotide sequence of the anti-human complement scFv. This is the 
nucleotide sequence of the scFv designed from sequence data of the CRL1757 hybridoma 
line (ATCC, Manassas, VA). The original sequenced gene is aligned to the codon-
optimized gene sequence. Comp orig = original gene sequence. comp opt = optimized 
gene sequence. 
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Figure 2.12. Codon usage. This is the codon usage determination of the original anti-
Pfs48/45 gene sequence as compared to mouse codon usage throughout the genome. The 
frequency of each codon in the sequence is displayed by the bar immediately above it. 
Red is used to indicate those codons occurring at or below a 15% frequency. Such rare 
codons determine where the ribosome slows translation, and they tend to occur in groups. 
Figure continued on next two pages. 
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Figure 2.12 continued. Codon usage. This is the codon usage determination of the 
original anti-Pfs48/45 gene sequence as compared to mouse codon usage throughout the 
genome. The frequency of each codon in the sequence is displayed by the bar 
immediately above it. Red is used to indicate those codons occurring at or below a 15% 
frequency. Such rare codons determine where the ribosome slows translation, and they 
tend to occur in groups. Figure continued on next page. 
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Figure 2.12 continued. Codon usage. This is the codon usage determination of the 
original anti-Pfs48/45 gene sequence as compared to mouse codon usage throughout the 
genome. The frequency of each codon in the sequence is displayed by the bar 
immediately above it. Red is used to indicate those codons occurring at or below a 15% 
frequency. Such rare codons determine where the ribosome slows translation, and they 
tend to occur in groups. 
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Figure 2.13. RNA hairpin-forming region of the anti-Pfs48/45 scFv gene. The 
predicted free energy at the start of the scFv gene was -49.60 kcal/mol, which is far lower 
than the -9 kcal/mol necessary to arrest translation. This hairpin-forming region was 
altered to prevent the formation of these secondary structures. 
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Figure 2.14. Bacterial recombination cloning protocol. The linearized pBBR1MCS-2 
plasmid and bla PCR product with 40 nucleotides of homology to the vector on each end 
(shown in blue) were transformed into MG1655 E. coli competent cells. Native E. coli 
recombination functions combine the two pieces of DNA into a circular plasmid. The 
plasmid was selected by plating on LB medium with ampicillin, guaranteeing activity of 
the inserted bla gene. 
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Figure 2.15. pBBR1MCS-2. The vector pBBR1MCS-2 from (Kovach 1995), which was 
modified to create protein expression vectors. ori = replication origin. oriT = origin of 
transfer. neo = neomycin phosphotransferase, kanamycin resistance. lacZ alpha = β-
galactosidase alpha fragment. 
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Figure 2.16. Plasmid constructs generated. The recombination product that replaced 
lacZ in pBBR1MCS-2 with bla, a new multiple cloning site, and a translational enhancer. 
ori = replication origin. oriT = origin of transfer. neo = neomycin phosphotransferase, 
kanamycin resistance. bla = beta lactamase, ampicillin resistance. enh = translational 
enhancer. Plac = promoter from the lac operon. 
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Figure 2.17. Plasmid constructs generated. The pNB20 plasmid with the lac promoter 
replaced by the nptII promoter. ori = replication origin. oriT = origin of transfer. neo = 
neomycin phosphotransferase, kanamycin resistance. bla = beta lactamase, ampicillin 
resistance. enh = translational enhancer. PnptII = promoter from neomycin 
phosphotransferase. 
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Figure 2.18. Modular scFv gene constructs. The plasmid pNB39 was produced by 
cloning the synthesized anti-Pfs25 scFv gene into plasmid pNB20. Afterwards, both the 
promoter and signal peptide were replaced to create a variety of protein/signal 
combinations using the gene fragments and promoters shown above. The gene fragments 
inserted or removed were directionally cloned using the restriction enzyme sites shown at 
the top of this figure. Ultimately, the gene constructs built and tested included the lac 
promoter with anti-BSA scFv and each leader peptide (Table 2.1 pNB55 and pNB59-66), 
the lac promoter with anti-Pfs25 scFv and the 5 Gluconobacter leader peptides (Table 
2.1 pNB44-48), the nptII promoter with anti-Pfs25 scFv and each leader peptide (Table 
2.1 pNB57 and pNB67-76), and both lac and nptII promoters with gfp (Table 2.1 pNB49 
and pNB50). PnptII = promoter from neomycin phosphotransferase. Plac = promoter 
from the lac operon. 
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Figure 2.19. Protein production by E. coli and P. agglomerans expressing optimized 
scFv secretion constructs using the PelB leader. Protein was detected by an anti-Myc 
antibody from pellet and supernatant fractions of liquid bacteria culture. “pel” = pellet 
and “sup” = supernatant. The predicted size of the positive control HlyA-secreted scFv 
from pBS49 (Bisi 2011) is 60 kDa, and the predicted sizes of the PelB-secreted pNB39 
product, anti-Pfs25 scFv, and the pNB38 product, anti-Pfs230 scFv, are each 
approximately 26 kDa. No protein was detected using either secretion construct, but the 
positive control was present. 
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Figure 2.20. Northern blot of RNA from E. coli strains expressing scFv genes. RNA 
was extracted from induced E. coli cultures expressing various scFv proteins and using 
different promoters. Each culture produced the correct size transcript as predicted. Each 
sample had two lanes, the first lane of each was uninduced sample, and the second was 
induced with IPTG for those plasmids under control of the lac promoter. Samples are: 1.) 
E. coli negative control, 2.) pDB51 anti-BSA scFv potitive control, 3.) pMAL MRA316 
anti-Pfs48/45 scFv 4.) pDB48  anti-Pfs48/45 scFv, 5.) pBBR anti-Pfs48/45 scFv, 6.) 
pBBR anti-Pfs230 scFv clone 22, 7.) pBBR anti-Pfs230 scFv clone 23 
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Figure 2.21. pNB49. The GFP gene was inserted into plasmids pNB20 and pNB51 to 
produce plasmids for the expression of GFP by either the lac promoter (pNB49) or the 
nptII promoter (pNB50). ori = replication origin. oriT = origin of transfer. neo = 
neomycin phosphotransferase, kanamycin resistance. gfp = green fluorescent protein. enh 
= translational enhancer. Plac = promoter from the lac operon. 
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Figure 2.22. pNB50. Expression vector with gfp driven by the promoter from neomycin 
phosphotransferase. ori = replication origin. oriT = origin of transfer. neo = neomycin 
phosphotransferase, kanamycin resistance. gfp = green fluorescent protein. enh = 
translational enhancer. Plac = promoter from the lac operon. 
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A.      B.  
Figure 2.23. Expression of GFP by Asaia bogorensis. Asaia containing GFP expression 
plasmid constructs were viewed under a fluorescence microscope under excitation 
wavelength light of 395 nm. A.) Asaia transformed with the pNB49 plasmid, which has 
the gfp gene transcribed by the lac promoter, showed no fluorescence signal. B.) Asaia 
transformed with the pNB50 plasmid, which has the gfp gene transcribed by the nptII 
promoter, showed a strong fluorescence signal. 
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Figure 2.24. Protein production of Asaia expressing heterologous scFv secretion 
constructs using leader peptides from related species. Western blot detection of 
protein from Asaia strains containing scFv secretion constructs with Gluconobacter and 
Gluconacetobacter leader peptides. “pel” = pellet and “sup” = supernatant. The predicted 
sizes of the scFv constructs were 26 kDa. No protein was detected in pellet or supernatant 
fractions. 
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Figure 2.25. Protein production of Asaia expressing heterologous scFv secretion 
constructs using leader peptides from related species. Western blot detection of 
protein from Asaia strains containing scFv secretion constructs with Gluconobacter and 
Gluconacetobacter leader peptides. “pel” = pellet and “sup” = supernatant. (+) = anti-
BSA scFv positive control protein expressed in E. coli, ~33kDa. The predicted sizes of 
the other scFv constructs were ~26 kDa. No protein was detected in pellet or supernatant 
fractions. 
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Table 2.1. Plasmids used in this study 
Plasmid Relevant Characteristics Source 
pBBR1MCS-2 KanR, pBBR origin, oriT, MCS, used for plasmid construction Kovach 1995 
pSC189 AmpR; used to amplify the beta lactamase (bla) gene Chiang 2002 
pHM2-GFP KanR; used to amplify the neomycin phosphotransferase (nptII) promoter Favia 2007 
pNB20 KanR; pBBR1MCS-2 w/ beta-lactamase and translational enhancer this study 
pNB51 KanR; pNB20 w/ promoter region changed to PnptII this study 
MRA315 AmpR; codon optimized MRA315 anti-Pfs25 scFv as synthesized this study 
MRA316 AmpR; codon harmonized MRA316 anti-Pfs48/45 scFv as synthesized this study 
MRA316opt AmpR; codon optimized  MRA316 anti-Pfs48/45 scFv as synthesized this study 
MRA878 AmpR; codon optimized  MRA878 anti-Pfs230 scFv as synthesized this study 
IgG scFv AmpR; codon optimized anti-human IgG scFv as synthesized this study 
pNB20 KanR; pBBR1MCS-2 with a novel cloning site this study 
pNB21 KanR; pNB20 with an AscI restriction site added for cloning purposes. this study 
pDB48 GentR; pelB-AscI-6His-myc-STOP cloned in pMQ64 MCS Bisi 2011 
pDB51 GentR;  pelB-Anti-BSA scFv (positive control for experiments) Bisi 2011 
pDB49 AprR;  hlyA-Anti-BSA scFv (positive control for experiments) Bisi 2011 
pVDL9.3 CamR; production of hlyB and hlyD transporters (Tzschaschel  
1996) 
pNB39 KanR; pNB20 with anti-Pfs25 scFv insert this study 
pNB38 KanR; pNB20 with anti-Pfs230 scFv insert this study 
pNB37 KanR; pNB20 with anti-Pfs48/45 scFv insert this study 
pNB44 KanR; anti-Pfs25 scFv with G. oxydans endonuclease I signal peptide  this study 
pNB45 KanR; anti-Pfs25 scFv with G. oxydans endonuclease II signal peptide  this study 
pNB46 KanR; anti-Pfs25 scFv with G. oxydans poly phosphate porin signal peptide  this study 
pNB47 KanR; anti-Pfs25 scFv with G. oxydans aminopeptidase signal peptide  this study 
pNB48 KanR; anti-Pfs25 scFv with G. oxydans acid phosphatase signal peptide  this study 
pNB49 KanR; pNB20 with Plac GFP this study 
pNB50 KanR; pNB20 with PnptII GFP this study 
pNB55 KanR; pNB39 with anti-BSA scFv this study 
pNB57 KanR; pNB51 with   PnptII  G. diazotrophicus levansucrase signal, Pfs25 scFv this study 
pNB59 KanR; pNB55 with G. diazotrophicus organic solvent tolerance signal peptide this study 
pNB60 KanR;  pNB55 with G. diazotrophicus poly phosphate porin signal peptide this study 
pNB61 KanR;  pNB55 with G. diazotrophicus endonuclease II signal peptide this study 
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pNB62 KanR;  pNB55 with G. diazotrophicus aminopeptidase signal peptide this study 
pNB63 KanR;  pNB55 with G. diazotrophicus phospholipase signal peptide this study 
pNB64 KanR;  pNB55 with G. diazotrophicus acid phosphatase signal peptide this study 
pNB65 KanR;  pNB55 with G. diazotrophicus endonuclease I signal peptide this study 
pNB66 KanR;  pNB55 with G. diazotrophicus levansucrase signal peptide this study 
pNB67 KanR; pNB57 with G. diazotrophicus organic solvent tolerance signal peptide this study 
pNB68 KanR; pNB57 with G. oxydans aminopeptidase signal peptide this study 
pNB69 KanR; pNB57 with G. ozydans endonuclease I signal peptide this study 
pNB70 KanR; pNB57 with G. oxydans endonuclease II signal peptide this study 
pNB71 KanR; pNB57 with G. diazotrophicus aminopeptidase M28 signal peptide this study 
pNB72 KanR; pNB57 with G. diazotrophicus polyphosphate porin signal peptide this study 
pNB73 KanR; pNB57 with G. diazotrophicus invasion-associated locus B signal peptide this study 
pNB74 KanR; pNB57 with G. diazotrophicus phospholipase C signal peptide this study 
pNB75 KanR; pNB57 with G. diazotrophicus glycoside signal peptide this study 
pNB76 KanR; pNB57 with G. diazotrophicus putative aminopeptidase signal peptide this study 
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Table 2.2. Oligonucleotides used in this study 
Oligo Sequence 5' - 3' Purpose 
 Vκ 5' Sense Primers  
MSCVK-1 GGG CCC AGC CGG CCG AGC TCG AYA TCC AGC TGA CTC AGC 
C 
antibody V-region 
amplification 
(Barbas 2001) 
MSCVK-2 GGG CCC AGC CGG CCG AGC TCG AYA TTG TTC TCW CCC AGT C '' 
MSCVK-3 GGG CCC AGC CGG CCG AGC TCG AYA TTG TGM TMA CTC AGT 
C 
'' 
MSCVK-4 GGG CCC AGC CGG CCG AGC TCG AYA TTG TGY TRA CAC AGT C '' 
MSCVK-5 GGG CCC AGC CGG CCG AGC TCG AYA TTG TRA TGA CMC AGT 
C 
'' 
MSCVK-6 GGG CCC AGC CGG CCG AGC TCG AYA TTM AGA TRA MCC AGT 
C 
'' 
MSCVK-7 GGG CCC AGC CGG CCG AGC TCG AYA TTC AGA TGA YDC AGT 
C 
'' 
MSCVK-8 GGG CCC AGC CGG CCG AGC TCG AYA TYC AGA TGA CAC AGA 
C 
'' 
MSCVK-9 GGG CCC AGC CGG CCG AGC TCG AYA TTG TTC TCA WCC AGT 
C 
'' 
MSCVK-10 GGG CCC AGC CGG CCG AGC TCG AYA TTG WGC TSA CCC AAT 
C 
'' 
MSCVK-11 GGG CCC AGC CGG CCG AGC TCG AYA TTS TRA TGA CCC ART C '' 
MSCVK-12 GGG CCC AGC CGG CCG AGC TCG AYR TTK TGA TGA CCC ARA C '' 
MSCVK-13 GGG CCC AGC CGG CCG AGC TCG AYA TTG TGA TGA CBC AGK 
C 
'' 
MSCVK-14 GGG CCC AGC CGG CCG AGC TCG AYA TTG TGA TAA CYC AGG 
A 
'' 
MSCVK-15 GGG CCC AGC CGG CCG AGC TCG AYA TTG TGA TGA CCC AGW 
T 
'' 
MSCVK-16 GGG CCC AGC CGG CCG AGC TCG AYA TTG TGA TGA CAC AAC 
C 
'' 
MSCVK-17 GGG CCC AGC CGG CCG AGC TCG AYA TTT TGC TGA CTC AGT C '' 
 VΚ 3' REVERSE PRIMERS, SHORT LINKER  
MSCJK12-B GGA AGA TCT AGA GGA ACC ACC TTT KAT TTC CAG YTT GGT 
CCC 
'' 
MSCJK4-B GGA AGA TCT AGA GGA ACC ACC TTT TAT TTC CAA CTT TGT 
CCC 
'' 
MSCJK5-B GGA AGA TCT AGA GGA ACC ACC TTT CAG CTC CAG CTT GGT 
CCC 
'' 
 VΚ 3' REVERSE PRIMERS, LONG LINKER  
MSCJK12-BL GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC 
ACC GCC ACC AGA GGA TTT KAT TTC CAG YTT GGT CCC 
'' 
MSCJK4-BL GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC '' 
 86 
ACC GCC ACC AGA GGA TTT TAT TTC CAA CTT TGT CCC 
MSCJK5-BL GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC 
ACC GCC ACC AGA GGA TTT CAG CTC CAG CTT GGT CCC 
'' 
 VΛ 5' SENSE PRIMER  
MSCVL-1 GGG CCC AGC CGG CCG AGC TCG ATG CTG TTG TGA CTC AGG 
AAT C 
'' 
 VΛ 3' REVERSE PRIMER, SHORT LINKER  
MSCJL-B GGA AGA TCT AGA GGA ACC ACC GCC TAG GAC AGT CAG TTT 
GG 
'' 
  
VΛ 3' REVERSE PRIMER, LONG LINKER 
 
MSCJL-BL GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC 
ACC GCC ACC AGA GGA GCC TAG GAC AGT CAG TTT GG 
'' 
 VΗ 5' SENSE PRIMERS  
MSCVH1 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR MAG CTT CAG 
GAG TC 
'' 
MSCVH2 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTB CAG CTB CAG 
CAG TC 
'' 
MSCVH3 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG CTG AAG 
SAS TC 
'' 
MSCVH4 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAR CTG CAA 
CAR TC 
'' 
MSCVH5 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAG CTB CAG 
CAR TC 
'' 
MSCVH6 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAR CTG CAG 
CAG TC 
'' 
MSCVH7 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAC GTG AAG 
CAG TC 
'' 
MSCVH8 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAS STG GTG 
GAA TC 
'' 
MSCVH9 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AWG YTG GTG 
GAG TC 
'' 
MSCVH10 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG SKG GTG 
GAG TC 
'' 
MSCVH11 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAM CTG GTG 
GAG TC 
'' 
MSCVH12 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG CTG ATG 
GAR TC 
'' 
MSCVH13 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAR CTT GTT 
GAG TC 
'' 
MSCVH14 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR AAG CTT CTC 
GAG TC 
'' 
MSCVH15 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAR STT GAG 
GAG TC 
'' 
MSCVH16 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTT ACT CTR AAA 
GWG TST G 
'' 
 87 
MSCVH17 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAA CTV CAG 
CAR CC 
'' 
MSCVH18 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAC TTG GAA 
GTG TC 
'' 
MSCVH19 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG GTC ATC 
GAG TC 
'' 
 VΗ 3' REVERSE PRIMERS  
MSCG1ab-B CCT GCG GCC GCA CTA GTG ACA GAT GGG GST GTY GTT TTG 
GC 
antibody V gene 
amplification and 
cloning with NotI 
restriction site 
MSCG3-B CCT GCG GCC GCA CTA GTG ACA GAT GGG GCT GTT GTT GT '' 
MSCM-B CCT GCG GCC GCA CTA GTG ACA TTT GGG AAG GAC TGA CTC 
TC 
'' 
 OVERLAP EXTENSION PRIMERS  
RSC-F sense GAG GAG GAG GAG GAG GAG GCG GGG CCC AGC CGG CCG AGC 
TC 
'' 
RSC-B reverse GAG GAG GAG GAG GAG GAG CCT GCG GCC GCA CTA GTG '' 
pBBR rec F ggaattgtgagcggataacaatttcacacaggaaacagctTTAACTTTAAGAAGG
AGactgCATATGagtattcaacatttccg 
bacterial 
recombination to 
generate pNB20 
pBBR rec R taacaaaaatttaacgcgaattttaacaaaatattaacgcGAATTCggatccGGC
CGGCCcctgcaggTTAATTAAggtctgacagttaccaatgc 
'' 
PnptII F NsiI TAatgcatAACCGGAATTGCCAGCTGGG nptII promoter 
directional cloning 
in pNB51 
PnptII R 
NdeI 
taCATATGTTTTTCCTCCTTATAAAGTTAATC '' 
Gd 
levansucrase F 
NdeI 
TACATATGGCGCATGTACGCCGAAAAG Gluconacetobacter 
diazotrophicus leader 
cloning 
Gd 
levansucrase R 
AscI 
TAGGCGCGCCATTCCCTTGCGCCAGCGCAC '' 
Gd TrbJ F 
NdeI 
TACATATGAAATACGGCATGCGTCTTTATG '' 
Gd TrbJ R 
AscI 
TAGGCGCGCCGTTCGCACCGTCATACAC '' 
Gd 
aminopeptidas
e F NdeI 
TACATATGCGTTCCATGCCCC '' 
Gd 
aminopeptidas
e R AscI 
TAGGCGCGCCCGGCGCCCACGGGGAC '' 
Gd IalB F 
NdeI 
TACATATGAAACTTTTCACTCCTG '' 
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Gd IalB R 
AscI 
TAGGCGCGCCATGCGTCGAGGCCTGGGCCAC '' 
Gd OSP F 
NdeI 
TACATATGATGCCGATCCTGATGTC '' 
Gd OSP R 
AscI 
TAGGCGCGCCCTGGACCTGCGCATGGG '' 
Gd 
phospholipase 
C F NdeI 
TACATATGGCCACACGCAGAGATTTC '' 
Gd 
phospholipase 
C R AscI 
TAGGCGCGCCATTCGGTGCAATGGCGAAAG '' 
Gd Peptidase 
M28 F NdeI 
TACATATGCCCCCCCATCGTC '' 
Gd Peptidase 
M28 R AscI 
TAGGCGCGCCCCACGGGGACGCGGCATGCG '' 
Gd glycoside 
F NdeI 
TACATATGACCGGGTTCCGTCCATC '' 
Gd glycoside 
R AscI 
TAGGCGCGCCCAGACCGCCGGCCGAAG '' 
GFP F NdeI TACATATGAGTAAAGGAGAAG gfp gene cloning 
GFP R EcoRI TAGAATTCCTATTTGTATAGTTCATCCATGCC '' 
GluconoEndon
uc 1-5’ NdeF 
ATCATATGCGCTTTCTGATTGCCGTTTTAC 
 
Gluconobacter 
oxydans leader 
cloning 
GluconoERnd
onuc1 leader 
Asc R 
ATGGCGCGCCTGCGATGGCTGGAGATGTG 
 
'' 
GluconoAPho
s 5’ NdeF 
ATCATATGTCCATGAAGCGCGTACAAC 
 
'' 
GluconoAPho
s leader AscR 
ATGGCGCGCCCGCAGAAGAAGACGCTGCCAGCC 
 
'' 
GluconoAmPe
p 5’ NdeF 
ATCATATGACACAGAAGACATTCCC 
 
'' 
GluconoAmPe
p leader AscR 
ATGGCGCGCCGGCATGACCGGTGACCGGAG 
 
'' 
GluconoEndon
uc 2 5’ NdeF 
ATGATATGAATTTCCTGTCGTATCTTC 
 
'' 
GluconoEndon
uc2 leader 
AscR 
ATGGCGCGCCAGCCTGCGCCGGAAGCACGA  
 
'' 
GluconoPolyP
hosPorin 5’ 
NdeF 
ATCATATGGTTTTTTCTTTCCGCCG 
 
'' 
GluconoPolyP
hosPorin 
leader AscR 
ATGGCGCGCCGGCCCGGGCATGGCCACAAAGAG 
 
'' 
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Table 2.3. Bacterial strains used in this study 
Strain Genotype Purpose 
E. coli K-12 
MG1655 
F- lambda- ilvG- rfb-50 rph-1 (McKenzie 
2006) 
bacterial 
recombination 
E. coli Top10 F' F´{lacIq, Tn10(TetR)} mcrA Δ(mrr-hsdRMS-
mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(ara leu) 7697 galU galK rpsL 
(StrR) endA1 nupG (from life technologies 
#C3030-03) (Durfee 2008) 
molecular cloning 
and plasmid 
propagation 
Asaia SF2.1 wild type (from Guido Favia, University of 
Camerino, Italy) (Favia 2007) 
gene expression, 
paratransgenesis 
Pantoea 
agglomerans 
wild type (Gavini 1989) gene expression, 
paratransgenesis 
Gluconobacter 
oxydans 
wild type (ATCC cat# 33448) (Angyal 1996) amplification of 
leader peptides 
Gluconacetobacter 
diazotrophicus 
wild type (ATCC cat# 49039) (Yamada 1997) amplification of 
leader peptides 
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Table 2.4. Secretion signals cloned from acetic acid bacteria 
Protein leader sequence Path Species 
acid phosphatase MSMKRVQRAKSGLAVLLSGSILLPSVGLAASSSA Sec G. oxydans 
aminopeptidase MTQKTFPRRSLFLATVLTAVLLAPVTGHA Sec G. oxydans 
endonuclease I MRFLIAVLLACTSPAIA Sec G. oxydans 
endonuclease II MNFLSYLPICALLVVLPAQA Sec G. oxydans 
polyphosphate porin MVFSFRRTTALLATTTLVSLLPLCGHARA Sec G. oxydans 
TrbJ MKYGMRLYVTIGVISITIISSARAQWAVYDGAN Sec G. diazotrophicus 
phospholipase C MATRRDFLKYALLSGAAGGASLLSDPIRRAFAIAPN Tat G. diazotrophicus 
organic solvent 
tolerance 
MMPILMSRRLFRPARGQRSQARGTLLAAGLLGSTF
LGAVIQVHRAHAQVQ 
Sec G. diazotrophicus 
peptidase M28 MPPHRPRAALVSAMLLAAASPAHAASPW Sec G. diazotrophicus 
levansucrase MAHVRRKVATLNMALAGSLLMVLGAQSALAQGN Sec G. diazotrophicus 
invasion-associated 
locus B 
MKLFTPVPLVAVIGGAAAALTLGVAYSGHSGPGVA
QASTH 
Sec G. diazotrophicus 
glycoside hydrolase MTGFRPSHVLVIACLVCLVMAGGAARAASAGGL Sec G. diazotrophicus 
aminopeptidase 
m28 
MRSMPPHRPRAALVSAMLLAAASPAHAASPWAP Sec G. diazotrophicus 
Secretion signals were cloned in-frame with expression constructs by PCR amplification 
with primers and directional cloning by restriction enzyme digestion and insertion into 
plasmids. Secretion signal pathways identified using PRED-TAT 
(http://www.compgen.org/tools/PRED-TAT/). 
 91 
Chapter 3 
Fighting malaria with engineered symbiotic bacteria from 
vector mosquitoes 
 
Sibao Wang, Anil K. Ghosh, Nicholas Bongio, Kevin A. Stebbings, David J. Lampe, 
and Marcelo Jacobs-Lorena 
 
Reprinted from Proceedings of the National Academy of Sciences, Vol.109, No. 31, 
Sibao Wang, Anil K. Ghosh, Nicholas Bongio, Kevin A. Stebbings, David J. Lampe, and 
Marcelo Jacobs-Lorena, Fighting malaria with engineered symbiotic bacteria from vector 
mosquitoes. pages 12734-12739., Copyright (2012) with permission from PNAS. 
 
CHAPTER 3 ATTRIBUTIONS  
 I performed the molecular cloning of hemolysin secretion constructs and tested 
them for secretion by western blot. 
 Kevin A. Stebbings, an undergraduate in Dr. Lampe's laboratory, was mentored 
by me and contributed to the molecular cloning and testing of secretion 
constructs. 
 Sibao Wang, a post-doc in Dr. Marcelo Jacobs-Lorena's laboratory, conducted 
transmission-blocking assays. 
 Anil K. Ghosh, a post-doc in Dr. Marcelo Jacobs-Lorena's laboratory, performed 
the immunofluorescence assays. 
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INTRODUCTION 
 Malaria is one of the most lethal infectious diseases. Close to half of the 
population of the world is at risk, about 300–500 million contract the disease annually, 
and about 1.2 million people die of malaria every year (Murray 2012). Continuous 
emergence of mosquito insecticide resistance and parasite drug resistance, combined with 
the lack of an effective malaria vaccine, severely limits our ability to counteract this 
intolerable burden (Enayati 2010, Trape 2011). New weapons to fight the disease are 
urgently needed. 
 Unlike the other two major infectious diseases (AIDS and tuberculosis) that are 
transmitted directly from person to person, transmission of Plasmodium, the causative 
agent of malaria, strictly depends on the completion of a complex developmental cycle in 
vector mosquitoes (Ghosh 2000). A mosquito may ingest on the order of 103 to 104 
gametocytes from an infected human that quickly differentiate into male and female 
gametes that mate to produce zygotes, which, in turn, differentiate into 102 to 103 motile 
ookinetes. Ookinetes then migrate within the blood bolus until they reach the midgut 
epithelium, where they then traverse and differentiate into oocysts. Upon maturation, 
each oocyst releases thousands of sporozoites into the hemocoel, followed by invasion of 
the mosquito salivary glands. The transmission cycle is completed when the infected 
mosquito bites the next vertebrate host and delivers some of the sporozoites with the 
saliva (Whitten 2006). Clearly, a severe bottleneck occurs during the mosquito midgut 
stages of parasite development: even in areas of high transmission, mosquitoes typically 
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carry five or fewer oocysts (Whitten 2006). This bottleneck makes the mosquito midgut a 
prime target for intervention (Eappen 2004, Drexler 2008). 
 One option to interfere with parasite transmission is to genetically modify 
mosquitoes for midgut expression of “effector genes” that inhibit parasite development. 
Past evidence suggests that this strategy works successfully in the laboratory (Ito 2002, 
Isaacs 2011, Marrelli 2007, Corby-Harris 2010). However, one unresolved challenge is 
how to drive transgenes into wild mosquito populations. Various genetic drive 
mechanisms have been proposed to accomplish this goal (Chen 2007, Windbichler 2011), 
but these are technically very challenging, and it is not clear in what time frame they will 
succeed. An important additional challenge faced by genetic drive approaches, in general, 
is that anopheline vectors frequently occur in the field as reproductively isolated 
populations, thus posing a barrier for gene flow from one population to another. 
 An alternative strategy to deliver effector molecules is to engineer symbiotic 
bacteria from the mosquito midgut microbiome to produce the interfering proteins 
(paratransgenesis) (Durvasula 1997). A key strategic consideration is that the mosquito 
microbiome (Pumpuni 1996, Straif 1998) resides in the same compartment where the 
most vulnerable stages of malaria parasite development occur (Drexler 2008). Moreover, 
bacteria numbers increase dramatically (hundreds- to thousands-fold) after ingestion of a 
blood meal (Pumpuni 1996), and output of anti-Plasmodium effector molecules from 
engineered bacteria can be expected to increase proportionally. 
 Paratransgenesis has shown promise for the control of other insect-borne disease 
(Durvasula 1997). Chagas disease caused by the parasitic protozoan Trypanosoma cruzi 
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is transmitted by the triatomid bug, Rhodnius prolixus. In proof-of-concept experiments, 
an obligate commensal Gram-positive bacterium was genetically modified to secrete 
cecropin A, a peptide that kills Trypanasoma cruzi, making the bug refractory to the 
parasite (Durvasula 1997). Our previous study using the rodent malaria parasite 
Plasmodium berghei and the Anopheles stephensi vector mosquito suggested that 
recombinant Escherichia coli expressing on their surface either a dimer of the salivary 
gland and midgut peptide 1 (SM1) or a modified phospholipase reduced oocyst formation 
(Riehla 2007). Yoshida et al. 2001 also showed that recombinant E. coli expressing a 
single-chain immunotoxin significantly reduces P. berghei oocyst density in A. stephensi 
mosquitoes. One limitation of these earlier experiments is that they used E. coli, an 
attenuated laboratory bacterium that survives poorly in the mosquito gut (Riehla 2007). A 
second limitation was that the recombinant effector molecules either remained attached to 
the bacterial surface (Riehla 2007) or formed an insoluble inclusion body within the 
bacterial cells (Yoshida 2001), thus preventing diffusion of the effector molecules to their 
parasite or mosquito midgut targets. 
 Here, we describe a substantially improved strategy to deliver effector molecules 
by engineering a natural symbiotic bacterium Pantoea agglomerans(previously known as 
Enterobacter agglomerans) to secrete antimalaria proteins in the mosquito midgut. We 
found that the development of the human parasite Plasmodium falciparum and the rodent 
parasite P. berghei in the mosquito was efficiently suppressed by up to 98%. 
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MATERIALS AND METHODS 
Mosquito and Parasite Maintenance. 
 We used two mosquitoes (A. gambiae Keele strain and A. stephensi Dutch strain) 
and two parasites P. falciparum strain NF54 and P. berghei ANKA 2.34. Mosquitoes and 
parasites were maintained as described in SI Text. 
 
Bacterial Introduction into Mosquitoes via Sugar Meals. 
P. agglomerans were introduced into mosquitoes by feeding them with cotton pads 
soaked with a bacteria suspension (109 cells/mL) in 5% (wt/vol) sugar as described in SI 
Text. 
 
Plasmid Construction and Protein Expression. 
The synthesized DNA encoding anti-Plasmodium effector molecules were optimized 
with the P. agglomerans preferred codon usage. Plasmid construction, bacterial genetic 
transformation, and verification of protein secretion using Western blot analysis were 
performed as described in SI Text. 
 
P. falciparum Transmission-Blocking Assays. 
 Recombinant bacterial suspensions [1 × 109 cells/mL of 5% (wt/vol) sugar] 
soaked in cotton pads were fed to 2-d-old A. gambiae for 24 h, which were then starved 
for 8 h and allowed to feed for 30 min on a P. falciparum NF54 gametocyte–containing 
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blood meal. Fully engorged mosquitoes were separated within 24 h. Success of parasite 
infection was evaluated by counting oocyst numbers at 8 d postinfection. 
 
P. berghei Transmission-Blocking Assays.
 Different groups of bacteria-fed mosquitoes were allowed to feed on the same P. 
berghei–infected mouse for 6 min and then maintained at 19 °C at 80% relative humidity. 
Success of parasite infection was evaluated by counting oocyst numbers at 14 d 
postinfection. 
 
Immunofluorescence Assays. 
 Recombinant P. agglomerans bacteria expressing (SM1)2 were introduced to 2-d-
old A. gambiae females via sugar meal (1 × 109cells/mL) for 24 h. The mosquitoes were 
then allowed to feed on a noninfected mouse for 30 min. Midgut sheets were prepared at 
18 and 24 h after blood feeding and fixed overnight in 4% (wt/vol) paraformaldehyde at 4 
°C, washed in PBS, and blocked with 4% (wt/vol) BSA at 4 °C. The gut sheets were then 
probed with anti-SM1 peptide antibody (1:1,000), followed by Alexa Fluor–conjugated 
goat anti-rabbit IgG (Sigma; 1:1,000). Nuclei were stained with 4′,6-diamidino-2-
phenylindole (DAPI). 
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RESULTS 
Administration of Transgenic P. agglomerans via Sugar Meals and Rapid 
Proliferation After a Blood Meal. 
 P. agglomerans is a natural symbiotic bacterium whose occurrence is widespread 
in anopheline mosquitoes (Pumpuni 1996, Straif 1998, Riehle 2007). Our strain was 
originally isolated from midguts of an Anopheles gambiae laboratory colony and 
subsequently further selected for improved adaptation to the A. gambiae and A. stephensi 
midgut environments (Riehle 2007). To examine recombinant P. agglomerans 
colonization and survival in the mosquito midgut, we transformed P. agglomerans with a 
highly stable plasmid pPnptII:gfp (Stiner 2002) that expresses green fluorescent protein 
(GFP). We found the GFP-tagged bacteria were easily administered to mosquito midguts 
via sugar meals (Figure S1). Midguts of female mosquitoes that had been fed GFP-
tagged P. agglomerans became strongly fluorescent after ingestion of a blood meal 
(Figure 3.1 A and B), indicating rapid bacteria proliferation. To quantify the dynamics 
of bacteria numbers, mosquitoes that had been fed GFP-tagged P. agglomerans were 
dissected at different times after a blood meal and midgut homogenates were plated on 
selective kanamycin-containing plates. Bacteria numbers increased dramatically by more 
than 200-fold during the first 2 d after a blood meal (Figure 3.1C). Thereafter, bacteria 
numbers decreased to about prefeeding levels, presumably because the majority was 
excreted together with the remnants of blood digestion. 
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Recombinant P. agglomerans Strains Efficiently Secrete Anti-Plasmodium Effector 
Molecules. 
 As mentioned previously, for maximum effectiveness of intervention, it is crucial 
that the effector molecules be secreted from the engineered bacteria to allow diffusion to 
the parasite or mosquito midgut targets. We used the E. coli hemolysin (Hly)A system 
(Fernandez 2000, Tzschaschel 1996, Fernandez 2001) to promote protein secretion from 
P. agglomerans. This type 1 secretion system requires three components to form a 
membrane pore (inner membrane components HlyB and HlyD and outer membrane 
component TolC). The HlyB–HlyD complex recognizes the C-terminal secretion signal 
of HlyA to guide direct export of HlyA-fusion proteins from the bacterial cytoplasm into 
the extracellular environment bypassing the periplasmic space (Figure S2A). 
 We used the HlyA secretion system to test the following anti-Plasmodium 
effector molecules (Table S.1): (i) two copies of the 12-aa SM1 peptide [(SM1)2], which 
binds to the luminal surface of the mosquito midgut and blocks ookinete midgut invasion 
(Ghosh 2001); (ii) a mutant phospholipase mPLA2 that inhibits ookinete invasion, 
probably by modifying the properties of the midgut epithelial membrane (Moreira 2002); 
(iii) a single-chain immunotoxin (pbs21scFv-Shiva1), composed of a single-chain 
monoclonal antibody (scFv) targeting the P. berghei major ookinete surface protein 
pbs21 and linked to the lytic peptide Shiva1 (Yoshida 2001); (iv) a chitinase propeptide 
(Pro) that inhibits the enzyme and blocks ookinete traversal of the mosquito peritrophic 
matrix (Bhatnagar 2003); (v) a synthetic antiparasitic lytic peptide, Shiva1 (Jaynes 1988); 
(vi) a scorpion (Pandinus imperator) antimalaria lytic peptide, scorpine, which has 
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hybrid properties of the lytic peptides cecropin and defensin (Conde 2000); (vii) four 
copies of Plasmodium enolase–plasminogen interaction peptide (EPIP) [(EPIP)4] that 
inhibits mosquito midgut invasion by preventing plasminogen binding to the ookinete 
surface (Ghosh 2011); and (viii) a fusion peptide composed of Pro and EPIP (Pro:EPIP). 
All genes were synthesized with the P. agglomerans preferred codon usage (Table S2) 
and cloned in frame with an E-tagged C-terminal secretion signal domain of HlyA in a 
high-copy expression vector (Figures S2B and S3). The resulting plasmids were 
individually transformed into P. agglomerans together with the low-copy plasmid 
pVDL9.3 coding for HlyB and HlyD (Fernandez 2000). Constitutive expression and 
secretion of a fusion protein of the predicted size by each recombinant P. agglomerans 
strain were verified by Western blot analysis (Figure 3.2A). The smaller sized peptides 
[(EPIP)4, Shiva1, and Pro:EPIP] were more abundant in the culture supernatant than the 
larger sized proteins (mPLA2 and pbs21fsFv-Shiva1) (Figure 3.2A). The recombinant P. 
agglomerans strain expressing (EPIP)4 had the highest secretion level, appearing to be 
more efficient than the recombinant strain carrying the parental E-HlyA plasmid (Figure 
3.2A). In vivo secretion of anti-Plasmodium effector molecules in the mosquito midgut 
was confirmed by use of immunofluorescence assays that detected the binding of the 
bacteria-produced SM1 peptide to the midgut epithelial surface (Figure 3.2B). Control 
midguts from mosquitoes fed on recombinant P. agglomerans expressing E-tagged HlyA 
alone (HlyA) had no fluorescence above background. 
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Recombinant P. agglomerans Strains Efficiently Impair P. falciparum Development 
in Mosquitoes. 
 To assess the effectiveness with which recombinant bacteria interfere with the 
development of the human malaria parasite P. falciparum in mosquitoes, recombinant P. 
agglomerans were administered to mosquitoes via cotton pads soaked with bacteria 
suspended in 5% (wt/vol) sucrose solution. Thirty-two hours later, mosquitoes were 
provided a P. falciparum–infected blood meal. Success of parasite development was 
evaluated by counting oocyst numbers on day 8 after the infectious blood meal. Initial 
experiments were conducted to evaluate the inhibition potential of recombinant P. 
agglomerans secreting a chitinase propeptide (Pro) compared with administration of the 
synthetic propeptide mixed with the blood meal. The propeptide inhibits Plasmodium 
chitinase activity and, thus, prevents crossing of the peritrophic matrix, resulting in 
decreased number of ookinetes that reach the midgut epithelium (Bhatnagar 2003). As 
shown in Figure S4, inhibition by P. agglomerans expressing the propeptide was 
effective, on the order of 59% inhibition in highly infected mosquitoes (also see 
comments concerning infection intensity under Discussion). Next, we evaluated the 
inhibitory capacity of the various recombinant P. agglomerans strains. As shown in 
Figure 3.3, the recombinant P. agglomerans strain expressing E-tagged HlyA alone did 
not significantly inhibit oocyst formation compared with minus bacteria controls. 
Recombinant P. agglomerans expressing mPLA2, Pro:EPIP, or Shiva1 had a 85%, 87%, 
and 94% decrease in oocyst numbers, respectively. Recombinant P. agglomerans 
expressing scorpine or (EPIP)4 had the highest inhibition (98%) of oocyst formation 
(Figure 3.3). Importantly, infection prevalence (percentage of mosquitoes that have one 
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or more oocysts) was 90% in −Bact (control) mosquitoes and was reduced to 14% in 
mosquitoes carrying scorpine-secreting bacteria, representing an 84% transmission-
blocking potential. 
 To evaluate the persistence of the inhibitory effect, we compared oocyst numbers 
in mosquitoes that were fed the same batch of infective blood meal at either 2 d (our 
standard procedure) or 4 d after bacterial administration. These experiments also 
evaluated the effect of mixing bacteria expressing two different effector proteins, [shiva1 
+ (EPIP)4] and [scorpine + (EPIP)4], on inhibition of P. falciparum infection. As shown 
in Figure 3.4, inhibition of oocyst development was similar at both time points. Thus, the 
inhibitory effect of the bacteria lasts for at least 4 d after bacteria administration. Also, 
inhibition by a mixture of bacteria expressing two effectors (Figure 3.4) was similar to 
that of bacteria expressing a single effector (Figure 3.3). Possible reasons for this are 
considered under Discussion. 
 
Recombinant P. agglomerans Strains Efficiently Impair P. berghei Development in 
Mosquitoes. 
 We also evaluated the effectiveness of recombinant P. agglomerans strains to 
inhibit development of the rodent malaria parasite P. berghei in A. stephensi mosquitoes. 
Mosquitoes harboring various recombinant bacterial strains were allowed to feed on the 
same P. berghei–infected mouse, followed by determination of oocyst numbers on day 14 
post infection. The recombinant P. agglomerans strain expressing (SM1)2 reduced mean 
oocyst counts by 68%, an equal mixture of bacteria expressing pbs21scFv-shiva1 + 
(EPIP)4 reduced oocyst counts by 79%, and a mixture of scorpine- and (EPIP)4-
 102 
expressing bacteria reduced oocyst counts by 83% (Figure 3.5), despite relatively high 
infection rates (>60 oocysts per midgut; also see Discussion). No significant reduction 
was observed in the presence of the recombinant P. agglomerans strain expressing E-
tagged HlyA alone (HlyA). 
 
Recombinant P. agglomerans Strains Do Not Affect Mosquito Longevity. 
 A recombinant bacterium with minimal fitness cost to mosquitoes is also an 
important factor for the success of future field applications. To examine the impact of 
recombinant P. agglomerans strains expressing anti-Plasmodium molecules on mosquito 
lifespan, mosquitoes were fed on sugar alone or on various recombinant P. agglomerans 
and, 32 h later, were allowed to feed on a noninfected mouse. Thereafter, mortality was 
monitored twice daily. No significant differences in mosquito lifespan was detected 
among any of the mosquito groups (Figure 3.6), suggesting these recombinant anti-
Plasmodium products pose no obvious negative impact on mosquito fitness in laboratory 
conditions. 
 
DISCUSSION 
 Although current malaria control strategies targeting the mosquito vector and the 
parasite have helped alleviate the malaria burden in many endemic areas (Greenwood 
2008), the emergence and rapid spreading of insecticide-resistant mosquitoes and drug-
resistant parasites undermine such efforts (Trape 2011). The Malaria Eradication 
Research Agenda (malERA) consultative group recently noted that malaria eradication 
will not be achieved without help of novel control tools (Baum 2011). Here, we report on 
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an alternative strategy to deliver antimalaria effector molecules to the mosquito midgut 
via engineered symbiotic bacteria. 
 The mosquito midgut serves as a prime target for blocking parasite transmission 
with engineered bacteria for two main reasons: (i) the most vulnerable part of the 
Plasmodium cycle in the mosquito and a bottleneck in parasite numbers occur in the 
mosquito midgut lumen (Whitten 2006); and (ii) the midgut compartment is shared 
between Plasmodium and the mosquito microbiome, directly exposing parasites to 
compounds secreted by resident bacteria. Furthermore, the number of bacteria in the 
mosquito midgut increases dramatically (by two to three orders of magnitude) after 
ingestion of a blood meal, consequently increasing the output of effector molecules 
produced by recombinant bacteria. The drop in recombinant bacteria number at 3 d after 
the blood meal (Figure 3.1C) is of no consequence to the effectiveness of intervention 
because most of ookinete invasion of the mosquito midgut occurs at 24 to 36 h after the 
blood meal. 
 Symbiotic bacteria are thought to be beneficial to their insect hosts by providing 
nutritional supplements, tolerance to environmental perturbations, and manipulation of 
host immune homeostasis (Weiss 2011). In recent years, the relationship between 
symbionts and their hosts has attracted increasing attention from the perspective of 
engineering symbionts to combat pathogens (Durvasula 1997, Riehle 2007, Rao 2005). 
Several bacterial species have been identified from the midgut of field-collected 
anophelines, mostly Gram-negative proteobacteria and enterobacteria (Straif 1998, Wang 
2011). A recent study found that the bacterial population structure of laboratory-reared 
adult mosquitoes is similar to that of field mosquitoes, suggesting that the mosquito gut 
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harbors its microbiome in a selective way (Wang 2011). A nonpathogenic bacterium P. 
agglomerans was reported as a dominant symbiotic bacterium in different mosquito 
species in Kenya and Mali (Straif 1998) and also found in laboratory-reared A. stephensi, 
A. gambiae, and Anopheles albimanus mosquitoes (Pumpuni 1996, Riehle 2007). It also 
occurs in the desert locust Schistocerca gregaria (Dillon 2002) and the honey bee Apis 
mellifera (Loncaric 2009). A possible source of P. agglomerans for mosquitoes in the 
field is flower nectar, given that this bacterium was found on plant surfaces and blossoms 
(Andrews 2000, Pusey 2002, Pusey 1997). These considerations are relevant to future 
efforts to introduce recombinant bacteria into field mosquito populations. Importantly, P. 
agglomerans strains have been used as microbial control agents against the plant disease 
fire blight in the United States (Pusey 2002). These facts make P. agglomerans an 
excellent candidate for delivery of antimalarials to mosquitoes in the field. 
 Our data demonstrate that five potent anti-Plasmodium effector molecules 
secreted by P. agglomerans are able to efficiently inhibit P. falciparum development 
during early sporogony. The availability of multiple effector proteins, each acting by a 
different mechanism, greatly reduces the probability of selection of resistant parasites. 
Initial experiments indicated that mixing bacteria that secrete different effector molecules 
had no additive effect on inhibition of Plasmodium development (Figures. 3.4 and 3.5). 
This may be because the number of bacteria expressing each effector is cut in half in the 
mixture fed to mosquitoes.  
 Perhaps more important than the inhibition of oocyst formation [up to 98% for 
scorpine and (EPIP)4] are the data on prevalence. The percentage of P. falciparum–
infected mosquitoes was 90% in controls and was reduced to 14–18% in mosquitoes 
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carrying scorpine or (EPIP)4 transgenic bacteria. This would represent an 80–84% 
reduction in the proportion of infected mosquitoes. The effectors appear to be similarly 
efficient in controlling a human and a rodent parasite, raising the possibility that they also 
will be effective in the control of other human parasites such as Plasmodium vivax. 
 We note that in the field, mosquitoes carry a mean of five oocysts or fewer in 
their midguts (Whitten 2006). In some experiments, mosquitoes fed with blood 
containing high P. falciparum gametocytemia produced abnormally high oocyst numbers 
(mean >200 oocysts) (Figure S5). However, even under these conditions, inhibition of 
parasite development was highly significant and in line with the results presented in 
Figure 3.3, although the extent of inhibition was lower (up to 68% inhibition for 
mosquitoes carrying scorpine-secreting bacteria). 
 There are around 460 species of anopheline mosquitoes, over 100 of which are 
suitable vectors for human malaria (Raghavendra 2011). Very few of these have been 
genetically transformed (Coutinho-Abreu 2010). We found that the effector molecules 
investigated in this study are equally effective with A. gambiae (an African mosquito) 
and with A. stephensi (an Asian mosquito). The paratransgenesis strategy may well be 
“universal” as effectiveness does not appear to be influenced by mosquito species. 
Moreover, the fact that many major vector anopheline species exist as reproductively 
isolated populations (cryptic species) imposes an important technical barrier for the 
introduction of transgenes into mosquito populations in the field but does not affect the 
paratransgenesis strategy. It is important to note that paratransgenesis is compatible with 
current mosquito control tools (insecticides, population suppression) and even with 
genetically modified mosquitoes. Should the technical barriers for transgene introgression 
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into mosquito populations be solved, we envision the concomitant application of both 
strategies (genetically modified mosquitoes and paratransgenesis), because they can 
complement each other. However, more work lays ahead before this approach can be 
implemented in the field. One key issue is how to effectively introduce engineered 
bacteria into mosquitoes in the field. Our preliminary results suggest that this could be 
accomplished by placing baiting stations (cotton balls soaked with sugar and bacteria 
placed in clay jars) around villages where malaria is prevalent. Another important 
challenge is the resolution of regulatory, ethical, and social issues related to the release of 
genetically modified organisms. 
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Figure 3.1. Transgenic P. agglomerans rapidly proliferate in the midgut after a 
blood meal. GFP-tagged P. agglomerans were administered to 2-d-old A. gambiae via a 
sugar meal, and, 32 h later, the insects were fed on blood. (A) Visualization of GFP-
tagged bacteria in the midgut at 24 h after a blood meal. The upper midgut is from a 
mosquito that had been fed GFP-tagged bacteria, and the lower midgut was from a 
control mosquito that did not feed on recombinant bacteria. A differential interference 
contrast image (Right) is paired with a fluorescent image (Left). (B) GFP-fluorescent 
bacteria recovered from a mosquito midgut. (C) Population dynamics of GFP-tagged P. 
agglomerans as a function of time after a blood meal. Fluorescent bacteria were fed to 
mosquitoes as described above, and midguts were dissected at the indicated times after a 
blood meal. Fluorescent bacteria colony-forming units (CFUs) were determined by 
plating serially diluted homogenates of midguts on LB/kanamycin agar plates. Data were 
pooled from three biological replicates.  
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Figure 3.2. The engineered P. agglomerans strains efficiently secrete anti-
Plasmodium effector proteins. (A) Western blot analysis. Culture supernatants were 
concentrated using Amicon Ultra-4 Centrifugal Filter Units. Aliquots originating from 
the same volume of supernatant were fractionated by SDS/PAGE and subjected to 
Western blot analysis using a rabbit anti-E-tag antibody. The supernatant from 
nontransformed P. agglomerans (WT) served as a negative control. Images were taken 
using the same exposure time. (B) In vivo binding of the secreted SM1 peptide to the 
mosquito midgut epithelium. A. gambiae were fed on sugar solution containing 
recombinant P. agglomerans strains expressing either the (SM1)2 or E-tagged HlyA 
alone (HlyA) and then fed on mouse blood. Midguts were dissected 18 or 24 h after 
blood meal, opened into a sheet, fixed, and incubated with an anti-SM1 antibody, 
followed by incubation with a fluorescent secondary antibody. Nuclei were stained with 
DAPI (blue). The differential interference contrast (DIC) images of the same field are 
shown to the right.  
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Figure 3.3. Inhibition of P. falciparum development in vector mosquitoes by 
recombinant P. agglomerans strains. A. gambiae mosquitoes were fed on 5% (wt/vol) 
sugar solution supplemented with either PBS (−Bact) or recombinant P. agglomerans 
strains and 32 h later fed on a P. falciparum–infected blood meal. Oocyst numbers were 
determined 8 d after blood meal. Each dot represents the oocyst number of an individual 
midgut and horizontal lines indicate mean values. Data were pooled from four biological 
replicates. Recombinant P. agglomerans strains were engineered to express the E-tagged 
HlyA leader peptide alone (HlyA) or mPLA2, Pro:EPIP, Shiva1, scorpine, and (EPIP)4 
(Table S1), fused to HlyA (Figure S3), as indicated. Inhibition, inhibition of oocyst 
formation relative to the −Bact control; Mean, mean oocyst number per midgut; Median, 
median oocyst number per midgut; N, number of mosquitoes analyzed; Prevalence, 
percentage of mosquitoes carrying at least one oocyst; Range, range of oocyst numbers 
per midgut; Tbp, transmission-blocking potential: 100 − {(prevalence of mosquitoes fed 
with recombinant P. agglomerans)/[prevalence of control (−Bact) mosquitoes] × 100}.  
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Figure 3.4. Comparison of P. falciparum development between mosquitoes that fed 
on an infectious blood meal at either 2 or 4 d after administration of recombinant P. 
agglomerans. A. gambiae females were fed on 5% (wt/vol) sugar solution supplemented 
with either PBS (−Bact) or recombinant P. agglomerans strains as follows: HlyA, P. 
agglomerans expressing the E-tagged HlyA leader peptide alone; Shiva1 + (EPIP)4 or 
scorpine + (EPIP)4 (Table S1), a mixture of the two recombinant bacteria in equal 
numbers. Two days (2 dpPa) or 4 d (4 dpPa) after administration of bacteria, mosquitoes 
were fed on a P. falciparum–infected blood meal. Oocyst numbers were determined 8 d 
after the blood meal. Each dot represents the oocyst number of an individual midgut and 
horizontal lines indicate mean values. Data were pooled from three biological replicates. 
% Inhibition, inhibition of oocyst formation relative to the −Bact control; Mean, mean 
oocyst number per midgut; Median, median oocyst number per midgut; N, number of 
mosquitoes analyzed; Prevalence, percentage of mosquitoes carrying at least one oocyst; 
Range, range of oocyst numbers per midgut.  
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Figure 3.5. Inhibition of P. berghei development in mosquitoes harboring 
recombinant P. agglomerans strains. A. stephensi females were fed on 5% (wt/vol) 
sugar solution supplemented with either PBS (−Bact) or recombinant P. agglomerans 
strains engineered to express E-tagged HlyA alone (HlyA), (SM1)2, pbs21scFv-
Shiva1/(EPIP)4 (50–50 mixture) or scorpine/(EPIP)4 (50–50 mixture)] (Table S1 and 
Figure S3) and 32 h later the five groups of mosquitoes were fed on the same P. berghei-
infected mouse. Plasmodium infections were evaluated 14 d after infection. Each dot 
represents the number of oocysts in an individual midgut. Horizontal lines indicate mean 
values. Data pooled from three biological replicates. N, number of mosquitoes analyzed; 
Range, range of oocyst numbers per midgut; Prevalence, percentage of mosquitoes 
carrying at least one oocyst; Mean, mean oocyst number per midgut; Median, median 
oocyst number per midgut; Inhibition, inhibition of oocyst formation relative to the −Bact 
control.  
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Figure 3.6. Impact of recombinant P. agglomerans strains on lifespan of Anopheles 
gambiae females. A. gambiae mosquitoes were fed on 5% (wt/vol) sugar solution 
supplemented with either PBS (−Bact), or recombinant P. agglomerans strains as 
follows: HlyA, P. agglomerans expressing the E-tagged HlyA leader peptide alone; 
Shiva1 + (EPIP)4 or scorpine + (EPIP)4, a mixture of the two recombinant bacteria in 
equal numbers (Table S1 and Figure S3). Thirty two hours later, mosquitoes were fed 
on a noninfected mouse, and mosquito survival was measured twice daily. Data were 
pooled from three independent experiments. There was no significant difference in 
survivorship among the groups. 
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Chapter 4 
 
Identification of secretion signals from Asaia sp. SF2.1, a 
mosquito midgut bacteria 
 
ABSTRACT 
 Bacteria chosen for paratransgenesis in mosquitoes must be selected from among 
the group of symbiotic species that inhabit the mosquito midgut. Previous experiments 
used Pantoea agglomerans to secrete antimalarial proteins into the midgut environment 
(Wang 2012). This species secreted antimalarial proteins in high amounts and 
demonstrated effective parasite killing in vivo. This species, however, has no drive 
mechanism that will cause the the paratransgenic organism to remain in the mosquito 
population long-term or to spread the bacteria within a population of mosquitoes from 
one individual to another. Bacteria of the genus Asaia, first discovered in plant nectar, are 
much better candidates for paratransgenesis (Yamada 2000, Favia 2008). The bacterial 
strain Asaia sp. SF2.1, which was originally isolated from Anopheles stephensi 
mosquitoes, has been successfully cultured and manipulated in the lab (Favia 2007). 
These bacteria are prime candidates for paratransgenesis due to the ease with which they 
can be introduced into a population of mosquitoes and the rate at which they can spread 
throughout a population (Damiani 2008). 
 In order to utilize Asaia for paratransgenesis against malaria, certain tools must be 
available for their manipulation. One important tool is a secretion system that will allow 
the bacteria to transport the antimalarial proteins outside the cell. To make use of these 
bacteria, a functional genetic screen was used to identify native secretion signals in 
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Asaia. Novel secretion signals were demonstrated both to mediate the secretion of active 
proteins and peptides from Asaia into the mosquito midgut and to inhibit the invasion of 
Plasmodium into host tissues. 
 
BACKGROUND 
 Bacteria of the genus Asaia are Gram-negative, rod-shaped, peritrichously 
flagellated, acetic acid bacteria belonging to the α-proteobacteria. They were initially 
isolated from the flower nectar of Indonesian orchid trees and plumbago plants (Yamada 
2000). Since their discovery, Asaia have been found in many plant-feeding insects, 
including anopheline mosquitoes that acquire the bacteria by feeding on nectar (Chouaia 
2010). 
 Asaia is ideal to use for paratransgenesis in anopheline mosquitoes due to its 
beneficial microbial ecology in the host. Asaia stably associates with anopheline 
mosquitoes and is present in the female midgut and salivary glands, which are important 
targets for transmission-blocking interventions, as well as in the male reproductive tract, 
which aids in the dissemination of the bacteria through the mosquito population (Favia 
2007, Damiani 2010). Asaia is transmitted from male to female during copulation, and 
from mother to progeny during egg laying, which can potentially facilitate the spread of 
paratransgenic strains released in the wild (Damiani 2008). The bacteria can survive the 
shedding of the meconium following the mosquito's transformation until the mosquito is 
a mature adult (Damiani 2008). The meconium is a peritrophic matrix within the larval 
midgut that, when shed, removes all of the contents of the midgut, thereby sterilizing it 
(Moll 2001). 
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 Asaia is a very widespread genus and has been identified in diverse genera and 
orders of sugar-feeding insects (Crotti 2009). Strains of Asaia taken from one insect 
species can be transferred to other insect species and colonize their body tissues (Crotti 
2009). Due to its ability to colonize a variety of species, Asaia may be important for other 
insect-related problems that could be solved by paratransgenesis, such as other insect-
vectored human diseases or agricultural crop diseases. 
 The microbiota of mosquitoes play a large role in immunity, particularly against 
Plasmodium infection (Dong 2009, Boissiere 2012). The microbiota of the mosquito 
affects transcriptional activation of immune-related genes, increasing expression of 
certain anti-Plasmodium factors (Dong 2009). Asaia has a mutually beneficial symbiosis 
with anopheline mosquitoes; it inhabits the environment of the midgut and proliferates 
upon the female mosquito taking a blood meal. The mosquito benefits from its 
association with the bacteria because Asaia naturally induces an increased immune 
response against Plasmodium (Capone 2013). This natural immune stimulation makes 
Asaia ideal for the addition of further antimalarial molecule delivery. 
 Paratransgenesis involves altering the host's phenotype through genetic 
modification, with modification occurring to the symbiont of the host organism rather 
than to the host itself. Paratransgenic bacteria that can combat malaria will provide the 
host mosquito with added defense against invasion of the Plasmodium parasite. The 
research presented here aimed to identify secretion signals that can be used in Asaia to 
enable the bacteria to secrete antimalarial proteins directly into the mosquito midgut 
where they could inhibit the sexual life stages of the parasite. 
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 To create paratransgenic strains of Asaia, a functional secretion system is needed 
that will allow the bacterium to translocate diverse antimalarial proteins, such as 
enzymes, single-chain antibodies, and antimicrobial peptides, outside the cell. Asaia are 
Gram-negative bacteria; they have two cell membranes through which transport must 
take place for a protein to be secreted. This would be easily managed if the bacteria were 
capable of utilizing any of the commonly-used secretion systems for lab-cultured 
bacteria. However, my previous work has demonstrated that the Type I hemolysin 
secretion system cannot be easily inserted into a plasmid or transposon for use in Asaia 
(Bongio, unpublished results). The hemolysin system requires multiple proteins that 
compose the secretory complex in the membrane, including HlyB, HlyD, and TolC, and 
the fitness cost of producing so many proteins may make the modified organism unable 
to compete against wild type bacteria (Fernandez 2000). 
 Common secretion signals have been tested in Asaia, including the E. coli Type II 
OmpA and TolB leader peptides, as well as the PelB leader from Erwinia carotovora. 
These signals do not function in Asaia (Bisi, personal communication). Thirteen Type II 
signal sequences from the closely-related species Gluconobacter oxydans and 
Gluconacetobacter diazotrophicus were cloned into expression vectors and tested for 
activity in Asaia, but none mediated secretion (this dissertation, Chapter 2). 
 Due to the failure of both the hemolysin transport system and secretion signal 
peptides, the identification of a native Asaia protein secretion pathway was necessary. 
Accordingly, a genetic screen was used to directly identify proteins that are either 
secreted or surface displayed in Asaia. The E. coli alkaline phosphatase enzyme (PhoA) 
was used as a tool to detect protein secretion. When PhoA is secreted past the inner 
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membrane, it can cleave 5-bromo-4-chloro-3'-indolyl phosphate (BCIP), producing a blue 
color. Including BCIP in the growth media allowed for a quick and easy screen for blue 
colonies. By creating random gene fusions with phoA, it was possible to detect which 
fusion proteins were secreted from the cell, since they would translocate the PhoA protein 
as well, resulting in the blue color phenotype. 
 
MATERIALS AND METHODS 
Media and antibiotics 
 Top10 F' E. coli cells were used during the molecular cloning and plasmid 
propagation stages of the experiments. The Top10 F' cells were cultured in standard Luria 
Bertani (LB) broth (10 g Tryptone, 5 g NaCl, 5 g yeast extract, in a final volume of 1 L 
distilled water) or LB agar (LB broth plus 15 g/L agar). For selection of plasmids with 
kanamycin, media was supplemented with 30 μg/ml kanamycin. All E. coli cultures were 
grown at 37 °C, with agitation for liquid broth cultures. 
 Asaia SF2.1 bacteria were cultured in Mannitol broth (5 g yeast extract, 3 g 
peptone, 25 g mannitol, in a final volume of 1 L distilled water) or Mannitol agar 
(Mannitol broth plus 15 g/L agar). Media was adjusted to pH 6.5 before sterilization. For 
selection of plasmids with kanamycin, media was supplemented with 120 μg/ml 
kanamycin. All Asaia cultures were grown at 30 °C, with agitation for liquid broth 
cultures. 
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BCIP selection of secreting strains of bacteria 
 To identify the secretion of protein constructs in bacterial colonies, media was 
supplemented with 5-bromo-4-chloro-3'-indolyl phosphate (BCIP). E. coli was screened 
on LB media supplemented with 25 μg/ml BCIP.  Asaia was screened on Mannitol agar 
supplemented with 25 μg/ml BCIP and 25 μg/ml Na2HPO4. Sodium phosphate was 
included in the media as an inhibitor of the natural phosphatase activity demonstrated by 
wild type Asaia to reduce false positives. 
 
Genomic library construction and screening 
 The phoA gene was inserted in pNB51 in such a way that genomic DNA can be 
cloned 5' to it to allow gene fusions. phoA was amplified by PCR from E.coli K12 
genomic DNA using primers “PhoA F NdeI” and “PhoA R PacI” (Table 4.3). The 
product was directionally cloned into the expression vector pNB51 replacing the beta-
lactamase gene, to create a plasmid with a cloning site usable for gene fusions with phoA, 
named pNB90 (Figure 4.1).  
 Asaia gDNA was partially digested with the MseI restriction enzyme and the 
expression vector pNB90 was fully digested with the NdeI restriction enzyme.  Digested 
genomic DNA was size-selected for fragments 2-4 kb in size by gel electrophoresis, 
recovered, and ligated into the NdeI site of pNB90 to create a fusion library between 
phoA and Asaia genomic inserts. The library was  transformed into E. coli Top10 F' 
electrocompetent cells and plated on  LB agar containing 30 μg/ml Kanamycin and 25 
μg/ml BCIP, and grown 12 h at 37°C. 
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 The library was screened in E. coli due to growth restrictions of Asaia on 
selective media and the inefficiency of DNA transformation into Asaia. Approximately 
0.9% of colonies turned blue after 1 day of growth at 37 °C. More than 200,000 clones 
were collected and pooled to provide over 100-fold coverage of the 3.53 Mb genome, and 
these were stored in 50% glycerol at -80 °C to make the library. 
 Individual blue colonies were inoculated into 5 ml LB broth supplemented with 
kanamycin and grown at 37 °C for 12 h. Plasmid DNA was extracted from these cultures 
using a Qiagen plasmid miniprep kit. One hundred and sixty blue clones were plasmid 
prepped and sequenced using the primer “PhoA seq R1” (Table 4.3). Each sequence read 
was identified by a BLAST search (NCBI) for the closest related homologous protein 
identity. 
 The 160 library clones resulted in 16 unique identified genes, and one plasmid for 
each unique clone (Table 4.2, all pNB91.* plasmids) was transformed into Asaia cells. 
These were plated on selective media to confirm that secretion functions similarly to the 
activity seen in E. coli. 
 
Western blot detection of secreted proteins from phoA library clones 
 Asaia liquid cultures were grown to an OD600 of 1.5. Protein samples were 
prepared from these by centrifuging 1 ml of the culture at 12,000 RPM in a desktop 
centrifuge. From the supernatant fraction, 750 μl was removed, mixed with 250 μl of 3X 
Laemmli sample buffer (BioRad, Hercules, CA, #161-0737), and boiled for 10 minutes. 
Eight μl of the Colormark plus prestained protein ladder (New England Biolabs, Ipswich, 
MA, #p7712), and 20 μl of each protein sample were loaded into wells of a 5% stacking 
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and 10% separating polyacrylamide gel. Proteins were separated by electrophoresis at 
120 V for 1 h, then transferred onto a PVDF membrane in a BioRad transfer apparatus 
using Tris-Glycine transfer buffer (25mM Tris, 150mM glycine, 10% methanol) at 95 V 
for 75 minutes. The membrane was blocked with a 4% bovine serum albumin (BSA) 
TBS-T solution (50 mM Tris-CL, 150 mM NaCl, 0.1% Tween20, 4% w/v fraction V 
BSA, pH 7.5) for 3 h at 4 °C with agitation. The blocking buffer was then replaced with 
the primary antibody solution containing rabbit polyclonal anti-bacterial alkaline 
phosphatase 1:50,000 (Abcam, Cambridge, England, ab7319-1) in blocking buffer and 
incubated overnight at 4 °C. The next day, the membrane was washed four times in TBS-
T for 15 min each time. Following washes, the secondary antibody was applied, goat 
anti-rabbit HRP (BioRad, Hercules, CA, 170-5046), and the blot was incubated for 1 h at 
room temperature. The wash steps were repeated, then 2 ml of Supersignal West Femto 
Maximum Sensitivity Substrate (Thermo Scientific, Waltham, MA, # 34095) was added 
to the blot and incubated for 5 minutes. The blot was exposed to X-ray film (Thermo 
Scientific, Ipswich, MA, #34090) and developed using an automatic developer. 
 
ELISA to detect PhoA in cell culture fractions 
 Asaia expressing the PhoA secretion constructs were grown to OD600 of 1.5, then 
centrifuged. Supernatant, live cell, and cell lysate fractions were isolated and bound to 
wells in a 96-well plate overnight at 4 °C. These plates were washed three times with 
Tris-buffered saline (TBS) (50mM Tris-CL, 150 mM NaCl, pH 7.5), then blocked by 
adding 200 μl of 2% BSA TBS (TBS with 2% w/v fraction V BSA) and incubating 2 h at 
room temperature. This was washed again three times with TBS, then 100 μl of a 1/3000 
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dilution of anti-BAP-HRP (bacterial alkaline phosphatase) antibody (Abcam, Cambridge, 
England, ab7319-1) in 2% BSA TBS was added to each well and incubated for 1 h at 
room temperature. The plate was washed 8 times with TBS-Tween20 0.1% for 2 minutes 
per wash. To visualize the protein, 50 μl of 1-Step Ultra TMB-ELISA (Thermo 
Scientific, Ipswich, MA, #34028) was added and incubated for 10-20 min at room 
temperature. HRP from the bound antibodies reacts with the TMB substrate to produce a 
blue color (Figures  4.2 and 4.3).  
 
p-Nitrophenyl phosphate plate assay for PhoA activity 
 Asaia expressing the PhoA secretion constructs were grown to OD600 of 1.5, then 
centrifuged. Supernatant, live cell, and cell lysate fractions were isolated and bound to 
wells in a 96-well plate overnight at 4 °C. PhoA activity was detected by rinsing the 
plates with PBS, and adding 100 μl of p-Nitrophenyl phosphate (PNPP) substrate (Sigma 
Aldrich, St. Louis, MO, #P7998). PhoA cleaves the phosphate group from PNPP 
substrate, producing a yellow color (Figures 4.2 and 4.3). 
 
Cloning of anti-Plasmodium effector genes into secretion constructs 
 A new plasmid was generated to modify the identified secretion constructs to 
include a cloning site into which anti-Plasmodium effector genes could be inserted. First, 
the phoA gene was amplified by PCR using primers “PhoA F NdePacSbf” and “PhoA R 
Fse” (Table 4.3). This PCR product and the pNB51 plasmid were digested to completion 
with the NdeI and FseI restriction enzymes, and the plasmid was treated with calf 
intestinal phosphatase. The PCR product was ligated into the linearized plasmid using T4 
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DNA ligase at 16 °C overnight. The ligated DNA was transformed into top10 E. coli cells 
and selected on LB media containing kanamycin. Clones isolated from this selection 
were verified by sequencing to ensure there were no mutations introduced. The new 
plasmid created was named pNB92 (Figure 4.4). This plasmid is identical to pNB90 
(Figure 4.1), but with the addition of the PacI and SbfI restriction sites for in-frame 
insertion of effector genes into the fusion protein construct. 
 The siderophore receptor and YVTN beta-propeller proteins were amplified by 
standard PCR using primers “siderophore F NdeI” and “siderophore R MYC PacI”, or 
“YVTN F NdeI” and “YVTN R MYC PacI”, respectively, and directionally cloned into 
pNB92 by restriction enzyme digestion and ligation. The resultant gene constructs 
contain both the secretion protein, a MYC epitope tag, a cloning site for effector 
molecules, and phoA. These plasmids were named pNB93 (Figure 4.5, contains YVTN 
beta-propeller repeat) and pNB95 (Figure 4.6 contains TonB-dependent siderophore 
receptor). Each of these cloned genes are longer than the predicted proteins in the 
genome annotation, perhaps due to mutation. The cloned genes were sequenced to verify 
that there are no errors. 
 Into these plasmids, eleven genes were cloned in-frame, including two control 
proteins that are not antimalarial. The cloned genes encoded GFP, anti-bovine serum 
albumin (anti-BSA) scFv (Bisi 2011), prochitinase peptide, PLA2, enolase-plasminogen 
interacting protein (EPIP)4, Shiva1, anti-Pbs21 scFv-Shiva1, prochitinase-EPIP, 
scorpine, (Wang 2012) anti-Pfs48/45 scFv (Chapter 2 page 62) and anti-Pfs25 scFv 
(Chapter 2 page 61). Each gene was amplified by PCR using primers that add PacI and 
SbfI restriction digest sites to either end of the amplicon (see Table 4.3 for primers used). 
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These PCR products were directionally cloned into pNB93 and pNB95 by restriction 
enzyme digestion and ligation as described previously to create a set of anti-Plasmodium 
secretion constructs (Figure 4.7). Clones were selected on LB agar containing 
kanamycin. The YVTN beta-propeller protein constructs would not grow properly in E. 
coli, possibly due to lethality of the cloned constructs, therefore following the molecular 
cloning and sequence verification, Asaia SF2.1 cells were transformed with each of the 
siderophore receptor effector plasmids only, and they were selected for on Mannitol Agar 
supplemented with kanamycin. 
 
Western blot detection of protein with MYC epitope tag 
 Samples were prepared, separated by acrylamide gel electrophoresis, and 
transferred to PVDF membrane exactly as described in the western blot protocol for the 
detection of secreted proteins from phoA library clones (page 117). The PVDF 
membrane was blocked for 18 h with 1% BSA TBS-T (50mM Tris-CL, 150 mM NaCl, 
0.1% Tween20, 1% w/v fraction V BSA, pH 7.5) with agitation at 4 °C. Next, the 
blocking solution was replaced with the primary antibody, a mouse anti-myc antibody 
(Invitrogen, Thermo Scientific, Waltham, MA, #45-0603) 1:5000 in blocking buffer, and 
incubated at 4 °C for 24 h with agitation. The primary antibody solution was removed, 
and the blot was washed four times in TBS-T for 15 min each time. Following washes, 
the secondary antibody, goat anti-mouse HRP (BioRad, Hercules, CA, #170-5046), was 
applied, and the blot was incubated for 1 h at room temperature. The wash steps were 
repeated, and 2 ml of Supersignal West Femto Maximum Sensitivity Substrate (Thermo 
Scientific, Waltham, MA, #34095) was added to the blot and incubated for 5 min. The 
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blot was then exposed to X-ray film (Thermo Scientific, Waltham, MA, #34090 ) for 
multiple time exposures ranging from 10 sec to 10 min and developed using an automatic 
developer (Figure 4.8). 
 
Parasite inhibition testing in Anopheles stephensi mosquitoes 
 Two-day old Anopheles stephensi adults were collected and separated into cups 
with screen lids containing 50 female mosquitoes each. Asaia expressing the siderophore 
protein secretion constructs with Pro-EPIP, scorpine, anti-Pbs21-Shiva1, and PLA2 
effectors, and a control strain expressing PhoA alone were fed to individual mosquito 
cups for 48 h by cotton balls soaked with a mixture containing 1x109 cells/ml of bacteria 
in a 5% sugar solution. 
 The parasitemia of a P. berghei infected female Swiss Webster mouse was 
determined by blood smear. A drop of blood was taken from the mouse's tail and placed 
on a slide. This was smeared with the edge of another glass slide to create a thin layer of 
blood. This slide was fixed in methanol for ten seconds, then transferred to a 10% 
Giemsa stain solution: 5 ml Giemsa stock solution (Ricca Chemical Company, Arlington, 
TX, #3250-4) plus 45 ml phosphate buffer (0.35g KH2PO4 plus 0.5g Na2HPO4 in a final 
volume of 500ml distilled water). This was allowed to stain for 30 min, after which it was 
rinsed with tap water and dried. Parasitemia was determined by counting the number of 
infected cells and dividing by the total number of cells in a given microscope field. Full 
fields were counted until at least 500 cells were evaluated. 
 After determining the parasitemia, the mouse was sacrificed using a CO2 
chamber, and the total blood volume removed by cardiac puncture surgery with a 
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heparinized needle (100 μl of 1 mg/ml heparin in PBS, 26 G needle). This blood was 
diluted with phosphate buffered saline to reach 5x107 infected cells per 200 μl. A volume 
of 200 μl of the diluted blood was immediately injected into three naïve mice 
intraperitoneally. 
 The newly infected mice were checked for infectivity by exflagellation testing 2-3 
days post-injection. A drop of blood was extracted from the mouse's tail, and 2 μl of the 
blood was combined with 2 μl heparin (1 mg/ml heparin in PBS) and 6 μl exflagellation 
media (1 pkg of RPMI 1640 medium (1L / pkg Gibco, Thermo Scientific, Waltham, MA, 
#23400-021) with 2mM Hepes, 2mM glutamine in 1L distilled water pH 8.4, 
supplemented with 2 g sodium bicarbonate, 50 mg hypozanthine, and 100 μM 
xanthurenic acid). The mixture was incubated at 21 °C for 10 min. After incubation, the 
entire 10 μl was transferred to a microscope slide and covered with a coverslip. At 100X 
magnification, exflagellation events were counted per field, in uncrowded fields that 
show only a single layer of cells; these are estimated at 500 cells per field. 
 The mosquitoes that were previously fed the paratransgenic Asaia strains were 
given a P. berghei infective blood meal from a mouse with exflagellation rates of 
between 2-3 events per field. The mice were anesthetized by intraperitoneal injection of 
150 μl of anesthetising agent (Ketaject [100 mg/ml] 2 ml, acepromazine [10 mg/ml] 1 ml, 
saline [0.9% w/v NaCl] 7 ml). The mouse was placed on the screen top of each cup 
consecutively, and mosquitoes were allowed to feed for 6 min. Two trials were 
performed, each with a control cup fed Asaia expressing a plasmid with no effector, and 
two cups that were fed different antimalarial Asaia strains. The infected mosquitoes were 
kept at 21 °C with 10% sugar solution for two weeks. Midguts were dissected and stained 
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with 0.2% mercurochrome which stains the oocysts. The number of oocysts per midgut 
was counted using a light microscope (Figures 4.9-4.11). 
 
Cloning short signal peptides into expression vectors 
 Leader peptides were identified by predictive algorithms using both the 
SignalP4.1 artificial neural network Hidden Markov models (Nielsen 1997), and the 
PRED-TAT hidden Markov models (Bagos 2010). The predictions are shown in Figures 
4.12-4.15. The leader peptides predicted using the SignalP4.1 and PRED-TAT algorithms 
were cloned into pNB92 exactly as described in the generation of plasmids pNB93 and 
pNB95, except the primers used were “siderophore F NdeI” “Sider51 R MYC PacI” to 
amplify the siderophore receptor signal, or “YVTN F NdeI” and “YVTN34 R MYC 
PacI” to amplify the YVTN beta-propeller protein signal. This produced plasmids 
pNB124 and pNB125 (Figures 4.16 and 4.17). 
 
Asaia genome prediction of secreted proteins 
 Asaia SF2.1 gDNA was prepared and sent to ACGT Inc (www.acgtinc.com) to be 
sequenced, and the genome was submitted to NCBI (Genbank ID 873348) and annotated 
by the NCBI Annotation Pipeline version 2.0 (https://www.ncbi.nlm.nih.gov/ 
genome/annotation_prok) (Shane 2014). This annotation identified 3,005 total protein-
coding genes. The protein amino acid sequences were analyzed using the SignalP4.1 
signal peptide prediction software as described previously, however using the 
downloaded Linux version of the software that can process large datasets (Nielsen 1997). 
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RESULTS 
Genetic screen for secreted proteins in Asaia 
 The genetic screen for secreted Asaia proteins identified sixteen unique genes 
(Table 4.1) encoding proteins that are either secreted from the cell or membrane-bound.  
Less than 1% of the clones in the genomic library secreted PhoA into the growth medium 
and produced a blue phenotype. This is a reasonable number of clones to obtain 
considering that half of the inserted DNA will be in the incorrect orientation, and another 
two-thirds of the remaining inserts will be in the incorrect reading frame for translation. 
Furthermore, only 228 of the 3,005 (7.6% of all genes) proteins in the Asaia genome 
were predicted by SignalP4.1 to have signal peptides, which is close to that of E. coli 
which has 7.1% of its proteins located in the membrane, periplasm, or secreted. The 
sequenced genes were originally identified by homology to secreted or membrane-bound 
proteins found in Gluconobacter or Gluconacetobacter, close relatives of Asaia. They 
have since been compared to the Asaia SF2.1 genome and have been given the new 
designations and shown in Table 4.1. 
 
Activity of cloned genes in Asaia 
 The unique, cloned plasmids from this screen were transformed into 
electrocompetent Asaia cells and plated on Mannitol agar with BCIP and sodium 
phosphate. These clones grew at varying rates and showed different levels of phosphatase 
activity. Secretion was tested by an ELISA assay which shows the greatest amount of 
secreted protein in the supernatant with the siderophore receptor protein and YVTN beta-
propeller protein fusions (Figure 4.2 top). A multiwell plate assay was prepared, but with 
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PNPP substrate added, which turns yellow in the presence of active PhoA (Figure 4.2 
bottom). The PNPP assay shows activity of the secreted alkaline phosphatase in both the 
siderophore receptor and YVTN beta-propeller supernatant samples. The siderophore 
receptor protein construct displays the most active enzymatic activity. 
 The two best secreting fusion proteins are a siderophore receptor and a YVTN 
beta-propeller repeat protein. The siderophore receptor protein is an outer membrane pore 
complex that receives siderophores which transport metal ions (Faraldo-Gomez 2003). 
The YVTN beta-propeller protein is a structural protein that forms part of a protective S 
layer on the outside of the cell (Jing 2002). Each of these proteins is typically localized at 
the cell surface. 
 
Cloning effector proteins into secretion constructs 
 The siderophore receptor and YVTN beta-propeller proteins were amplified by 
PCR and cloned into pNB92, creating gene constructs that contain both the secretion 
protein, a MYC epitope tag, a cloning site, and PhoA (Figures 4.5 and 4.6). Multiple 
antimalarial genes and control genes that are not expected to be harmful to the expressing 
strain were cloned into the siderophore receptor plasmid and sequenced to confirm that 
there were no mutations. The YVTN beta-propeller protein plasmid was difficult to clone 
genes into and cloning attempts produced either no colonies on the selective plates or 
only false positives. 
 Asaia SF2.1 cells were transformed with each of the siderophore receptor effector 
plasmids, and these strains were grown in Mannitol broth supplemented with kanamycin 
to allow expression of the transgenes. Secretion of the fusion proteins was determined by 
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western blot utilizing an antibody against the PhoA protein (Figure 4.8). The bands 
detected on this western display degradation of the protein constructs, probably due to 
periplasmic proteases. Membrane proteases are important for regulating the turnover of 
proteins that are localized in the periplasm or the plasma membrane (Dalbey 2012). The 
siderophore receptor protein is most likely mis-folding and unable to anchor in the 
membrane properly, therefore that portion of the fusion protein construct is degraded in 
the periplasm. A search using the “DAS” transmembrane domain predictor 
(http://www.sbc.su.se/~miklos/DAS/maindas.html) with the amino acid sequence of the 
cloned gene fragment did not find any such domains. The remainder of each fusion 
protein seems to remain intact including the PhoA protein and the anti-Plasmodium 
effector proteins and peptides. The protein sizes indicated by the bands highlighted in 
Figure 4.8 all correspond with the predicted molecular weight of the effector protein plus 
PhoA. 
 
Activity of paratransgenic Asaia against P. berghei 
 Paratransgenic Asaia SF2.1 strains secreting Pro-EPIP, scorpine, anti-Pbs21-
Shiva1, and PLA2 effectors by the siderophore fusion protein were tested in vivo for 
inhibition of P. berghei invasion within the mosquito host Anopheles stephensi. The 
YVTN beta-propeller protein constructs were not able to be transformed into Asaia 
SF2.1, and were not tested for activity. The paratransgenic strains were fed to An. 
stephensi mosquitoes which were then challenged with an infective blood meal from a P. 
berghei infected mouse two days later. Two weeks after the blood meal, the mosquitoes 
were dissected and oocysts per midgut were counted. The oocyst counts indicate a 
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significant level of parasite killing from the scorpine effector, and a weaker effect from 
the anti-Pbs21 scFv Shiva1 effector  (Figures 4.9-4.11, oocyst counts in Table 4.6 and 
4.7). Both the anti-Pbs21 Shiva1 results and the scorpine results were significant (p-value 
0.0006 and  <0.0001 respectively). 
 
Increasing the efficiency of constructs 
 The identified Asaia genes were fully sequenced and analyzed using the SignalP 
4.1 algorithms to predict Gram-negative bacterial secretion signals (Figures 4.12 and 
4.13). A possible secretion signal was identified in both of the highly active clones, the 
TonB-dependent siderophore receptor protein and the YVTN beta-propeller repeat 
protein. The sequences were analyzed using the PRED-TAT algorithms as well (Figures 
4.14 and 4.15). This set of algorithms identified the YVTN secretion peptide as a Sec-
dependent pathway signal, and the siderophore receptor peptide as a potential Tat-
dependent pathway signal. These predicted secretion signals were re-cloned into the phoA 
expression vector to test the efficacy of secreting a smaller protein this way. The first 51 
amino acids from the siderophore receptor protein and the first 34 from the YVTN repeat 
protein were chosen to retain a conservative amount of the original protein after the 
signal sequence cleavage site. These leaders were directionally cloned into pNB92 in-
frame with phoA (Figure 4.16 and 4.17). Blue (secreted) clones of each were isolated in 
E. coli by screening on LB media containing BCIP. 
 The truncated secretion constructs were transformed into Asaia and grown in 
liquid culture. SDS protein samples of the supernatant and pellet fractions from overnight 
cultures of these strains were prepared and analyzed by western blot using an antibody 
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against the Myc epitope tag. As seen in (Figure 4.18), the truncated constructs mediate a 
high amount of secretion utilizing only the predicted secretion signals. These signal 
peptides have not yet been tested for the secretion or activity of antimalarial effector 
proteins due to the time needed to clone effector genes and transform Asaia strains with 
the plasmids. 
 
Asaia SF2.1 genome prediction of secretion signals 
 The Asaia SF2.1 genome secretion signal prediction by SignalP4.1 produced 228 
hits for proteins which may be secreted by Type II secretion systems (top predictions 
listed in Table 4.5). Among the top predictions, there were secreted proteases (peptidyl-
dipeptidase DCP, and gamma-glutamyltranspeptidase), transporter proteins (multiple 
TonB dependent receptor proteins, and an ammonium transporter), a folding chaperone 
(peptidyl-prolyl cis-trans isomerase), and a digestive enzyme (alginate lyase). 
 The PhoA genetic screen clones were reevaluated by a protein BLAST search 
against the Asaia SF2.1 genome (Table 4.1). The protein previously identified as 
homologous to Gluconobacter YVTN beta-propeller repeat protein came up as 
‘unidentified protein’ in and NCBI BLAST search of the Asaia SF2.1 genome. It was, 
however, identified as a potentially secreted protein in the SignalP analysis of the 
predicted proteins. The protein previously identified as homologous to an Acetobacter 
outer membrane siderophore receptor came up as ‘unidentified protein’ in the Asaia 
SF2.1 genome on NCBI. Although the siderophore receptor protein was not identified in 
the genomic prediction for Type II secretion, there were many predictions for other 
TonB-associated transporters, similar to the PhoA screen results. 
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DISCUSSION 
 Malaria has plagued mankind throughout history and is a major cause of human 
morbidity and mortality annually (WHO 2013). Despite decades of interventions against 
the disease, it is still a widespread global problem. New technologies are needed to help 
reduce the burden that malaria causes and hopefully eradicate the Plasmodium parasite 
entirely. 
 Bacterial paratransgenesis is a relatively recent technology that has been 
successfully used to combat human diseases, including Chagas disease, African sleeping 
sickness, HIV, and malaria (Durvasula 1997, De Vooght 2012, Chang 2003, Fang 2012). 
For example, Rhodococcus rhodnii was engineered to secrete the antimicrobial peptide 
Cecropin A to inhibit the transmission of Trypanasoma cruzi by Rhodnius prolixus, thus 
preventing Chagas disease (Durvasula 1997); Sodalis glossinidius was modified to 
secrete nanobodies to target the variant surface glycoprotein of Trypanosoma bruci, the 
cause of African sleeping sickness (De Vooght 2012); Lactobacillus jensenii was 
modified to secrete functional human CD4, which inhibits HIV entry into host T-cells 
(Chang 2003); and Pantoea agglomerans was engineered to secrete multiple effector 
proteins utilizing the hemolysin secretion system to interfere with transmission of P. 
berghei and P. falciparum malaria by anopheline mosquitoes (Wang 2012). 
 Asaia was proposed as a candidate for antimalarial paratransgenesis due to its 
natural microbial ecology that allows it to colonize anopheline mosquito tissues and to 
easily transmit itself through the mosquito population (Favia 2007). The primary goal of 
this work was to modify Asaia to enable it to secrete proteins into the mosquito midgut 
and to hinder the life stages of Plasmodium that develop there following an infective 
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blood meal. Interfering with this vulnerable stage of the malaria parasite would prevent 
human infection by rendering the mosquito an inhospitable host. The experiments 
performed enable the use of the Asaia sp. SF2.1 midgut symbiont of anopheline vector 
mosquitoes as a delivery vessel for heterologous effector proteins. 
 
Genetic screen for protein secretion 
 The results of the alkaline phosphatase fusion library screen produced a list of 
sixteen candidate genes that could potentially be useful for secretion of effectors in 
paratransgenic constructs (Table 4.1). All of the identified fusion proteins that mediated 
secretion were identified as homologous to either secreted or surface-displayed proteins 
in related species. These are all logical proteins to expect from a phoA library screen, 
since either periplasmic, membrane-bound, surface-displayed, and secreted fusion 
proteins can all translocate the PhoA enzyme into the periplasm where it can cleave the 
BCIP molecule used for screening (Hoffman 1985). This is the reason that clones 
required further testing to determine exactly where each protein was localized: within the 
periplasm or secreted from the cell. 
 
Localization and activity of secreted PhoA 
 The analysis of the activity of PhoA fusion constructs demonstrated a high level 
of secretion mediated by the siderophore receptor fusion protein and the YVTN beta-
propeller fusion protein, both of which are homologs of known bacterial membrane 
proteins (Faraldo-Gomez 2003, Jing 2002). The alkaline phosphatase protein that was 
secreted into the supernatant by these systems was found to be active by a plate assay 
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with PNPP. Since active alkaline phosphatase protein requires disulphide bond formation 
to achieve an active conformation (Sone 1997), this means that the secreted proteins must 
spend time in the oxidizing environment of the periplasm long enough to allow these 
bonds to form before leaving the cell. The PhoA secreted by the siderophore receptor 
fusion protein showed a much more robust amount of phosphatase activity which 
indicates that the protein may have spent a greater amount of time in the periplasm and 
been allowed to achieve the correct conformation and form disulphide bonds. Disulphide 
bonds are important for the stability and activity of some single-chain antibody effectors 
that could be secreted by paratransgenic strains (McAuley 2007). 
 The western results (Figure 4.8) show that the effector proteins secreted by the 
siderophore receptor pathway remain intact, while the Asaia siderophore receptor fusion 
protein is most likely degraded by periplasmic proteases (Dalbey 2012). This is expected, 
since the fusion protein should only retain a portion of the original Asaia gene, and it 
likely cannot achieve its stable native conformation, nor can it insert into the membrane. 
This is not necessarily a problem for delivery of effector molecules from a paratransgenic 
organism, however the bulk of the fusion protein is not remaining intact and is simply 
wasted energy for the Asaia producing it. These constructs can be reduced in size by 
identifying the signal peptide responsible for secretion and eliminating the remainder of 
the fusion protein. 
 
Anti-Plasmodium activity in vivo 
 The use of paratransgenic Asaia in mosquitoes demonstrates that, despite the large 
size of the fusion proteins, the Asaia siderophore receptor protein is capable of mediating 
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secretion of heterologous proteins outside the cell efficiently enough to supply 
antimalarial effector proteins directly into the mosquito midgut environment despite the 
large size of the fusion proteins. The significant in vivo anti-Plasmodium results 
demonstrate the ability of paratransgenic Asaia to disrupt the critical life stages of 
Plasmodium berghei in the Anopheles stephensi mosquito midgut. There were two 
significant effectors: (1) scorpine, a peptide effector which disrupts the plasma membrane 
of microbes, killing them (Carballer-Lejarazu 2008), and (2) anti-Pbs21 Shiva1, a single-
chain antibody-antimicrobial peptide combination which binds to a 21 kDa ookinete 
surface protein of P. berghei preventing the transformation from ookinete to oocyst and 
which is linked to the Shiva1 toxin, another lytic peptide (Yoshida 2001). The Pbs21-
Shiva1 effector significantly reduced oocyst numbers by 27.8% as calculated using the 
median number of oocyst per midgut, while the scorpine peptide effector significantly 
reduced oocyst numbers by 73.5% as calculated by the median number of oocysts per 
midgut. The scorpine effector was previously demonstrated to block nearly 100% of 
infections in lab tests using the HlyA secretion system in Pantoea agglomerans (Wang 
2013). 
 The anti-Pbs21-Shiva1 and scorpine constructs were re-tested to gain a larger 
sample size and to increase the significance of the data. The combined data showed a 
32.0% reduction in oocysts by the Pbs21 immunotoxin, and a 80.1% reduction by the 
scorpine peptide as calculated by the median number of oocysts. The Pbs21 immunotoxin 
reduced prevalence by only 0.3%, but the scorpine construct reduced prevalence by 
20.1%, which is a large reduction considering the mean number of oocysts per midgut in 
the control mosquitoes was 120.4. 
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 These experiments waere not ideal, considering the very high number of oocysts 
in the control mosquitoes that were fed control Asaia strains not expressing effector 
proteins. In the lab, Plasmodium berghei-infected mosquitoes regularly produce a large 
number of oocyts regularly, but this does not correlate with the level of infection that 
would be seen in other Plasmodium species (Whitten 2006). In the wild, individual P. 
falciparum-infected mosquitoes do not achieve infections of this magnitude, so the results 
of these tests remain promising. Scorpine and anti-Pbs21-Shiva1 should still be tested for 
parasite inhibition in vivo against P. falciparum because they may reduce prevalence 
even more. The prevalence of oocysts per mosquito is an important metric for 
transmission blocking since even a single oocyst can produce thousands of sporozoites 
and make the mosquito infective. To be an effective intervention, a paratransgenic 
bacteria strain would need to reduce prevalence to zero in a significant number of 
mosquitoes. 
 
Increasing the efficiency of secretion 
 Due to both the presence of some protein remaining in the periplasm of cells 
expressing these secretion constructs and the fitness cost associated with expressing large 
proteins, the efficiency of these pathways need to be increased. Accordingly, to achieve 
this, the genes for the siderophore receptor protein and the YVTN beta-propeller protein 
were analyzed by predictive software to identify the signal peptide which directs protein 
transport within the cell. 
 The siderophore receptor signal sequence is quite long compared to most bacterial 
secretion signals. This, along with the amino acid sequence of the signal, indicates that 
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the siderophore receptor protein most likely utilizes the twin-arginine translocation (Tat) 
pathway (Figure 4.14). Tat pathway signals tend to be longer than signal sequences 
targeted to the Sec pathway of Gram-negative bacteria, and the signal sequence from the 
siderophore receptor protein is around 51 amino acids long. There is a domain within the 
signal sequence which partially matches the conserved amino acids in Tat signal 
sequences of other bacteria. The consensus sequence of Tat signals in other bacteria is 
Ser/Thr-Arg-Arg-X-Phe-Leu-Lys, where X can be any polar amino acid (Lee 2006). The 
region of the siderophore receptor protein from amino acids 22 to 28, Thr-Arg-Arg-Lys-
Arg-Pro-Leu,  show some similarity to this. Use of the Tat pathway would also be an 
explanation for the much higher activity of the alkaline phosphatase protein secreted 
using this signal as tested in the PNPP plate assay (Figure 4.3). Proteins secreted by the 
Tat pathway are translocated into the periplasm in the folded conformation, thereby 
retaining the conformation of the protein as it folded in the cytosol (Lee 2006). This 
could be beneficial for certain proteins secreted using this signal that require folding in 
the cytosolic environment to achieve the correct conformation. 
 The YVTN beta-propeller repeat protein is most likely dependent on the general 
secretory pathway for its translocation, as was predicted by the PRED-TAT analysis 
(Figure 4.15). The leader peptide is short, around 26 amino acids in length and has a 
strong hydrophobic domain. This may be the reason that alkaline phosphatase secreted by 
this pathway does not have a high level of activity, since proteins secreted using this 
pathway are translocated in the unfolded conformation into the periplasm where they 
must refold. The Asaia periplasm may not be the correct environment for this to take 
place. The difference in PhoA activity secreted by the Sec and Tat leader peptides 
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indicate that, in Asaia, PhoA folds best in the cytosol as demonstrated by the 9-fold 
increase in activity for protein secreted by the Tat pathway (Figure 4.3). 
 
Asaia genome prediction of secreted proteins 
 The Asaia SF2.1 secreted proteins which may be secreted by Type II secretion 
systems are shown in Table 4.5.  Among the top hits in this SignalP4.1 search, there were 
secreted proteases: peptidyl-dipeptidase DCP and gamma-glutamyltranspeptidase; 
transporter proteins: multiple TonB dependent receptor proteins and an ammonium 
transporter; a folding chaperone: peptidyl-prolyl cis-trans isomerase; and an enzyme: 
alginate lyase. The enzyme alginate lyase is involved in mannose digestion, and mannitol 
media is one of the growth media with which Asaia sp. bacteria can be cultured (Preiss 
1962). In the future, it may be useful to use the secretion signals from these various 
proteases to attempt to secrete heterologous proteins.  
 The YVTN protein identified in the genetic screen was hit 152 out of 228 
predicted secretion signals from the genome. This leader signal would have been 
overlooked if experimental design relied solely on genomic data. Furthermore, the 
siderophore receptor protein that was the best candidate isolated from the PhoA library 
screen was not identified at all from the genomic analysis. This means that at least two 
useful signal sequences would never have been explored if only the bioinformatic 
approach had been used. Each method of discovery has benefits and drawbacks, however, 
they each provide different results and can be used in conjunction to perform a more 
thorough search for secretion signals. The signal peptides identified from the genome 
predictions remain to be evaluated. 
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There are inherent strengths and weaknesses in each of the genetic screen and the 
genomic prediction approaches to secreted protein identification. The genetic screen's 
primary benefit is the direct identification of actively transported proteins using any 
secretory pathway; the fusion proteins identified can be rapidly tested to determine the 
localization and amount of protein no matter what mechanism mediates transport. 
Reliance on the secretion of fusion proteins in the genetic screen may cause certain 
secreted proteins to be missed due to either the fitness cost associated with the fusion 
construct or the lack of necessary secretory proteins that may not be present under the 
screen conditions. The genomic prediction's strength is that it can identify any protein 
with a type II secretion signal, even those that may not be expressed in a large amount or 
that may not always be actively translocated. These proteins can still be identified by 
their signal peptide sequences. The weakness of the genomic prediction is the predicted 
genes may not be secreted, but instead may be localized in the periplasm or membrane-
bound. Each secretion signal from a genomic prediction would need to be cloned and 
tested individually to determine its function. 
Conclusions 
 These positive results have built on the previous proof-of-concept trials with 
Pantoea agglomerans by bringing functionality to a new paratransgenic species, Asaia 
sp. SF2.1. There is now at least one possible secretion signal that can be used in 
paratransgenic Asaia strains to deliver antimalarial proteins into the mosquito midgut 
(siderophore receptor signal), and a second that requires further testing to prove useful 
(YVTN protein signal). Further signal peptides may be found that are useful if the 
genomic data are explored further. 
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 This research has moved malaria paratransgenesis one step closer to practical use 
in the field. Asaia is a more useful symbiont of anopheline mosquitoes than previous 
paratransgenic species considered due to its beneficial microbial ecology, and now that it 
has been given the capability to secrete heterologous effector molecules, these 
characteristics can be taken advantage of. The antimalarial constructs tested in these 
experiments prove that Asaia can be effectively modified and used to deliver 
heterologous proteins into the mosquito midgut and to inhibit the sexual life stages of P. 
berghei malaria. 
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Figure 4.1. Plasmid for phoA fusion library construction. A leaderless alkaline 
phosphatase gene was cloned downstream of the nptII promoter and translational 
enhancer of pNB51. This construct also contains an NdeI restriction site at the start codon 
of the phoA gene into which random genes can be cloned in-frame. pBBR ori = 
replication origin. oriT = origin of transfer. neo = neomycin phosphotransferase, 
kanamycin resistance. ‘phoA = C-terminal domain of alkaline phosphatase, lacking a 
secretion signal. enh = translational enhancer. PnptII = promoter from neomycin 
phosphotransferase. 
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Figure 4.2. PhoA-Asaia protein fusion plasmids expressed in Asaia. The top ELISA 
used an anti-PhoA-HRP antibody to detect the presence of the alkaline phosphatase 
protein. The Tsr and Ybp fusions show a high amount of protein present in the 
supernatant fraction. The bottom plate assay used a PNPP substrate, which turns yellow 
when cleaved by active PhoA. Both Tsr and Ybp fusion proteins show activity from the 
secreted PhoA, however the Tsr signal is far more robust. Quantitative results are shown 
in Figure 4.3. PhoA = alkaline phosphatase. Tsr = TonB-dependent siderophore receptor. 
Aap = amino acid permease. Trp = TonB-dependent receptor plug. Gdh = glucose 
dehydrogenase. Ybp = YVTN beta-propeller repeat protein. Csy = cellulose synthase. 
Amu = aminomutase. Ptp = peptide transport permease. 
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 Asaia WT PhoA Tsr Asp Trp Gdh Ybp Csy Amu Ptp 
AVG PhoA 
abundance 
0.081 0.023 1.167 0.026 0.075 0.019 0.616 0.025 0.029 0.028 
AVG PhoA 
activity 
0.055 0.058 1.951 0.057 0.081 0.057 0.380 0.062 0.059 0.060 
 
Figure 4.3. Secreted protein abundance and activity from PhoA-Asaia protein fusion plasmids expressed in Asaia. Both the ELISA 
and PNPP plates were repeated five times, and quantified using a plate reader. Signal intensity was read at 450 nm for the ELISA and at 400 
nm for the PNPP assay. Although there was a similar amount of protein secreted by Tsr compared to Ybp, PhoA activity was more than five 
times stronger when secreted by Tsr. PhoA = alkaline phosphatase. Tsr = TonB-dependent siderophore receptor. Aap = amino acid 
permease. Trp = TonB-dependent receptor plug. Gdh = glucose dehydrogenase. Ybp = YVTN beta-propeller repeat protein. Csy = cellulose 
synthase. Amu = aminomutase. Ptp = peptide transport permease. 
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Figure 4.4. pNB92. The pNB51 plasmid was modified by cloning ‘phoA into the plasmid 
with additional restriction sites 5' to the gene, generating pNB92. pBBR ori = replication 
origin. oriT = origin of transfer. neo = neomycin phosphotransferase, kanamycin 
resistance. ‘phoA = C-terminal domain of alkaline phosphatase, lacking a secretion 
signal. enh = translational enhancer. PnptII = promoter from neomycin 
phosphotransferase. 
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Figure 4.5. pNB93.  The N-terminal domain of ybp was cloned into the pNB51 plasmid 
with the addition of a Myc epitope tag and multiple-cloning-site between ybp’ and ‘phoA. 
pBBR ori = replication origin. oriT = origin of transfer. neo = neomycin 
phosphotransferase, kanamycin resistance. ‘phoA = C-terminal domain of alkaline 
phosphatase, lacking a secretion signal. enh = translational enhancer. PnptII = promoter 
from neomycin phosphotransferase. ybp’ = N-terminal domain of YVTN beta-propeller 
repeat. 
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Figure 4.6. pNB95.  The N-terminal domain of tsr was cloned into the pNB51 plasmid 
with the addition of a Myc epitope tag and multiple-cloning-site between tsr’ and ‘phoA. 
pBBR ori = replication origin. oriT = origin of transfer. neo = neomycin 
phosphotransferase, kanamycin resistance. ‘phoA = C-terminal domain of alkaline 
phosphatase, lacking a secretion signal. enh = translational enhancer. PnptII = promoter 
from neomycin phosphotransferase. tsr’ = N-terminal domain of TonB-dependent 
siderophore receptor. 
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Figure 4.7. Antimalarial effector constructs. Effector genes were cloned in-frame with 
the siderophore receptor gene. The first construct depicted above is the basic PhoA 
secretion construct pNB95 with no effector. Each of the remaining constructs has a 
different protein inserted into the multiple cloning site of the former plasmid. Restriction 
sites used to assemble these constructs are shown at top. 
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Figure 4.8. Western blot of the supernatant of Asaia cultures detecting proteins 
secreted using the siderophore receptor fusion protein. Proteins were detected using a 
rabbit polyclonal anti-PhoA primary antibody and goat anti-rabbit HRP secondary. The 
red boxes are highlighting the predicted protein size of the full fusion proteins on top, and 
the predicted size of the effector molecules plus alkaline phosphatase without the 
siderophore receptor protein. All proteins show proteolysis of the native Asaia fusion 
protein. 
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sample set control Pro-EPIP anti Pbs21-Shiva1 
N 49 29 53 
Range 500 457 420 
Prevalence 91.8 86.2 98.1 
Tbp -- 6.1 -6.9 
Mean 188.6 173.3 119.9 
Mean % Inhibition - 8.1% 36.4% 
Median 144 175 104 
Median % Inhibition -- -21.5% 27.8% 
P-value -- 0.609 0.005 
Figure 4.9. Disruption of Plasmodium berghei development by Pro-EPIP and Pbs21-
Shiva1 constructs. Three-day old Anopheles stephensi mosquitoes were fed paratransgenic 
strains of Asaia expressing either PhoA alone with no secretion signal, or expressing one of the 
fusion constructs combining the siderophore receptor protein, an effector protein, and PhoA. 
These mosquitoes were then fed on an infective mouse and the parasite was allowed to develop 
for 10-14 days. The mosquitoes were then dissected, and oocysts on the midgut were counted for 
each individual. Each dot on the chart represents a single midgut count. The median number of 
oocysts for each data set is marked with a horizontal line. Inhibition, inhibition of oocyst 
formation relative to the −Bact control; Mean, mean oocyst number per midgut; Median, median 
oocyst number per midgut; N, number of mosquitoes analyzed; Prevalence, percentage of 
mosquitoes carrying at least one oocyst; Range, range of oocyst numbers per midgut; Tbp, 
transmission-blocking potential: 100 − {(prevalence of mosquitoes fed with recombinant P. 
agglomerans)/[prevalence of control (−Bact) mosquitoes] × 100}. Pbs21-Shiva1 effected 
significant Plasmodium inhibition of 27.8% calculated using the median. 
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sample set control scorpine PLA2 
N 45 22 23 
Range 279 330 176 
Prevalence 97.8 81.8 100 
Tbp -- 16.4 -2.2 
Mean 98.1 50.8 81.9 
Mean % Inhibition - 48.2% 16.5% 
Median 85.0 22.5 76.0 
Median % Inhibition -- 73.5% 10.6% 
P-value -- 0.014 0.330 
Figure 4.10. Disruption of Plasmodium berghei development by scorpine and PLA2 
constructs. Three-day old Anopheles stephensi mosquitoes were fed paratransgenic strains of 
Asaia expressing either PhoA alone with no secretion signal, or expressing one of the fusion 
constructs combining the siderophore receptor protein, an effector protein, and PhoA. These 
mosquitoes were then fed on an infective mouse and the parasite was allowed to develop for 10-
14 days. The mosquitoes were then dissected, and oocysts on the midgut were counted for each 
individual. Each dot on the chart represents a single midgut count. The median number of oocysts 
for each data set is marked with a horizontal line. Inhibition, inhibition of oocyst formation 
relative to the −Bact control; Mean, mean oocyst number per midgut; Median, median oocyst 
number per midgut; N, number of mosquitoes analyzed; Prevalence, percentage of mosquitoes 
carrying at least one oocyst; Range, range of oocyst numbers per midgut; Tbp, transmission-
blocking potential: 100 − {(prevalence of mosquitoes fed with recombinant P. 
agglomerans)/[prevalence of control (−Bact) mosquitoes] × 100}. The scorpine construct 
produced a significant inhibition of 73.5% calculated by the median oocyst number. 
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sample set control Anti-Pbs21-Shiva scorpine 
N 134 120 96 
Range 500 420 330 
Prevalence 83.6 83.3 63.5 
Tbp -- 0.4 24.0 
Mean 120.4 82.2 44.6 
Mean % Inhibition - 31.7% 63.0% 
Median 90.0 61.5 18.0 
Median % Inhibition -- 32.0% 80.1% 
P-value -- 0.0006 <0.0001 
 
Figure 4.11. Disruption of Plasmodium berghei development by anti-Pbs21-Shiva1 
immunotoxin and scorpine constructs. Three-day old Anopheles stephensi mosquitoes were 
fed paratransgenic strains of Asaia expressing either PhoA alone with no secretion signal, or 
expressing one of the fusion constructs combining the siderophore receptor protein, an effector 
protein, and PhoA. These mosquitoes were then fed on an infective mouse and the parasite was 
allowed to develop for 10-14 days. The mosquitoes were then dissected, and oocysts on the 
midgut were counted for each individual. Each dot on the chart represents a single midgut count. 
The median number of oocysts for each data set is marked with a horizontal line. Inhibition, 
inhibition of oocyst formation relative to the −Bact control; Mean, mean oocyst number per 
midgut; Median, median oocyst number per midgut; N, number of mosquitoes analyzed; 
Prevalence, percentage of mosquitoes carrying at least one oocyst; Range, range of oocyst 
numbers per midgut; Tbp, transmission-blocking potential: 100 − {(prevalence of mosquitoes fed 
with recombinant P. agglomerans)/[prevalence of control (−Bact) mosquitoes] × 100}. The 
scorpine construct produced a significant inhibition of 73.5% calculated by the median oocyst 
number. These are the combined data from the previous trials and repeated trials. 
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Figure 4.12. Signal sequence of the siderophore receptor protein. The signal sequence 
and cleavage site of Asaia bogorensis siderophore receptor protein were predicted using 
the software SignalP4.1 which uses a combination of several artificial neural networks 
and hidden Markov models (Nielssen 1997). In red is depicted the C-score, which shows 
likely the likely cleavage site of the signal peptide (Nielssen 1997). In green is the S-
score, which shows the predicted signal peptide domain as distinguished from the mature 
protein (Nielssen 1997). In blue is the geometric average of the C-score and the slope of 
the Y-score, which results in better cleavage site prediction (Nielssen 1997).  
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Figure 4.13. Signal sequence of the YVTN beta-propeller repeat protein. The signal 
sequence and cleavage site of Asaia bogorensis YVTN repeat beta-propeller protein were 
identified using the software SignalP4.1 which uses a combination of several artificial 
neural networks and hidden Markov models (Nielssen 1997). In red is depicted the C-
score, which shows likely the likely cleavage site of the signal peptide (Nielssen 1997). 
In green is the S-score, which shows the predicted signal peptide domain as distinguished 
from the mature protein (Nielssen 1997). In blue is the geometric average of the C-score 
and the slope of the Y-score, which results in better cleavage site preduction (Nielssen 
1997). 
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Figure 4.14. Tat and Sec signal peptide computational prediction for the 
siderophore receptor protein. The signal sequence of the siderophore receptor protein 
was identified computationally using the PRED-TAT application, which uses a hidden 
Markov model to predict both Sec and Tat signal peptides (Bagos 2010). The reliability 
score for this prediction is 0.687. 
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Figure 4.15. Tat and Sec signal peptide computational prediction for the YVTN 
beta-propeller repeat protein. The signal sequence of the YVTN beta-propeller repeat 
protein was identified computationally using the PRED-TAT application, which uses a 
hidden Markov model to predict both Sec and Tat signal peptides (Bagos 2010). The 
reliability score for this prediction is 0.988. 
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Figure 4.16. pNB124. This plasmid is identical to plasmid pNB95, except tsr was 
truncated to retain only the coding sequence for the 51 aa signal peptide of the 
siderophore receptor protein. 
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Figure 4.17. pNB124. This plasmid is identical to plasmid pNB93, except ybp was 
truncated to retain only the coding sequence for the 34 aa signal peptide of the 
siderophore receptor protein. 
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Figure 4.18. Western blot demonstrating the secretion of alkaline phosphatase from 
Asaia SF2.1 using only the 51 amino acid long siderophore receptor signal or the 34 
amino acid long YVTN beta-propeller repeat protein signal sequence. Protein 
samples loaded were 15 μl of supernatant from liquid culture (sup), or 5 μl of 
concentrated pellet (pel). The bands shown are of the correct predicted size for these 
contructs, 54 kDa.  
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Table 4.1. Proteins identified from genetic screen for secreted Asaia proteins. 
 
 Signal sequences were identified using the PRED-TAT software. Predicted signal 
sequences are highlighted in blue. Protein identification is from protein BLAST hits 
against the Asaia SF2.1 genome, with related species identity from whole NCBI database 
if the result was hypothetical shown in parentheses. 
 
protein identification Amino acid sequence Secretion pathway 
membrane protein 
glycerol transporter 
(Mgt) 
MTQITVVLLFGITTIHGVTQVGDFYA Sec-dependent 
(0.983 reliability 
score) 
hypothetical protein 
(Acetobacter outer 
membrane 
siderophore receptor) 
(Tsr) 
MTLLPRETHDSGRHNPIVAPSTRRKRPLAAGLMSATA
CVALLHFVSDARAQSVSASETSTIPVNAAKAPAKSKV
KVNAQSRSTRARAVSAPVGDAPATSR 
Tat-dependent 
(0.983 reliability 
score) 
major facilitator 
transporter (Mft) 
MMLARLAHLTYNPHSSFCKINSFSFKLRIYRKMSQLT
SHDNRLVGPYGYSALAIAALIFFAMGFVTWL 
no signal identified. 
transmembrane 
domain predicted 
carbohydrate porin 
(Chp) 
MDQMIWRSHTDPNRTISLFGRAMGAPQSDRVPIDFS
LNFGLTFNDPLPYRTDDTFGIGMGYTHVSGALANYD
RAVRRYSGAYSPTQGGETYVELTYQYQFTGWMQWQ
PDFQYIFNPGGGIPNPSHPDRRL 
no signal identified. 
transmembrane 
domain predicted 
multidrug ABC 
transporter (Mdt) 
MEMSIIRSIDVELGQYVKKGQVLAHLDPTITKADIVN
LKAQRDSYQATINRLHAEAEGKTFTPDL 
no signal identified 
TonB-dependent 
receptor (Tdr) 
MHRYGNLLLSMGLNINRTTLTHNGLSATGTPLLNAQ
TTAYLTSESPRSKIVLNAYYTLGNWDVNLRQSRYGQ
TVGMLTYQDWTPASAICPINGKALRGSNVCFAQFKN
TPRWLTDLEIGYRFNQHWHVAVGANNIF 
Sec-dependent 
(0.982 reliability 
score) 
hypothetical protein 
(Xanthobacter TonB-
dependent 
hemoglobin receptor) 
(Thr) 
MPAYRAITLAAANLTKYNLTTLGFEADNTSQFPIGPV
LASLNYGGEYYHDSVKTKDQTGYEGSTPSGGRGVG
SAFTQLALNWKIVQLTGALRYDTYHASGSGV 
Sec-dependent 
(0.949 reliability 
score) 
cell wall-associated 
hydrolase (Cwh) 
MLVRSLVSRPYGWGNYNFYNDCSAELRSLLIPFGIL
MPRNSLAQIQATSRTVDLGKEDVEARLDYLV 
no signal identified 
glucose 
dehydrogenase (Gdh) 
MTMLAVRADFTACRNRQVVSFSGAVTDNNSTKEPSG
VTRAFDLFTGKLVWVFDPSNPDPNEMPSGDHKYVA
NSPNSWITASYDANLGLVYIPTGVQTPDQWGGNRTP
DAERYASSVLALHADTGKLAWSYQTVHHDLWDMD 
Sec-dependent 
(0.718 reliability 
score) 
unidentified protein 
(Gluconobacter 
YVTN beta-propeller 
repeat protein) (Ybp) 
MKFSHHAFIVSLVGLSLATAQATRAQETPAAPAQAAS
APATASSAASGVTSQAPASAATTPSAAPSSSATPTSTT
AGSTTPASTAPVAPVVQVTPPAATSAATPVAGAVQTIP
GMPAVIDPKNIYSETISGKISPAIKDDLARVYVPNLRG 
Sec-dependent 
(0.988 reliability 
score) 
hypothetical protein 
(Asaia bogorensis 
cellulose synthase 
subunit AB) (Csy) 
MKHVRHSIAFLESWIDDAHHSPARTAIKTGLISFAILC
MVIAAFVHL 
no signal identified. 
transmembrane 
domain predicted 
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lysine 2,3-
aminomutase (Amu) 
MLSPRRLRHIIEALSAMPHIQTIRIHSRVPVADPARITS
AMLDALETDRALWIVLHANHASEMTGQARAAIRQI
QSRAIPVLSQSVLLRGVNDTEEALEALLRAFVTARIK
PYYLHQLDPAPGTSHFHVPI 
no signal identified 
peptide ABC 
transporter permease 
(Ptp) 
MIRLALRLRGLSGSGF no signal identified 
hypothetical protein 
(Gluconacetobacter 
fimbrial assembly 
family protein) (Faf) 
MQRDVTLPLAAEQDLAAILAYEMDRLTPFDAEALF
WDFIVLRRDEALGQIMLRLSVVPQAPLRPLFERLHLL
EAHPQAIADETGETLIRQPVARPLVTRLSDPRLALPLG
GCTLLACLLLGLFWHQSRVLSGYERQIDALRGPALE 
no signal identified 
amino acid ABC 
transport permease 
(Aap) 
MALPXSRAMSRFHDSVDXVLGDMMSDGTLQTILRR
WNLWTPEMAAMTGDPQRCVRCLLFAWLRYRDAMR
STARLGGAVPPLSRISAHHRQGGGADPCGVGPFHDP 
no signal identified 
Ribonuclease I (Rns) MGTYLAERAGLRVRHDDLMAFFRTASQTTLPRALQL
RCETDHEGRIVLTQLWFTLAPGKMHLFPAAESYLTSP
QNQDNCPAEFWV 
no signal identified 
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Table 4.2. Plasmids used in this study 
Plasmid Relevant Characteristics Source 
pNB51 pNB20 w/ promoter region changed to PnptII this study 
pNB90 pNB51 w/ phoA insert used for genomic library construction this study 
pNB91 genomic library of Asaia DNA-phoA fusions this study 
pNB91.1 possible heavy metal transport protein PhoA fusion this study 
pNB91.2 outer membrane siderophore receptor PhoA fusion this study 
pNB91.3 Sugar permease, glucose/galactose transporter PhoA fusion clone this study 
pNB91.4 carbohydrate-selective porin OprB PhoA fusion clone this study 
pNB91.5 HlyD family secretion protein PhoA fusion clone this study 
pNB91.12 TonB-dependent receptor plug  PhoA fusion clone this study 
pNB91.14 TonB-dependent hemoglobin receptor  PhoA fusion clone this study 
pNB91.17 putative cell wall-associated hydrolase PhoA fusion clone this study 
pNB91.18 Quinoprotein glucose dehydrogenase  PhoA fusion clone this study 
pNB91.24 YVTN family beta-propeller repeat protein PhoA fusion clone this study 
pNB91.25 cellulose synthase subunit AB PhoA fusion clone this study 
pNB91.112 L-lysine 2,3-aminomutase PhoA fusion clone this study 
pNB91.113 diguanylate cyclase  PhoA fusion clone this study 
pNB91.132 fimbrial assembly family protein  PhoA fusion clone this study 
pNB91.136 amino acid transport permease protein PhoA fusion clone this study 
pNB91.141 Rnase I PhoA fusion clone this study 
pNB92 pNB51 w/ phoA insert and MCS for gene fusion construction this study 
pNB93 pNB92 w/ YVTN beta-propeller repeat gene cloned this study 
pNB95 pNB92 w/ siderophore receptor gene cloned. this study 
pNB96 Siderophore receptor - Pro-EPIP - PhoA effector construct this study 
pNB97 Siderophore receptor - scorpine - PhoA effector construct this study 
pNB99 Siderophore receptor - PLA2 - PhoA effector construct this study 
pNB101 Siderophore receptor - prochitinase - PhoA effector construct this study 
pNB102 Siderophore receptor - anti-Pbs21 scFv-Shiva1 - PhoA construct this study 
pNB103 Siderophore receptor - Shiva1 - PhoA effector construct this study 
pNB105 Siderophore receptor - GFP - PhoA effector construct this study 
pNB106 Siderophore receptor - anti-BSA scFv - PhoA effector construct this study 
pNB107 Siderophore receptor - anti-Pfs25 scFv - PhoA effector construct this study 
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pNB108 Siderophore receptor - anti-Pfs48/45 scFv - PhoA effector construct this study 
pNB124 pNB92 w/ the siderophore receptor 51aa signal peptide cloned this study 
pNB125 pNB92 w/ the YVTN beta-propeller 34aa signal peptide cloned this study 
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Table 4.3. Oligonucleotides used in this study 
Oligo Sequence 5' - 3' Purpose 
PhoA F NdeI taCATATGcctgttctggaaaaccgggc phoA directional cloning 
for pNB90 library vector 
PhoA R PacI taTTAATTAAggtgacaaggcaggaaaccac '' 
PhoA seq R1 cggcagtaatttccgagtcc sequencing PhoA library 
inserts 
PhoA F NdePacSbf TACATATGTTAATTAAAACCTGCAGGATGCCTGT
TCTGGAAAACCGGGCTG 
phoA directional cloning to 
generate effector 
expression constructs 
PhoA R Fse taGGCCGGCCggtgacaaggcaggaaaccac '' 
siderophore F NdeI TAcatATGCCCAGAGCCGCTCGAC secretory leader protein 
directional cloning 
siderophore R 
MYC PacI 
TAttaattaaGTTCAGATCTTCCTCCGAGATCAGTTTC
TGTTCAACAATCGGCGCCTCAGCCTGG 
'' 
YVTN F NdeI TAcatATGAAGTTTTCACATCACGC '' 
YVTN R MYC 
PacI 
TAttaattaaGTTCAGATCTTCCTCCGAGATCAGTTTC
TGTTCAATGGCATAGGCCACATCATC 
'' 
scorpine F PacI taTTAATTAAaggctggattaacgaagagaagattc effector gene 
directional cloning 
scorpine R SbfI taCCTGCAGGaataagacaggggggtgccgc '' 
Shiva1 F taTTAATTAAaatgccgcgttggcgtctgttc '' 
Shiva1 R taCCTGCAGGaacccaccgcacgcgcatc '' 
PRO-EPIP F PacI taTTAATTAAaatggctagcgaagaaccgc '' 
PRO-EPIP R SbfI taCCTGCAGGacccggggctgcctttcac '' 
Pbs21Shiva F PacI taTTAATTAAaagcgaggtccagctgcagcagag '' 
Pbs21Shiva R SbfI taCCTGCAGGaacccaccgcacgcgcatc '' 
mPLA2 F PacI taTTAATTAAaatggctagctggcagatcc '' 
mPLA2 R SbfI taCCTGCAGGagtacttgcgcagatcgaacc '' 
EPIP4 F PacI taTTAATTAAagataaatccctggttaagg '' 
EPIP4 R SbfI taCCTGCAGGagcccggcgagcccttc '' 
Prochitinase F PacI taTTAATTAAagaagaaccgcataaggccg '' 
Prochitinase R SbfI taCCTGCAGGacttcttgccttcggcgctg '' 
Pfs25 F PacI taTTAATTAAaCCTTCTTCGATGTTCGCCTCtc '' 
Pfs R SbfI taCCTGCAGGaAGCCAGCGGATAGACGCTAGg '' 
Pfs48/45 F PacI taTTAATTAAaCAACCTGCTGAACTGGACATCG '' 
Pfs48/45 R SbfI taCCTGCAGGaACTTGTAACGCTAGGCGGTGTTG '' 
GFP F PacI taTTAATTAAaagtaaaggagaagaacttttcactg non-effector gene 
directional cloning 
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GFP R SbfI taCCTGCAGGatttgtatagttcatccatgccatgtg '' 
BSA F PacI taTTAATTAAaATGGCCGAGGTGCAGCTGTTG '' 
BSA  R SbfI taCCTGCAGGaTGCGGCCCCATTCAGATCCTC '' 
Sider51 R MYC 
PacI 
TAttaattaaGTTCAGATCTTCCTCCGAGATCAGTTTC
TGTTCCTGTGCCCGTGCGTCACTG 
Leader peptide directional 
cloning 
YVTN34 R MYC 
PacI 
TAttaattaaGTTCAGATCTTCCTCCGAGATCAGTTTC
TGTTCCTGTGCCGGAGCTGC 
'' 
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Table 4.4. Bacterial strains used in this study 
Strain Genotype Purpose 
E. coli Top10 F' F´{lacIq, Tn10(TetR)} mcrA Δ(mrr-hsdRMS-
mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 
Δ(ara leu) 7697 galU galK rpsL (StrR) endA1 
nupG (from life technologies #C3030-03) 
(Durfee 2008) 
molecular cloning 
and plasmid 
propagation  
Asaia SF2.1 wild type (from Guido Favia, University of 
Camerino, Italy) (Favia 2007) 
protein expression 
and 
paratransgenesis 
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Table 4.5. Secretion signal prediction from Asaia sp SF2.1 genome. 
 
 The Asaia sp. SF2.1 genome ORFs were processed using the SignalP4.1 signal 
prediction algorithms to identify Type II secretion signals. The secretion signals were 
further characterized using PRED-TAT to identify the type of signal used. 
Protein Score Amino Acid Sequence Type 
peptidyl-dipeptidase DCP  0.936 MPVFRHTAALAAVALPLLSSTALA Sec 
gamma-glutamyltranspeptidase  0.929 MKRVCTRVAALPLLLASISVSSLAQA Sec 
hypothetical protein 0.928 MLVFNRRLLTGVAALAMTLSAPAFA Sec 
hypothetical protein 0.924 MRSFTRRALAASTFAAAALAVMPVAHA Tat 
TonB dependent receptor 
protein 
0.919 MKLRKQRHALTLSLFCSPLALLSATAHA Sec 
TonB dependent receptor 
protein 
0.913 MAISRIRICRASMLLGATILAGASFTAQA Sec 
hypothetical protein 0.907 MFKTRFLPALALTALVAAPVAHA Sec 
ammonium transporter 0.905 MSRVFKALAPLALCALPLPAFA Sec 
peptidyl-prolyl cis-trans 
isomerase 
0.904 MRLTRPALFCAALISGTTLAAPAFA Sec 
hypothetical protein 0.902 MVSFPCRLVASTVLLASGLSALPAMA Sec 
hypothetical protein 0.901 MKKALPVLAALMLGLPLSAQA Sec 
alginate lyase 0.899 MKKGLFLFPACALASFVAAAHA Sec 
hypothetical protein 0.898 MTRFLSLLLVLGALPVAAFA Sec 
TonB dependent receptor 
protein 
0.893 MKLRHRLIISASLPALLIAAHSAAMA Sec 
hypothetical protein 0.888 MTPRSFAAFAASLPLCFLATTAHA Sec 
iron ABC transporter 0.888 MRRILFAFALLALASTGSSLA Sec 
peroxiredoxin  0.886 MKRCFIPVSAALLSLSLAAAVPSAHA Sec 
hypothetical protein 0.884 MQVQSFRRWRGAALAALAFAVAPAIAQA Sec 
pentapeptide MXKDX repeat 
protein 
0.884 MSFRTLALACAFSSAMLLGAPAFA Sec 
ABC-type phosphate transport  0.883 MQLSRIFGALSLSLALSCGVSHAA Sec 
hypothetical protein 0.883 MRFCSALILGLVSCASIAPLHA Sec 
copper resistance protein CopB  0.882 MNMRRHTINFLAGLAGTLLLSSGSHA Sec 
beta-lactamase  0.873 MVQRRHSFLRLLSVACGLALTAPAWA Sec 
hypothetical protein 0.870 MFAFTKSFIAAASLVALAAQPALA Sec 
Alpha/beta hydrolase family 
protein 
0.870 MALARLLLTLCGMGTALA Sec 
hypothetical protein 0.869 MKHVFKAALAVSALLAAPALTPAPAFA Sec 
pilus assembly chaperone 0.868 MVTLLRKTCALGFLAALIVHQAPAFA Sec 
tricorn protease-like protein 0.868 MRLSSLLASTAIASLTLLGLASPPAQA Sec 
hypothetical protein 0.867 MMLRRRSALLGLAASWSLGRSSLAFA Tat 
TonB-dependent receptor 0.866 MSSSFTHRCLMMLLAGTALA Sec 
gluconolactonase 0.863 MNPAMKRRSFLSAASVAPLLGVAGPALA Tat 
outer membrane efflux protein 0.862 MATRRNRDAAGRLLLAAAALIVSSGAARA Sec 
hypothetical protein 0.859 MAKLRRGAFLAATLFVLPAGTAFA Sec 
polyphosphate-selective porin O 0.859 MTSLPRACRLLLASVSLASLAIATPVRA Sec 
gluconolactonase 0.858 MKTRLTLCTLALSLAATLVSPPSYG Sec 
cupin 0.857 MKYLWPLPVFLAFLSTAVMVQA Sec 
3-carboxymuconate cyclase 0.855 MKTTISRRSFALGTLGLLGCGTAMA Tat 
cupin 0.854 MFAAYLARPLPCRRTLSSISILAAMMPFTAF
A 
Sec 
porin 0.853 MSQTLSSTVLRFFSACLAVSCLTPVAHA Sec 
hypothetical protein 0.852 MIRYTALILSLAAPGIAQA Sec 
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peptidase M61 0.851 MTIRLFRAGTFLAALVLGTHAVSAFA Sec 
glucose dehydrogenase 0.850 MRKPALMTATILGGLISATVAFA Sec 
hypothetical protein 0.847 MVNHAHSMRPFMFRAAFVGLIALMGYSV
PALA 
Sec 
hypothetical protein 0.847 MLKSFLLLTVAALTGISPALA Sec 
hypothetical beta-glucosidase 0.846 MTSSSIARKKYLALAVGMAALLAGSRAIA Sec 
TonB-dependent receptor 0.846 MRRITGLVALALAGATSLTTAQA Sec 
thiol:disulphide interchange 
protein DsbD 
0.846 MARPRGGRQFSSFTAIGLMLRKLSPVVLTL
LAFGSAPAFA 
Sec 
membrane protein 0.845 MKTSFKISTALLTGFVAAVAAPVAQA Sec 
membrane protein 0.844 MSIFSAARFVAASALLASVSLPSLAQA Sec 
hypothetical protein 0.840 MIRKLTGAAIALTAMTAVASAHA Sec 
Glutaryl-7-ACA acylase 0.839 MRVGHLTRSMLLVTSCLLGASQALA Sec 
TonB dependent receptor 0.838 MAYVFGRAKLKIGLAICLASATCLWQNFA
HA 
Sec 
peptidase S41 0.836 MRKARNCLLLSVFSLTPILAWA Sec 
peptidase M16 0.833 MSVLPPLRKALLASSLLVAPTLFVAVSAPS
MA 
Sec 
hypothetical protein 0.831 MMTRPKGLRHRLALSLFLCSVPAGLTAAP
AHA 
Sec 
hypothetical protein 0.830 MSRISLGVFLVLTISPALA Sec 
hypothetical protein 0.829 MSVKHSLCAVALLTGALTAAFAGNWCAVA Sec 
hypothetical protein 0.829 MRRLMSAGAALVALSAGFAVTPASA Sec 
purine nucleoside permease 0.826 MLPACLASLACVLDLGVASAHA Sec 
membrane protein 0.824 MRLRTALLAMTSMAAAPTIAMA Sec 
hypothetical protein 0.823 MKGWLCALSALPVFLALLAAQA Sec 
hypothetical protein 0.823 MLSRLCLGLTAVAGLTFAGASAHA Sec 
hypothetical protein 0.823 MMKMHLTKLAALGFALAVSPSLVATNALA Sec 
biopolymer transporter exbB 0.823 MTRLFRLPALAAPALAVTLAVAQGVVVPAV
ALAQETPAAQPAAPAPDAAAPAPAAPDAA
APAAPGAPAPDAAAPAPGAPAPDAAAPA 
Sec 
cadmium transporter 0.822 MKRVQAIPALLMTVCVTGALLFPAGAQA Sec 
Periplasmic phosphoanhydride 
phosphohydrolase 
0.818 MIRALILSLALALGGAGTAQA Sec 
Thiol-disulfide isomerase 0.816 MFHRKFGVLTSLALGLSTLSVAAPALTSNV
AYA 
Sec 
nuclease 0.815 MTRRSLFALPALLSVAALTLASKPAQA Sec 
NAD dependent epimerase 0.814 MTRPMPQPVPRALKSLSRLGCLMLAMVS
CTTLA 
Sec 
Inosine-uridine preferring 
nucleoside hydrolase 
0.812 MRCFLASLALAALTIGTASA Sec 
polyisoprenoid-binding protein 0.808 MNVQFRPLPVRQMIALFSVLLPMAGATLA
SA 
Sec 
GntR family transcriptional 
regulator 
0.807 MKRLALSLPIMCITLAAQPVMA Sec 
murein transglycosylase 0.807 MSRVKSLLLTSTLLLLGGCSTHA Sec 
phenylacetaldoxime dehydratase 0.806 MFMKRLSLFLAASALTVLSSSGHA Sec 
amino acid permease 0.804 MALRQHQQSKRPRYATALSLIAGISTLTAFA
APSFA 
Sec 
toluene transporter 0.803 MFKTCISFSRRAALGVLTTALVSVAALSTP
AHA 
Tat 
ABC transporter permease 0.801 MSVFDVRNAALLSLALSMTAGAATAMA Sec 
peptidylprolyl isomerase 0.800 MRISRSIKTLVAGASFLALAACG Sec 
aldose 1-epimerase 0.792 MKSAVCLVALAGIMDGAAQA Sec 
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Ferrichrome-iron receptor 0.791 MSLLTLSALNPGMPRPRRLALSALLMLSAT
LPCQAFA 
Sec 
anthranilate synthase subunit I 0.789 MMRPVAFLLAIMLAGSGLSRAHA Sec 
Endonuclease 0.784 MLRVFLSASAVFATLALPLTMAHA Sec 
sirohydrochlorin ferrochelatase 0.784 MKPELGLLATLMALPLAPLTAVA Sec 
ArsR family transcriptional 
regulator 
0.782 MIGPIIVLMLLVLGVAPALA Sec 
glycosyl transferase 0.778 MMRSRSSSPILVVKRLTMALCMGSAVQPAI
A 
Sec 
membrane protein 0.777 MKISALGATLMAATFAVATPAFA Sec 
ABC transporter 0.776 MSPRLSCTALALLALASAPQHARA Sec 
CTP synthetase 0.776 MTIPSLSALRRSLLTFVMAGAVTSVSAACA
QS 
Tat 
nitrogen utilization protein B 0.773 MKQSAPLRLFLCALGAGTVLMPALATA Sec 
peptidase S10 0.773 MAHDLFMRHFLSSAILVSALSLTACA Sec 
thioredoxin 0.769 MPGFRRGLLALPLLFSIWGSSQARA Sec 
phenylacetaldoxime dehydratase 0.768 MFMKRLSLFLAASALTVLSSSGHA Sec 
methionine ABC transporter 0.765 TRQLIPAIALGLLTGCASA Sec 
Xylose ABC transporter 0.765 MNKFLKTLLASTLITGSALSLASGKACA Sec 
glycosyl transferase family 1 0.764 MKRFIPLSPALLTGFALIGAVAHA Sec 
Glycerophosphoryl diester 
phosphodiesterase 0.763 MLSRRHALTLGAAGFCAPAFASRSFA 
Tat 
TonB dependent receptor 0.762 MKTFRIVYGIGLAILLPLGAQAEA Sec 
Ferrichrome-iron receptor 0.758 MSAKRVRPSHPLTLIVGMTLACTSAQAQA Sec 
Type I secretion outer 
membrane protein, TolC 
precursor 0.758 MKTDQLKAYTSLSVGLIALLNSTTALA 
Sec 
Glutamine cyclotransferase 0.757 MRLLLVCIASFSGLAMTACLFAPAGLA Sec 
Dipeptide-binding ABC 
transporter, periplasmic 
substrate-binding component  0.757 MRGRYGLILAGLGAVLLAPSLHSQGAQA 
Sec 
Outer membrane vitamin B12 
receptor BtuB 0.757 
MRPMRSLRACLLTGISLAPALGLLPLLPAA
LA 
Sec 
heat shock protein HtpX 0.756 
MIINPTRRLSARYRCALLALTSLSFALVPEI
GLAQAGPVSTPPGTVSAPVAPSVPSAERGP
QSPA 
Sec 
hypothetical protein 0.756 
MNSPILPPMKHAAASLLALLALGGAARHA
HA 
Sec 
FIG01225103: hypothetical 
protein 0.755 MRPYPALPALLLLAGSLPCAAHG 
Sec 
hypothetical protein 0.754 MRQLLLIILCALALHGLAGTSRAQS Sec 
secretory lipase 0.754 MRSVLAMMAVSALTLTACA Sec 
hypothetical protein 0.753 MTRKLALLAAVALALPAGGLAGVAQA Sec 
Cysteine desulfurase (EC 
2.8.1.7) 0.75 MTTSPNRRFLLKSFATGAPALLASSSVAA 
Tat 
FIG00688467: hypothetical 
protein 0.745 MGAMGLAVAVATLSGAMLASITPAQA 
Sec 
Various polyols ABC 
transporter, periplasmic 
substrate-binding protein 0.744 MKKSLLLASAALGLGLGAQAKA 
Sec 
Levansucrase (EC 2.4.1.10) 0.744 MLNLLLAGSMVATFTSQAAFA Sec 
Sigma-fimbriae tip adhesin 0.741 MRALAILAIGLCCGLITPAARSACA Sec 
Heavy metal RND efflux outer 
membrane protein, CzcC family 0.741 MRARCFLASSLVAVAALAPGARA 
Sec 
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Adenosine deaminase (EC 
3.5.4.4) 0.739 MLPRILPAFALAVPLVFSSASARA 
Sec 
TonB-dependent receptor 0.738 MRHLRRDLLVFCSAIVMNSVVGAIAAQA Tat 
hypothetical protein 0.73 MRHILKIGLAALPLIGLMGGAPMVQA Sec 
peptide chain release factor 2 0.73 MLMRPALLFLASLASALGLSACVPAPG Sec 
hypothetical protein 0.729 MNKSFLAGLTLVTFLAALPQAHA Sec 
Hypothetical membrane protein 0.728 MGFSRALAPLVLISSCALTACGSSTPA Sec 
hypothetical protein 0.728 
MSFSIVRPPIRRRARALLGFTLVVSTSLFVA
GQPHA 
Sec 
Outer membrane lipoprotein 
OmlA 0.726 
MKSASQKTSQRQKSHAGLARALLCIAPLA
LA 
Sec 
COG1744: Uncharacterized 
ABC-type transport system, 
periplasmic component/surface 
lipoprotein 0.724 MSLKRPALLTRRGLLAAGGCAALAGRASA 
Tat 
hypothetical protein 0.724 MTRYARQFLPLLAILGTGTALT Sec 
Ferrichrome-iron receptor 0.721 MSVSLRAALCLSSLLSAAMVPDALA Sec 
Gluconolactonase (EC 3.1.1.17) 0.717 
MMELKMPLARRGFLTTALGGAVCAALPAR
AATDVTA 
Tat 
FIG00687573: hypothetical 
protein 0.717 
MSRSRSRIQSFLRFGSVCLLLGSVSPLLTAC
G 
Sec 
Lipid A biosynthesis lauroyl 
acyltransferase (EC 2.3.1.-) 0.715 MARLALAALSSLPAAMA 
Sec 
Acid phosphatase 0.714 
MLSPLIMTRPTRSLAAVLLALTCLSPSLVAK
PAQA 
Sec 
hypothetical protein 0.714 MQKVLPVLTALLLSIIPQATLANA Sec 
Membrane fusion component of 
tripartite multidrug resistance 
system 0.712 MAYKKPLLFAGCTALVLTGLAWS 
Sec 
TonB-dependent receptor 0.705 
MVRRVTLPYRHRGLRQSTLMVALFCTVFA
APAEGLA 
Sec 
hypothetical protein 0.702 
MTNPTNFRRSARVLGGLAGLLMLAACEGT
A 
Sec 
Flagellar L-ring protein FlgH 0.701 MTRFFSRGSLTVLLLLGSCTSLS Sec 
hypothetical protein 0.7 MGLVLMLLVGMASQASAHA Sec 
Peptidase 0.699 MRSLRPSVAALIIGTVLTGMPARA Sec 
hypothetical protein 0.698 
MQTRNRTVTPGFLTQTRQALPGLFLGCILS
ASALSGCAQA 
Sec 
hypothetical protein 0.698 MRHLLGRTLMAASLIITLPQAMA Sec 
hypothetical protein 0.698 
MSQQSLRVSLHNRTRAALRRAALATLSVG
ALGLTCHSGMAYA 
Sec 
hypothetical protein 0.696 
MDFAERRNGLMIFMKSRLSKSASASLAML
GFSVALAPVPALS 
Sec 
hypothetical protein 0.696 MRRLSGLKLAASVVAVGAAFASHGASA Sec 
hypothetical protein 0.696 MTTASFLRTGALAVMLALPALG Sec 
MISCELLANEOUS; Unknown 0.695 MRTYLIAGALALASCVVVTGAFVSPTFA Sec 
Xylose ABC transporter, 
periplasmic xylose-binding 
protein XylF 0.693 
MFLFRFGFFKMITRTKFFLGALALSTVLAA
PAARA 
Sec 
hypothetical protein 0.693 
MKTRFALTLAHAGLLGVSLLAGCADTPAP
QPTQA 
Sec 
Prolyl endopeptidase (EC 
3.4.21.26) 0.691 MKRILMAMTSLVCTTFLPPVVGQALA 
Sec 
D-alanyl-D-alanine 0.691 MRTRRFLLSGAAGLAVSSQFAFA Sec 
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carboxypeptidase (EC 3.4.16.4) 
FIG00687971: hypothetical 
protein 0.689 
MALKLSHGHVLLAGLMLGGAACASSPAL
A 
Sec 
FOG: TPR repeat 0.688 
MRFPRCSRALLVASSLLAASSFVPVIGSSLV
TIAHA 
Sec 
surface antigen gene 0.686 MKFSHHAFIVSLVGLSLATAQATRA Sec 
Acid phosphatase, class B 0.686 
MNYSSIVHAVSRRRANRFGRALALASVLG
ATAAGAAHA 
Tat 
hypothetical protein 0.684 MSRRNAFICCLPLMMGLLLLA Sec 
hypothetical protein 0.684 MTALLLKRCVMLCAFLMIPHAGFCA Sec 
hypothetical protein 0.683 MPGSLFTTPLTRIFTALLFMAPFGTGMAVA Sec 
Flavodoxin reductases 
(ferredoxin-NADPH reductases) 
family 1 0.683 
MRRVFLSVSVVIMTLLVSMSEGFAQAPGES
PAVPAMSSGTMTGPTTGSPPPSLA 
Sec 
TPR domain protein 0.681 
MQTKHSPLRRVLLASLTAMPLAMVPGAAP
HA 
Sec 
hypothetical protein 0.681 MRSASLLLFLMVLAGCA Sec 
hypothetical protein 0.67 
MDPPAMPRVPSPAFGLALALLAWQPCPAL
A 
Sec 
FIG00687356: hypothetical 
protein 0.669 
MNVPRFFPLMLTAALAATPVLFVPWHAAH
A 
Sec 
TonB-dependent receptor 0.667 MKKSLLFAVSLMCLDSVRAQA Sec 
hypothetical protein 0.661 MTHTAFALFCLTCAVGLPGAARA Sec 
TonB-dependent receptor 0.659 MLLGAAIILSPVVTNVAAHA Sec 
hypothetical protein 0.659 
MRRLALGALLALSACSSVQYVPCPTLVTY
SKADQAALA 
Sec 
Metallopeptidase 0.659 
MTGKFKRTTSLWLGAVSVIALTHQVLPAA
HA 
Sec 
Rare lipoprotein A precursor 0.656 
MKSRKRAYSSTERCKKRLRARIGGIALLCT
VLAPKHGAHA 
Sec 
Bll0045 protein 0.656 MRPAFFLAVGITAIGVLAAA Sec 
hypothetical protein 0.655 MGKLMAFLVGALALTSCNGIDHAACA Sec 
Gluconate 2-dehydrogenase (EC 
1.1.99.3), membrane-bound, 
cytochrome c 0.654 MMKRLSLLLATGFTLIGTLAVPPMGHA 
Sec 
probable outer membrane 
protein 0.653 
MDLRCSKSRWPGARQVRAGSLSVLGLAV
MGATAHA 
Sec 
Heavy metal RND efflux outer 
membrane protein, CzcC family 0.651 MAASLAMALVSGGVATA 
Sec 
hypothetical protein 0.651 MQRFSALPVSDRRTLLLGLGALFLTGAAPA Tat 
hypothetical protein 0.651 
MSHSRFRPLPCAALLGVIGALSACSSPQSP
S 
Sec 
hypothetical protein 0.649 
MVAFSRSLPSRFLPPRHPLRFRFRAISAVAS
LALLAHAAPARA 
Sec 
Potassium efflux system KefA 
protein / Small-conductance 
mechanosensitive channel 0.648 
MSALKRRSALQLLYGLFLVFALSVSTFPAL
A 
Tat 
Phosphate-specific outer 
membrane porin OprP ; 
Pyrophosphate-specific outer 
membrane porin OprO 0.647 MRARSLTSLLLLCGVVMPETGFA 
Sec 
Carboxypeptidase-related 
protein 0.647 MSRKTLVVALLASACFALPRLPAGHA 
Sec 
putative hydroxylase 0.646 MLCSTSVLAAIPSAMA Sec 
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FIG00689409: hypothetical 
protein 0.645 
MTTRLFAPRFRPAMIKRAALLLLLFQAGYA
QPGHARA 
Sec 
hypothetical protein 0.644 MVRLRGSAITLVSALTLAACATKPVVQR Sec 
TonB-dependent receptor 0.641 
MPEHRSAYKKNLVVALISSTALFQVSSPSA
LA 
Sec 
hypothetical 
TRANSMEMBRANE protein 0.638 MRSRLPAITLYGSLACNAALLA 
Sec 
Tiorf138 protein 0.637 MISLGKAGLTGFFLLCMAPSFSYA Sec 
hypothetical protein 0.637 
MKRRVLLTCAASLALSGCAIGPNFHRPDM
LRTGGYQSKALPASIHGTTGTGSAGA 
Sec 
hypothetical protein 0.636 MPINRRQILAGLSAGPVLAILSRAAVA Tat 
FOG: TPR repeat 0.635 MKHAFGALAIGSGLWAGGALA Sec 
TonB-dependent receptor 0.633 
MSHDMHHRKTAYSWGNRIVLPRQAACMA
GLMLPLILPCETALA 
Sec 
Soluble lytic murein 
transglycosylase precursor (EC 
3.2.1.-) 0.632 
MRGISYFASSNSARAFMLCAMLVAGATFN
PLRA 
Sec 
Carbohydrate-selective porin 0.63 
MLKFKAARGRLPKTRRGQMLGASIGLVSA
FAPTAARA 
Sec 
Peptidase, T4 family 0.626 MKRRAFCLASLAATALA Sec 
TonB-dependent receptor 0.623 
MLLRSHTLLPSVARKGVFFLIASTCLMSCG
GEALA 
Sec 
Acylamino-acid-releasing 
enzyme (EC 3.4.19.1) 0.621 
MSLLSLSRVRLLGTSLLSLGMGSATLGGVT
LASAQA 
Sec 
Aldose 1-epimerase (EC 5.1.3.3) 0.62 
MCSPVTNKTPTDKSDTSNRDEARGTSRTR
RSARPIMAIASGSLAAALSLAPAHA 
Tat 
RND efflux system, outer 
membrane lipoprotein CmeC 0.62 MVSLPRRLCAFTFAASLLAGCTVGPA 
Sec 
hypothetical protein 0.616 MKNLILLALSIVSCLACTESRA Sec 
Organic solvent tolerance 
protein precursor 0.616 
MSKRRVAHHRRRSWLAASMLAGTVTFGA
IPEADA 
Tat 
hypothetical protein 0.613 
MMRRLIPALTLGSLLMGLPLAGVPLEALLC
PQAHA 
Sec 
Cytochrome c-552 precursor 0.613 MRAPLALALLAALALTACGKKSAGQ Sec 
Penicillin acylase (Penicillin 
amidase) (EC 3.5.1.11) 0.612 
MPSSPLTGRRALLQASACAALAACLPRPA
RA 
Tat 
Outer-membrane lipoprotein 
carrier protein 0.612 MTVRRGLAATGLAIALAGCAVSGTDGLTA 
Sec 
RND efflux system, outer 
membrane lipoprotein CmeC 0.611 
MKTGYGSRRYYPAKILIGLCLLSLGATGCQ
EGDFNLPKGSAVVAPA 
Tat 
PilL 0.61 MRGTPSLAAACALIMTGITGCA Sec 
hypothetical protein 0.609 MRRLGLAGGCLVPLSLAACTPAPPA Sec 
HtrA protease/chaperone protein 0.607 
MITPHPDGAKAGKIMTDAMPVRLTPSRKF
RSLALVAATALSIGVGASSPAWA 
Sec 
Membrane-bound lytic murein 
transglycosylase B precursor 
(EC 3.2.1.-) 0.606 
MLTRRSILAATAAAPCLYGTSLAGTLGHKG
SAHVHKQATSA 
Tat 
Outer membrane component of 
tripartite multidrug resistance 
system 0.606 
MRAGSRRRALRGSAAGAVFSLALLSGCDL
A 
Tat 
Outer membrane component of 
tripartite multidrug resistance 
system 0.602 MRPLLAPLLALLVAGCVA 
Sec 
Putative ABC transporter, 
periplasmic sugar binding 0.598 
MTLSRRGFMGVAASLTALTPFASARFSGAH
A 
Tat 
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protein precursor 
Periplasmic thiol:disulfide 
interchange protein DsbA 0.597 MSLYRRSFLAAMPALALMPKARA 
Tat 
D-alanyl-D-alanine 
carboxypeptidase (EC 3.4.16.4) 0.594 
MQSATKTNLIKVTRAGKARKWSVFTRALL
GAGLGLGTVAVSAPAHA 
Sec 
RND efflux system, outer 
membrane lipoprotein, NodT 
family 0.594 MTFSPSRSARRLSLLAACCTPLLSGCFMV 
Sec 
FIG00688280: hypothetical 
protein 0.591 
MNVGQKSCLRLLRRPFFSSLTALSLLVGSA
VLAPKAEA 
Sec 
Peptidyl-prolyl cis-trans 
isomerase 0.589 MPALVLLFPGLAAAATAPSPA 
Sec 
hypothetical protein 0.588 MRTAILSRRFAILAVVGLTGLSAGNPA Sec 
hypothetical protein 0.577 
MTKRVSFRSSRKLLAASACLGMLGLSACG
NPYDPGARA 
Sec 
hypothetical protein 0.573 MRTLPLLAAMLLLACCTHPHPPE Sec 
FIG01224591: hypothetical 
protein 0.573 MSERFKTALKLSLLGMSVGTSLTPVAARA 
Sec 
Peptide methionine sulfoxide 
reductase MsrB (EC 1.8.4.12) 0.572 MKFMTSRRQFCFASVCLALSGRAWG 
Sec 
hypothetical protein 0.564 MIVLWALAGLSLLTAMTIASA Sec 
Potassium efflux system KefA 
protein / Small-conductance 
mechanosensitive channel 0.561 
MLSLSRAPNPGATVLTLENRYSARRPFSWC
LLICLLVGSLCLQSGSARA 
Sec 
permease of oligopeptide ABC 
transporter 0.557 MLLAMGALLLLVLGAVAAPLYARA 
Sec 
hypothetical protein 0.546 
MSEASASGNKAASAVAMTASSAALACGV
CCVVPLALPA 
Sec 
FIG167255: hypothetical protein 0.543 
MKRTGIHALFQTQGHKRVLRLSGLTPVTVI
ALMTASSMPALA 
Sec 
FIG00688799: hypothetical 
protein 0.535 MARIVSGRVLAGALMGVMLLIGGHSVHA 
Sec 
hypothetical protein 0.529 
MTQLSSITIKAASAGRRKGAASRYAALGV
LALLSAPVASAALITPALA 
Sec 
FIG004453: protein YceG like 0.526 MKRVILALVLLLLLCPAGGA Sec 
ATP/GTP-binding site motif A 0.525 
MLCLRAVASAGASTLSGFWLALYGLGSPA
HA 
Sec 
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Control 1 Pro-EPIP anti-Pbs21-Shiva1 Control 2 Scorpine PLA2 
44 209 1 0 420 122 126 208 21 82 101 180 
259 500 228 21 10 87 99 133 3 0 132 73 
66 148 189 242 98 31 157 62 95 24 111 116 
115 169 175 248 195 49 87 3 35 24 151 76 
93 175 275 95 0 119 242 30 15 60 64 18 
142 107 250 280 90 8 76 128 126 2 120 28 
211 0 457 0 107 6 90 155 142 1 106 30 
427 0 155 174 300 5 101 75 330 45 30 114 
53 53 277 251 67 285 149 279 0 6 64 77 
9 111 0 324 237 63 135 69 8 0 180 4 
196 377 235 133 110 49 18 35 98 0 9 35 
149 500 320 126 84 43 130 95   65  
86 88 202 118 126 104 85 250     
142 0 83 168 8 122 28 50     
357 86 0  286 340 126 50     
302 111   221 69 91 267     
315 133   7 2 74 78     
405 350   200 177 12 82     
60 480   166 1 4 45     
287 400   93 154 8 55     
72 140   139 159 66 156     
170 214   136 138 0 79     
128 0   57 103 128      
357 300   75 24       
144    139 189       
    52 319       
    166        
 
Table 4.6. Oocyst counts from Anti-Plasmodium in vivo testing. Results from 
dissection and counting of oocysts with mercurochrome staining. 
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Control Scorpine anti-Pbs21-Shiva1    
24 175 27 2 60 0       
26 143 30 38 44 151       
28 40 0 0 41 28       
28 38 60 51 0 4       
120 194 168 28 59 31       
93 282 0 8 45 49       
287 222 293 0 49 58       
157 160 0 21 41 100       
101 97 108 4 62 87       
24 9 0 18 86 40       
36 120 18 5 26 49       
68 70 14  47 20       
61 125 71  101 44       
45 59 80  76        
202 98 157  93        
58  124  23        
130  40  69        
82  20  96        
44  66  99        
178  79  97        
95  74  61        
54  33  19        
63  0  132        
167  0  129        
178  60  133        
0  0  61        
144  41  128        
 
Table 4.7. Oocyst counts from repeated Anti-Plasmodium in vivo testing. Results 
from dissection and counting of oocysts with mercurochrome staining. These data are 
from repeated trials with scorpine and anti-Pbs21-Shiva1 effectors. 
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Chapter 5 
 
Summary and future directions 
 
SUMMARY 
 Malaria is a devastating disease that has significant health and economic 
ramifications worldwide. Novel approaches are needed to complement the existing 
methods of treatment and prevention in order to eradicate the disease. The mosquito 
midgut presents an excellent target for intervention. The work presented here 
demonstrates three methods which can be used to interfere with the vulnerable life stages 
of Plasmodium in the midgut: (1) The production of new anti-Plasmodium single-chain 
antibody effector molecules, (2) the modification of Pantoea agglomerans using the 
hemolysin secretion system to interfere with Plasmodium development, and (3) the 
discovery of native secretion signals in Asaia bogorensis and their use to modify Asaia 
sp. SF2.1 to interfere with Plasmodium development. 
 
Design and construction of single-chain antibody molecules 
 The three single-chain antibody genes that were synthesized have a potential to be 
used in paratransgenic strategies. These scFv molecules specifically target the life stages 
of the Plasmodium falciparum parasite within the mosquito and should have no negative 
impact on any other organism in the host microbiome, unlike some of the broad-range 
antimicrobial effectors used in similar experiments (Barr 1991, Roeffen 1995, 2001). One 
drawback to using these particular antibodies is that they bind only to the surface proteins 
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of Plasmodium falciparum (Roy 2009, Stowers 2000, Eksi 2006); therefore they will not 
provide any protection against the other species of malaria. Although P. falciparum is the 
most virulent Plasmodium species and causes the greatest human mortality of all malaria-
causing species (WHO 2013), interventions are still needed to combat the other 
Plasmodium species: P. knowlesi, P. malariae, P. vivax and P. ovale.  
 In particular, Plasmodium vivax causes tenacious infections and remains in the 
liver of the infected host for years, even after the blood-stage infection appears to have 
been cleared (Baird 2012). Hypnozoites, or “sleeping parasites,” lie dormant in the liver 
and emerge to reinfect the host, causing relapses of recurring blood infection and malaria 
symptoms. Currently, there is no cure for liver stage parasites, making it critical that P. 
vivax transmission is prevented before infection occurs (Baird 2012). Monoclonal 
antibodies are known to interfere with the P. vivax parasite development, and these could 
be converted for use in paratransgenesis as well (Sattabongkot 2003). 
 The single-chain antibodies presented in this work must be expressed and 
subsequently tested for activity against P. falciparum in vivo to assess whether they 
provide protection similar to previous paratransgenic constructs (Wang 2012). Antibodies 
may be modified to include antimicrobial peptides in the fusion protein that will further 
interfere with Plasmodium development and increase the overall inhibitory effect, as is 
the case with the anti-Pbs21 scFv with Shiva1 (Yoshida 1999). The combination of 
multiple effector molecules would help to prevent parasite evolution against either one, 
since a parasite that resists one of the anti-Plasmodium molecules would still be killed by 
the activity of the other. Likewise, artemisinin is used in combination with different drugs 
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to treat blood-stage malaria infections in order to lessen the possibility of resistance 
(Burrows 2013). 
 Although these antibodies are targeted to specific surface proteins of the parasite, 
evolution of resistance should not be as much of a problem as compared to the resistance 
that evolves against the drugs used to kill the blood-stage parasite (Hastings 2002). 
Because there is a strong bottleneck in the life cycle of Plasmodium within the mosquito 
midgut, with less than five oocysts in field-caught mosquitoes on average (Whitten 
2006), there is a far lower chance for the parasite to evolve resistance to interventions in 
the midgut than for the millions of blood-stage parasites present in an infected individual 
to resist antimalarial medications. 
 
HlyA secretion of effectors from Pantoea 
 Positive transmission-blocking results from Pantoea agglomerans strains 
secreting antimalarial effectors into the midgut provide proof of concept that 
paratransgenesis in the mosquito to combat malaria is a possibility (Wang 2012). 
Scorpine, EPIP4, and Shiva1 secreted by the hemolysin secretion system produced nearly 
100% inhibition of P. falciparum oocyst formation in in vivo lab tests and, importantly, 
prevalence was reduced nearly 100%, as well. If prevalence could be reduced, then the 
mosquitoes would no longer transmit malaria and would not pose a threat to us. 
 The successful testing of paratransgenic P. agglomerans strains is hopeful for the 
future of paratransgenesis in malaria. A large number of vector anopheline mosquito 
species are capable of transmitting Plasmodium to humans, and paratransgenic bacteria 
could be used as a powerful tool to simultaneously treat these species. Previous 
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approaches to transgene expression attempted expression of the effector protein from the 
mosquito host tissues (Ito 2001). Although testing of this approach was successful in the 
lab, utilization of this technique in the field would require both the genetic modification 
of many anopheline species and the subsequent replacement of the wild mosquito 
population with the transgenic strains (Raghavendra 2011). Paratransgenesis could solve 
this problem because the same bacteria can be introduced to many vector mosquitoes. 
This could be accomplished quickly and more easily than the currently used methods of 
creating and introducing transgenic mosquito species by feeding the bacteria to wild 
mosquitoes mixed into a solution of sugar water. 
 
Genetic screen for secreted proteins in Asaia 
 Two secretion signals that function in Asaia sp. bacteria were discovered that can 
be used to deliver antimalarial proteins into the mosquito host midgut and disrupt the 
gamete, zygote, and ookinete stages of Plasmodium that develop there. These signals 
include the native Sec-dependent signal from the YVTN beta-propeller repeat protein and 
the native Tat-dependent signal from the siderophore receptor protein. These experiments 
demonstrate that the siderophore receptor protein signal peptide is capable of secreting a 
wide range of proteins from peptides to single-chain antibodies, and therefore, it 
represents a great tool for secretion of active effector proteins. 
 In light of the recent genome sequence of Asaia SF2.1, the secretion signals 
identified from the functional genetic screen were compared to the predicted proteins that 
were identified using the bioinformatic approaches. The proteins identified in the screen 
did not match the top hits from the genome sequence, which would indicate that the best 
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predictions made by computer algorithms are either not accurate enough to rely on, or the 
secretion mechanisms that they employ will not allow heterologous proteins to be 
identified and detected by a genetic screen. The nature of the PhoA genetic screen, 
however, allowed for the quick selection of a leader peptide capable of secreting a 
heterologous protein and demonstrated the activity of the secreted PhoA protein in a 
simple plate assay. This is something that predictive software cannot provide. Therefore, 
the cloning and testing of random genes from a list of predicted signals can be a fruitless 
endeavor; however, when used in combination with a genetic screen, it can certainly be 
useful to have two sets of data to compare. 
 One of the greatest challenges for a paratransgenic strategy for malaria 
intervention is finding a suitable host from which effector molecules can be delivered. 
Asaia sp. SF2.1 has an ideal relationship with the anopheline host for malaria 
transmission-prevention strategies. This species associates with the midgut, salivary 
glands, and reproductive tissues of the host, and they are transmitted from parent to 
progeny and from male to female during copulation (Favia 2007, Damiani 2008). These 
factors allow Asaia to deliver effector molecules to the midgut, where Plasmodium is 
most vulnerable, as well as to the salivary glands where the sporozoite stage of the 
parasite resides. This presents an opportunity to target the sporozoite stage of the parasite 
with the same effectors used in the midgut or with different effectors that target 
sporozoite-specific antigens such as the circumsporozoite protein that coats the outer 
membrane of sporozoites (Foquet 2014). Antimicrobial peptides secreted into the salivary 
glands could function to provide an extra barrier to transmission if Plasmodium were to 
pass through the midgut. Monoclonal antibodies that bind the circumsporozite protein   
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target of transmission-blocking vaccines (Foquet 2014) would possibly be useful if they 
were converted into single-chain antibodies that could be secreted into the mosquito 
salivary glands by Asaia. 
 Paratransgenic strains of Asaia could be applied against other vector-borne 
diseases transmitted by anopheline mosquitoes, such as West Nile virus and Dengue. 
There have been effector proteins identified including antibodies targeting mosquito C-
type lectins necessary for Dengue infection and peptides targeting the West Nile Virus 
envelope proteins that are known to interfere with the transmission of each (Liu 2014, 
Bai 2007). A single paratransgenic strain of Asaia could be engineered to secrete proteins 
targeting multiple insect-vectored diseases in areas where multiple diseases are endemic 
by expressing the genes as part of an operon. There may be further applications in plants 
for paratransgenic Asaia strains to protect crops against pathogens of agricultural 
significance due to its association with plant nectar (Yamada 2000). Some plant-
associated bacteria have a detrimental effect on cultivation of plants, for example, a 
Gluconobacter sp. bacterium reduces plant-pollinator mutualism and lowers the success 
rate of seed production in the orange bush monkey-flower (Vannette 2013). 
 Now that Asaia has been proven to be a viable paratransgenic candidate in the 
laboratory setting, further work needs to be done to increase the efficiency of the 
transgenic constructs to make them viable for release in the wild for field testing. The 
identified native proteins that secrete in Asaia have already had their signal peptides 
identified and retested for activity. Constructs that combine these signal peptides and 
effector proteins need to be built and tested in vivo to determine if there is a decreased 
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fitness cost to the bacteria expressing the protein, as measured by their growth rate in 
culture, and to verify that the anti-Plasmodium activity is retained. 
 
FUTURE DIRECTIONS 
 The antimalarial constructs produced in this body of work have been successful to 
an extent. Plasmodium inhibition was achieved, however, more work must be done to 
improve the function of these antimalarial paratransgenic strains so that they can be 
tested in the field. The identified secretion signals of the siderophore receptor protein and 
YVTN beta-propeller protein will need to be cloned in-frame with anti-Plasmodium 
genes and compared against the constructs containing the full fusion proteins. Utilizing a 
signal peptide rather than a fusion protein for secretion will reduce the protein size 
produced so that it requires less resources for the bacteria to produce, and it should 
secrete more efficiently. Efficient secretion will prevent the membrane from getting 
“clogged” with proteins which is detrimental to the health of the organism. 
 
Transcriptional regulation of transgenes 
 The expression of transgenes using a strong constitutive promoter has a fitness 
cost on the bacterium that cannot be ignored (Rang 2003). The Asaia strains produced in 
this study have a decreased growth rate of at least half that of wild type Asaia 
(unpublished observations). Such a significant decrease would render the transgenic 
strain uncompetitive in the wild and  unlikely to remain in the mosquito population 
without constant reintroduction due to the competitive fitness disadvantage (Lenski 
1998). To counteract this effect, either a weaker promoter could be utilized or a 
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conditional promoter that is regulated in some way so it is repressed when not needed. A 
promoter that is turned on or off depending on the presence of a blood meal in the 
mosquito midgut could regulate the expression of the transgene so that the construct 
would have a minimal fitness burden. If such a promoter is identified, it would both allow 
the bacteria to compete with the other midgut microbiota normally and activate the anti-
Plasmodium effector genes only when an infected blood meal is taken by the host. 
 
Maintenance of transgenes without selection 
 Once efficient constructs are designed for the expression and secretion of 
antimalarial effectors, these gene constructs will need to be maintained without antibiotic 
selection so they can persist in bacteria living within wild anopheline mosquitoes. The 
simplest way to accomplish this is to introduce the transgene into the bacterial 
chromosome by a transposon insertion similar to that used in paratransgenic Alcaligenes 
sp. (Bextine 2004). These well-established transposons have been utilized in a broad 
range of bacterial species including the Tn5 and Himar1 transposon systems (Reznikof 
1993, Bextine 2005). Antimalarial effector constructs can be inserted into the 
chromosome of Asaia sp. SF2.1 using one of these systems with a single copy of the gene 
and without an antibiotic resistance marker. 
 
CLOSING REMARKS 
 With the progress in anti-Plasmodium paratransgenesis described in this work, 
there is a greater possibility for future laboratory tests of paratransgenic Asaia strains. 
These can potentially lead to future field testing and eventual use towards malaria 
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eradication. Paratransgenic bacteria present one more potential weapon in the arsenal 
necessary to combat this deadly disease and will complement both current and future  
interventions in the fight for a world without malaria. 
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Abstract 
Asaia sp. are abundant members of the microbiota of Anopheles sp. mosquitoes, the 
principle vectors of malaria.  Here we report the draft genome sequence of Asaia sp. 
strain SF2.1. This strain is under development as a platform to deliver antimalarial 
peptides and proteins to adult female Anopheles mosquitoes. 
 
Asaia sp. SF2.1 is a Gram-negative member of the alpha-Proteobacteria, family 
Acetobacteraceae (12).  Asaia sp. were first isolated from the nectar of tropical flowers 
and subsequently from insect midguts (3, 7, 12, 13).  The taxonomy of the genus Asaia is 
in flux and we are hesitant to assign Asaia sp. SF2.1 to a specific species, although it 
seems to be most closely related to either Asaia bogorensis or Asaia platycodi 
(unpublished obervations).  Asaia sp. SF2.1 was isolated from a laboratory colony of 
Anopheles stephensi where it is extremely abundant in the gut, salivary glands, ovaries 
and testes of this insect (5).  Asaia sp. have also been uncovered in Anopheles mosquitoes 
in the field, especially An. gambiae, the most important vector of malaria in Africa (3, 4, 
6).  Efforts to genetically engineer Asaia sp. SF2.1 are underway in order to provide a 
platform to deliver antimalarial effector molecules to Anopheles mosquitoes in the field 
in an effort to block transmission of malaria, a strategy called paratransgenesis (1, 6, 11).  
The sequence reported here is the first for the genus. 
 
Sequencing and annotation of the genome of Asaia sp. SF2.1 was performed by ACGT, 
Inc.  The standard protocol for the NexteraXT DNA sample preparation kit was used.  
The purified fragmented DNA was used as a template for a limited cycle PCR using 
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Nextera primers and index adaptors.  A second library was prepared using the Nextera 
Mate Pair Sample Preparation Kit. 
 
In order to generate clusters of DNA, both libraries were sequenced in a paired-end 2 x 
150 bp protocol by MiSeq™.   The sequence reads passing the Illumina purity filter were 
demultiplexed.  4,097,892 standard library reads were generated, giving an average 
coverage of 351X based on the 3.5Mb genome.  To generate additional mate pair reads, a 
second MiSeq run was done using the mate pair library.  This run generated 999,241 
mate pair reads (86X coverage). 
 
De Novo Sequence Assembly 
A 93X coverage subset of the small-insert library and the mate-pair library were 
assembled de novo using ABySS (10), Velvet (14), and SOAPdenovo2 (8).   The best 
Velvet, ABySS, and SOAPdenovo2 contig sets were combined together using CISA (9) 
to produce an assembly with 51 contigs. The largest contig is 506 kb, the N50 length is 
162 kb, and the total assembly length is 3.5 Mb. The GC content is 59.6%. 
 
Genome Annotation 
Annotation of the genome was performed by the NCBI Prokaryotic Genome Annotation 
Pipeline version 2.0 (https://www.ncbi.nlm.nih.gov/genome/annotation_prok/).   A total 
of 3098 genes were predicted using this method, including 3005 protein-coding genes, 44 
pseudogenes, 3 rRNAs, and 45 tRNAs. 
 
Nucleotide sequence accession numbers.   
This Whole Genome Shotgun project has been deposited at DDBJ/EMBL/GenBank 
under the accession AYXS00000000. The version described in this paper is version 
AYXS01000000. 
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Introduction 
The phenotype of any individual organism is the product of a complex interaction of the 
genotype and the environment.  For insect vectors of plant and animal diseases, the 
phenotype of interest is the ability to transmit the pathogen in question.  In principle, it 
should be possible to modify the vector phenotype to prevent disease transmission in two 
ways: by modifying the genotype through transgenesis (i.e., adding or removing genes in 
the genome) or by modifying some aspect of the vector’s internal environment.  For 
vector insects, the environments in question are the tissues and structures necessary for 
pathogen replication and transmission.   Very often these environments are co-colonized 
by symbiotic microorganisms.  Manipulation of these microorganisms can lead to a 
change in the pathogen transmission phenotype of the insect.  Changing the phenotype in 
this way is called paratransgenesis.  This review will cover efforts to implement 
paratransgenesis in mosquitoes and will focus mainly on efforts to control malaria.  Two 
recent reviews have already covered related material (Coutinho-Abreu et al., 2010; Wang 
& Jacobs-Lorena, 2013) therefore we will focus mainly on the microbial ecology of 
mosquitoes relevant to paratransgenesis and bacterial genetic tools that may prove useful 
in creating paratransgenic bacterial strains suitable for release in the field.  Although the 
examples used will emphasize mosquitoes, the methods should be generally applicable to 
paratransgenesis for other vectors of plant and animal diseases.  Other paratransgenesis 
systems are covered in this volume (AksoyX, DurvasulaX, FaviaX).  
 
Requirements for successful paratransgenesis.   
There are several requirements that must be met for a paratransgenesis program to be 
successful.   
Microbial ecology: Suitable microorganisms must be identified that live in the vector in 
proximity to the pathogen or parasite and that can be cultured in the laboratory.  The 
microorganisms must be closely associated with the vector in the life stage where 
transmission of the disease organisms occurs and the microorganism must be spread 
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within the vector population by some means;   
Effector molecules:  Effectors must be discovered that inhibit the parasite or pathogen 
within the vector.  The more specific the inhibition, the better since unwanted and 
unpredicted interactions with non-target organisms can be reduced; 
Effector delivery: The effectors must be delivered from the paratransgenesis organism in 
efficacious concentrations and at suitable periods of time; 
No fitness costs: There should be no negative fitness effects on either the vector or the 
paratransgenic microorganisms. 
Stable inheritance: The genes encoding the effectors must be inherited stably by the 
microorganisms without selection; 
Introduction and spread:  A means must be available to introduce and spread the 
paratransgenic strains in nature. 
 
Each of these requirements will be discussed below.  We would like to point out, 
however, that paratransgenesis can be thought of as a category of the emerging field of 
synthetic biology which seeks to create new microorganisms with carefully defined 
phenotypes.  Methods emerging from this field will no doubt find applications within 
paratransgenesis programs and the degree to which these methods can be standardized 
can only accelerate progress in paratransgenesis. 
 
Mosquito microbial ecology.  The microbial ecology of a wide range of insects has 
recently been reviewed (Engel & Moran, 2013).  The current understanding of the 
microbiota of mosquitoes has been recently reviewed as well (Minard et al., 2013a).   
 
The culturable microbiota of mosquitoes has been examined extensively for a number of 
mosquito species (Demaio et al., 1996; Pumpuni et al., 1996; Straif et al., 1998; 
Gonzalez-Ceron et al., 2003; Pidiyar et al., 2004; Lindh et al., 2005; Rani et al., 2009; 
Cirimotich et al., 2011a; Dinparast Djadid et al., 2011; Joyce et al., 2011; Apte-
Deshpande et al., 2012; Terenius et al., 2012; Ngwa et al., 2013; Valiente Moro et al., 
2013).  Because these studies only scored culturable species, they necessarily missed 
most of the bacterial species living in or on mosquitoes since most bacterial species are 
not easily cultured.  Other studies have used PCR to amplify the 16S genes of the midgut 
microbiota to create cloned libraries of sequences that provide a look at the unculturable 
microbiota (Pidiyar et al., 2004; Lindh et al., 2005; Rani et al., 2009; Ngwa et al., 2013).  
As of this writing, only a handful of deep-sequencing metagenomic studies of mosquito 
microbiota have been published, most for Anopheles species (Wang et al., 2011; 
Boissiere et al., 2012; Osei-Poku et al., 2012).  The most important result from these 
studies, from a paratransgenesis standpoint, is that there does not appear to be any species 
of bacteria that forms an obligate association with mosquitoes, although many are quite 
common.  Members of the genera Pantoea, Serratia, Enterobacter, and Elizabethkingia 
are routinely found in Anopheles sp., for example.  Asaia sp. bacteria are also very 
common in Anopheles and we direct the reader to a chapter in this volume for more 
information on this genus of bacteria (FaviaX).  Wolbachia, however, seems to be 
naturally absent from Anopheles, in contrast to Aedes sp. where it is widespread in nature.  
Wolbachia can be experimentally introduced into Anopheles, albeit with difficulty (Bian 
et al., 2013). Minard et al. (2013) contains a comprehensive table listing the genera of 
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bacteria found in numerous species of mosquitoes and we direct the reader there for more 
information. 
 
The role of the mosquito microbiota is not well understood.  Many presumed functions 
are reviewed in Minard et al. (2013).  Almost certainly, the microbiota are involved in 
nutrition, especially in females where they may contribute to the digestion of the blood 
meal (Gaio Ade et al., 2011) and both in males and females where they may provide 
nutrients in addition to the sugar meals taken by both sexes (Minard et al., 2013b).  It has 
been clearly demonstrated that the microbiota is involved in immune system activation in 
the midgut and that this activation plays a role in the ability of the mosquito to attack 
pathogens in the blood meal, especially Plasmodium sp. (Pumpuni et al., 1996; Dong et 
al., 2009; Cirimotich et al., 2011b; Sharma et al., 2013).  Other roles for the microbiota 
include the ability to positively influence egg hatching and to aid in larval growth 
(Ponnusamy et al., 2011; Chouaia et al., 2012). 
 
Exactly how mosquitoes acquire their microbiota is not entirely clear, although the 
microbiota of mosquitoes changes dramatically depending on the life stage.  Wang et al. 
(2011), for example, found that the microbiota of larvae and pupae of An. gambiae were 
dominated by cyanobacteria, clearly a product of feeding in an aquatic environment, and 
the dominant bacteria changed dramatically by the time of adulthood.  In some species, 
females deposit bacteria on the surface of eggs (i.e, “egg smearing”) and these can be 
acquired by larvae (Crotti et al., 2009; Damiani et al., 2010).  During metamorphosis, the 
microbial community in the midgut is drastically altered and the gut is sterilized or nearly 
so via the formation of a meconium (Pumpuni et al., 1996; Moll et al., 2001), although 
there is evidence that some bacteria survive transstadially (Damiani et al., 2008).  The gut 
is repopulated in the adult stage either through bacteria acquired from the water from 
which the adults emerge and/or a plant nectar meal taken upon eclosion (Lindh et al., 
2005; Wang et al., 2011; Minard et al., 2013b).   Some species of bacteria, namely Asaia 
sp., can be passed from males to females during mating (Damiani et al., 2008). The 
acquisition, composition, and change of the mosquito microbiota remains an area where 
further study is needed.  Studies in this area should be able to identify appropriate 
microbial species for paratransgenesis and inform strategies on how to spread 
paratransgenic strains in nature. 
 
2. Effector molecules  
After a suitable bacterial species is chosen for paratransgenesis, a critical step toward 
creating paratransgenic strains of bacteria is the isolation of anti-pathogen effectors.  In 
principle, these can be any molecules that block pathogen development or transmission 
from the insect vector and can include proteins, peptides, small molecules, or RNAs.  In 
this regard, the field of malaria paratransgenesis is rich with effectors and some of these 
may prove useful against other diseases.  Reviews of anti-malarial effectors have been 
recently published (Caljon et al., 2013; Wang & Jacobs-Lorena, 2013).  We will briefly 
treat each category below. 
 
Proteins.  Certain proteins have proved to be anti-malarial.  For example, a component of 
honey bee venom, phospholipase A2 has demonstrated anti-malarial activity.  
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Interestingly, its enzymatic activity is not necessary for its anti-malarial properties since 
mutants of it are also active against the parasite (Moreira et al., 2002; Rodrigues et al., 
2008).  There is speculation that the protein somehow alters the cell membranes of the 
mosquito midgut thereby blocking parasite invasion of that tissue. 
 
A very important class of anti-malarial proteins is antibodies and their derivatives 
(Kontermann, 2010).  Several monoclonal antibodies have been isolated that bind to 
surface proteins of the reproductive stages of malaria parasites and block different parts 
of the life cycle within the mosquito (Rener et al., 1983; Quakyi et al., 1987; Barr et al., 
1991). Native antibodies are complex proteins consisting of four polypeptide chains 
linked by disulfide bonds.  To use these antibodies in a paratransgenic strategy, the genes 
that encode the mature antibody must be converted into a single gene that encodes a 
protein that retains binding specificity and that can be translated and secreted by bacteria 
(Kipriyanov & Le Gall, 2004).  Such constructs are called single chain antibodies (scFvs) 
and are synthetic constructs that link the heavy chain and light chain variable regions of a 
specific antibody into a single open reading frame that, when translated, forms a protein 
that can reconstitute the specific binding structure of a mature vertebrate antibody.  There 
are numerous variations on this basic scFv theme (figure A.1) including single domain 
antibodies (containing only the heavy chain binding region and sometimes called 
nanobodies), diabodies (constructs that bind to two different antigens), and scFv-toxin 
constructs (scFvs that are fused to a toxin gene) (Kontermann, 2010).  The first successful 
demonstration of paratransgenesis against malaria used this latter kind of construct 
secreted by E. coli in Anopheles stephensi to cause a decline in the number of oocysts 
formed in the midgut by Plasmodium bergheii, although the effect was weak (Yoshida et 
al., 2001).  There is an extensive literature on the conversion of vertebrate IgGs to 
different single chain forms and we invite readers to explore that literature for specific 
applications (Fernandez, 2004).   
   
Peptides.  Peptides are another very important class of anti-malarial effectors which may 
also be useful against many other pathogens.  A major benefit of this class of effector is 
that they are typically short, sometimes no more than twenty amino acids in length.  
There are two important classes of effector peptides: peptides that directly kill the 
parasite and those that interfere with some specific parasite-vector interaction. 
 
Peptides that kill pathogens or parasites have been derived from venoms (for example, 
scorpine from scorpion venom) or, more commonly, from peptides that are secreted as 
part of the eukaryotic innate immune system.  Hundreds of these latter peptides have 
been described from many different eukaryotes, only a few of which have been used in 
paratransgenesis (Otvos, 2005; Nishie et al., 2012; Vila-Farres et al., 2012).  This is, 
obviously, a promising area for future research.  Indeed, the canonical paratransgenesis 
program against Chagas’ disease transmitted by triatomine bugs used cecropin A (a 
peptide of the innate immune system of the giant silkmoth, Hyalophora cecropia) 
secreted by the Gram-positive bacterium, Rhodococcus rhodnii, to kill Trypanasoma 
cruzi (Durvasula et al., 1997).    
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Other anti-malarial peptides interfere with some specific interaction between the parasite 
and the mosquito host and thus block some important life stage from proceeding.  For 
example, enolase-plasminogen interacting peptide (EPIP) is a 6 amino acid peptide that, 
when supplied in excess in Anopheles midguts, blocks the interaction of plasminogen 
with ookinetes (Ghosh et al., 2011).  Since the ookinetes cannot invade the midgut wall, 
they die and the life cycle of the parasite is aborted.  Another antimalarial peptide of this 
class is SM1 (salivary gland-midgut peptide 1) which blocks parasite-vector interactions 
in both the midgut and salivary glands of mosquitoes (Ghosh et al., 2001). 
 
Small molecules from biosynthetic pathways.  Many small molecules are known that kill 
malaria parasites ranging from drugs used to kill blood stage parasites (e.g., artemisinin) 
to reactive oxygen species.  Each of these molecules is the end product of some 
multigene biosynthetic pathway.  In principle, it should be possible to move the pathway 
for these small molecules into a paratransgenesis species.  For example, amorpha-4,11-
diene, a precursor to the anti-malarial drug artemisinin, can be produced in E. coli by 
adding heterologous genes from yeast and Artemisia annua (Tsuruta et al., 2009). 
 
RNAi.   To our knowledge, small double stranded RNAs (dsRNAs) have not been used 
as effector genes to interfere with parasite-vector interactions through RNA inhibition 
although they could offer a powerful route to either kill parasites outright or block some 
important interaction with the vector.  RNAi has been used in mosquitoes to knock out or 
repress particular genes by injecting the dsRNAs directly in to adults.  Delivery of 
dsRNA to the gut environment by bacteria expressing dsRNAs might target mosquito gut 
tissues or parasites directly.  Delivery of dsRNA via bacteria to silence genes is a 
standard technique in Caenorhabditis elegans biology (Timmons & Fire, 1998).  Strong 
caveats to using this method should be considered, especially the fact that many 
eukaryotic parasites lack a response to dsRNA because they lack the machinery to 
process it.  For example, Plasmodium sp. parasites and Trypanosoma cruzi lack this 
machinery although Trypanosoma brucei retains it (Kolev et al., 2011).  Obviously, the 
potential effectiveness of RNAi would have to be evaluated on an individual 
pathogen/vector basis.  
 
The need to express more than one effector.   Paratransgenic strains of bacteria that 
express a single effector against a parasite or pathogen can be expected to lose 
effectiveness quickly.  This is because the use of the effector will provide strong selective 
pressure and favor those parasite or pathogen variants that are resistant to the effector.  
The scientific literature is replete with instances of the failure of a drug or resistance 
strategy when single effectors or drugs are used by themselves.  Bacteria, viruses, 
eukaryotic pathogens, agricultural insect pests, weedy plants, and even cancer cells all 
display this phenomenon as the simple and entirely predictable result of directional 
natural selection.  Therefore, any paratransgenic strain that will be released into nature 
should express more than one effector.  A simple way to do this would be to construct an 
artificial operon with two or more effector genes driven by the same promoter.  
Importantly, the effectors should act in different ways to minimize the chances that 
resistant parasites or pathogens will evolve. 
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An aside: codon optimization.  Effector genes have their origin in a wide variety of 
organisms, many of them eukaryotes.  The native genes, therefore, reflect the codon 
usage bias of the organism from which they originated.  This bias can cause problems 
during translation in the paratransgenic bacteria.  A well-known solution to this problem 
is to optimize the codon usage of the effector gene to match that of the organism where 
translation will take place (Welch et al., 2009; Francis & Page, 2010).  In practice, this 
means resynthesizing the gene from scratch.  Commercial gene synthesis services are 
available that specialize in codon usage and we strongly recommend this practice.  A 
recent permutation on codon optimization is codon harmonization which seeks to reflect 
the inherent use of both common and rare codons in a single protein coding gene, with 
rare codons clustered in regions where translation naturally slows to allow the nascent 
protein sufficient time to fold before translation resumes (Angov et al., 2011).  
 
3. Effector delivery   
Once effectors are discovered that kill or impair the pathogen of interest, a way to deliver 
these from the paratransgenic bacterial species must be found.  If the paratransgenesis 
bacterium is Gram positive, efficient secretion of proteins or peptides can be achieved 
using simple secretion signals added to the N-terminus of the effector constructs.  This 
was the method used to secrete cecropin A from Rhodococcus rhodnii in the Chagas’ 
disease paratransgenesis system (Durvasula et al., 1997). 
 
Effector delivery is more complicated if the paratransgenesis species is Gram negative.  
Gram negative bacteria have two cell membranes bounding a compartment known as the 
periplasm that separates the cytoplasm from the exterior of the cell.  Any protein or 
peptide that is to be secreted has to traverse this complicated barrier.  Passage through the 
periplasm is beneficial in some cases, however, as it allows certain proteins to fold 
properly and form disulfide bonds within a reducing environment.  In nature, Gram 
negative bacteria have evolved at least 6 different mechanisms to secrete proteins and 
some of these have proved useful to secrete foreign proteins (Holland, 2010).  Two of 
these mechanisms and the structure of the Gram negative cell membranes and periplasm 
are shown in figure A.2. 
 
Heterologous secretion systems.  As a first step toward achieving secretion of effectors 
from a new paratransgenesis species, heterologous systems can be tried.  Two effective 
ones are the hemolysin A (HlyA) autotransporter secretion system from pathogenic E. 
coli and the pelB leader sequence from the pectate lyase gene of Erwinia carotovora. 
 
Hemolysin A is a toxin encoded by the hlyA gene in the hemolysin operon of particular 
pathogenic strains of E. coli (Blight & Holland, 1994; Holland, 2010).  This secretion 
system is designated as Type I, or an autotransporter.  These sorts of secretion systems 
are dedicated to the secretion of a single protein and usually accomplish secretion in one 
energy-dependent step across both the inner and outer membranes of the Gram negative 
cell.  Studies of various deletion constructs of HlyA have demonstrated that a C-terminal 
46-50 amino acids are the signal that directs the protein toward the secretion apparatus 
(Kenny et al., 1992).  That apparatus consists of the HlyB and HlyC proteins encoded by 
the hemolysin operon in addition to TolC, a native outer membrane protein.  Together, 
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HlyB, HlyC, and TolC form the transport mechanism that moves HlyA from the 
cytoplasm to the outside of the cell.  Any protein or peptide linked to the HlyA signal 
sequence can also be transported using this system and it is highly efficient (Tzschaschel 
et al., 1996; Fernandez et al., 2000; Bisi & Lampe, 2011).  Using the HlyA system, Wang 
et al. (2012) were able to secrete 7 different anti-malarial effector proteins from the Gram 
negative bacterial species Pantoea agglomerans in both An. gambiae and An. stephensi 
midguts.  
 
Two caveats should be mentioned when discussing HlyA, however.  The first is that, 
although very efficient, proteins secreted in this way do not spend any time in the 
periplasmic space (Holland, 2010).  The periplasm is an important environment that 
allows many proteins to fold correctly before final secretion takes place.  Secondly, the 
HlyA system depends on the presence of a host membrane protein, TolC.  The success of 
malaria paratransgenesis in P. agglomerans using HlyA was achieved in no small 
measure due to the fact that P. agglomerans has a native TolC protein that can function 
with the E. coli HlyA system (Bisi & Lampe, 2011; Wang et al., 2012).  Not all bacterial 
species are likely to have a homologue of TolC and thus HlyA-based secretion is not 
likely to work in them.  For example, genome sequences Gluconobacter oxydans and 
Gluconacetobacter diazotrophicus, to which Asaia sp. are related (see chapter X, this 
volume), have no closely-related tolC homologues (unpublished results, Lampe and 
Bongio). 
 
Another heterologous system that has proved effective at secreting foreign proteins is the 
pelB secretion system.   PelB encodes the pectate lysase gene which is secreted from the 
plant pathogen Erwinia carotovora (Lei et al., 1987).  The PelB protein is secreted via a 
Type II secretory mechanism, a category that includes several different pathways grouped 
together under what is termed the general secretory pathway (Sec) (see figure 2).  This 
pathway is universal in Gram negative bacteria and seems to be homologous to secretion 
from eukaryotic cells (see reviews of the system in (Pugsley et al., 2004; Holland, 2010).  
Proteins that are synthesized with short N-terminal hydrophobic leader sequences are 
targeted to the inner membrane where they pass through the membrane in an energy 
dependent process involving numerous proteins in the secretion apparatus.  Once in the 
periplasm, proteins cross the outer membrane to be inserted into the outer membrane or 
to be secreted outside the cell.  Protein passage out of the cell is mediated by numerous 
mechanisms, many of which are poorly understood.  Type II secretion using leader 
sequences like pelB have been very successful in secretion of a variety of proteins, 
especially scFvs and their variants (Dammeyer et al., 2011). 
 
There are many positive features of heterologous Type II secretion.  The main one is 
simplicity.  The addition of a pelB or other leader sequence to a gene encoding an 
effector protein is trivial unlike the HlyA system which requires the presence of several 
other heterologous proteins.  The downside to using Type II secretion is that, while 
simple, proteins cannot be targeted easily to exit past the outer membrane.  Thus, proteins 
secreted by Type II secretion often get “stuck” in the periplasm which can have 
deleterious effects on cell fitness.  We and others have noticed a strong correlation 
between efficient secretion and cell fitness (Bisi & Lampe, 2011). 
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Native secretion systems.  If heterologous secretion systems fail to function it may be 
necessary to develop native secretion systems for a given bacterial species.   If a genome 
sequence is available it can be mined using bioinformatic methods to identify candidate 
secretion signals (Nielsen et al., 1997; Petersen et al., 2011).  Bioinformatic methods are 
likely to miss many secreted proteins since it is known that many secreted proteins 
contain leaders that do not conform well or at all to any secretion consensus sequence 
(Payne et al., 2012).  Alternatively, secreted proteins can be identified directly via 2D 
electrophoresis followed by MALDI-TOF which, again, requires the use of genomic data.   
 
More than likely, the genome sequence will not be available for many candidate 
paratransgenesis species.  Even if a genome sequence does exist, it can be difficult to 
identify secreted proteins based on computer algorithms alone, as noted above.  In either 
case, classical microbial genetics can be used to identify candidate secretion signals.  
Identification of secreted proteins by genetic means is based on the use of a modified E. 
coli phoA gene that encodes alkaline phosphatase (AP) lacking its native secretion signal.  
When secreted into solid media containing 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP), AP hydrolyzes BCIP turning it blue.  BCIP cannot penetrate the inner membrane 
of Gram negative bacteria so the screen can identify proteins secreted, membrane bound, 
or periplasmic.  
 
AP can be used in two different ways to identify native secretion signals.  The first 
method is through the use of the transposon TnphoA (Manoil & Beckwith, 1985; Boquet 
et al., 1987; Gutierrez et al., 1987; Manoil et al., 1990).  This transposable element, 
derived from a modified miniTn5, carries a phoA gene lacking a secretion signal 
sequence placed very close to the end of the transposable element. TnphoA is introduced 
into the target species (commonly by conjugation with E. coli) where it inserts randomly 
into the chromosome.  If it jumps into a gene that encodes a secreted protein, the phoA 
gene in TnphoA may be fused with the secretion signal of the chromosomal gene.  When 
a library of these random insertions is plated on agar with BCIP, blue colonies indicate 
the insertion of TnphoA into a gene encoding a secreted, membrane-bound, or 
periplasmic protein.  Because the genes are “tagged” by the transposon, it is trivial to 
recover the sequence of the insertion site by anchored PCR techniques.  There are, 
however, important caveats to consider when using this method, the main one being that 
TnphoA insertions will only recover secretion signals of genes that are active under the 
conditions used for the screen (i.e., on the agar plate) so some genes may be missed.  In 
addition, the screen will only work if the transposon is active in the species in question 
and there are reports that Tn5 is not universally active in all bacteria.  In that case, a 
similar transposon can be built based, for example, on Himar1, which seems to have 
fewer species barriers (Choi & Kim, 2009).  Finally, the paratransgenesis species may 
have endogenous AP activity.  This can be overcome by including Na PO4 in the medium 
which dampens the endogenous signal so that the TnphoA AP signal can be seen (Bina et 
al., 1997). 
 
The second method to identify native secretion signals is to construct a plasmid library of 
genomic fragments fused to a leaderless phoA gene (Bina et al., 1997).  Typically, 
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genomic DNA from the paratransgenesis species is incompletely digested with a 4bp 
cutting restriction enzyme, size-selected to isolate 1-3 kb fragments, and then cloned 
upstream of a leaderless phoA gene.  Importantly, this system incorporates a constitutive 
promoter so, in principle, any secreted protein can be recovered circumventing a shortfall 
of TnphoA.  The library is transformed into the paratransgenic species and then plated on 
suitable media that includes BCIP.  Blue colonies are picked and the positive clones are 
sequenced to determine the signal sequence directing secretion of AP.  Not surprisingly, 
there are caveats to this method as well.  If it is difficult to transform the paratransgenic 
species, then it may be preferable to transform the library first into E. coli and perform a 
screen for secretion there.  Positive clones isolated in E. coli can then be transformed 
later into the paratransgenesis species to confirm that they secrete.  The use of E. coli to 
perform the initial screen, however, means that some secreting clones may be missed.  
Despite the caveats of TnphoA or the construction of a secretion library, both of these 
methods allow direct identification of native secretion signals without the need for a 
genome sequence and should be considered even if a genome sequence is available. 
 
4. Fitness considerations for paratransgenic bacteria 
As noted at the beginning of this chapter, the fitness of paratransgenic organisms must be 
kept in mind.  Ultimately, paratransgenic strains are destined for release into the 
environment where they must compete with wild strains and species.  Any severe fitness 
disadvantage will eliminate them before they can colonize vectors and suppress parasites 
or pathogens.  We have already discussed several areas where fitness concerns can be 
addressed, including ensuring efficient secretion, codon optimization of effector genes, 
and the use of conditional promoters (see below).  Ultimately, fitness levels of 
paratransgenic strains will have to be measured empirically. 
 
Transcription of effector genes.  Effector genes must be transcribed in the 
paratransgenesis species.  Ideally, transcription would be strong, ensuring an abundance 
of the effector product.  The kind of transcription necessary for a particular 
paratransgenesis program should be considered carefully.  Does the effector need to be 
produced continuously or only under the specific conditions when the pathogen or 
parasite is present?  Can the two conditions be distinguished?  The answers to these 
questions will determine what kind of promoter to use to drive effector gene 
transcription. 
 
Constitutive promoters.  If a continuous supply of effector gene product is desired, the 
gene should be placed under the control of a constitutive promoter.  Heterologous 
constitutive promoters exist that function in a wide variety of bacterial species.  One such 
promoter is that from the neomycin phosphotransferase II gene (nptII) (Auerswald et al., 
1981; Beck et al., 1982; Reiss et al., 1984).  If a genome sequence is available, then the 
native promoters for genes like the homologues of E. coli rpsL (30S ribosomal subunit 
protein S12) and groEL (an E. coli chaperonin) should be considered.  Of course, any 
gene expressed in a constitutive manner can be considered as long as the promoter is 
sufficiently active to produce the desired amount of effector gene transcript.  For the 
laboratory demonstration of paratransgenesis for malaria using P. agglomerans, we used 
the nptII promoter (Wang et al., 2012). 
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Conditional promoters.  If the parasite or pathogen enters the insect vector under specific 
conditions, then the use of conditional promoters should be considered.  Female 
mosquitoes that transmit malaria, for example, acquire the parasite in a blood meal, 
which leads to a dramatically different gut environment than does sugar feeding.  
Conditional promoters offer distinct advantages over constitutive ones in this context.  In 
particular, bacterial strains that only express the anti-pathogen effector proteins under 
narrow conditions are more likely to be able to compete with wild strains since the 
potential fitness cost of expressing the effectors is limited in time. 
 
Bacterial genetic screens have been developed to detect genes that are activated under 
specific conditions.  The most common and successful of these screens are in vivo 
expression technology (IVET) and differential fluorescence induction (DFI).  Many 
permutations of both of these screens as well as their relative strengths and weaknesses 
have been reviewed (Rediers et al., 2005; Jackson & Giddens, 2006; Hsiao & Zhu, 2009).  
Both consist of methods to fuse bacterial DNA from the species of interest to some 
reporter gene to create a library, and then a screen of this library under the desired 
conditions to detect promoters that drive the reporter under the desired conditions.  The 
hypothetical use of DFI to isolate blood meal induced promoters from a paratransgenic 
strain of bacteria is described in figure 4.  Briefly, a library of size-selected genomic 
fragments from the paratransgenic species is cloned upstream of a promoterless 
fluorescent protein gene (typically, some variant of GFP) on a plasmid.  This library is 
transformed into the paratransgenic bacterium and this population of bacteria is fed to 
mosquitoes in a blood meal.  After a suitable amount of time, the midguts of the blood-
fed mosquitoes are dissected, homogenized, and the bacterial cells sorted in a 
fluorescence-activated cell sorter which selects and enriches the population of bacteria 
that are expressing GFP.  The selected fluorescent bacteria are collected and the process 
repeated however many times the user feels is necessary.  Individual clones are then 
transformed back into the paratransgenic bacterium, and the individual strains re-
screened to ensure that no false positives were selected and that the promoter is truly 
conditional.   
 
5. Genetically stable paratransgenic strains suitable for field release 
Insertion of effector constructs into the chromosome.  For a paratransgenic strain to be 
stable and to reduce the odds of horizontal transfer of the effectors it will be necessary to 
insert the promoter-effector construct into the chromosome of the paratransgenic strain.  
Insertion into the chromosome insures that all progeny will inherit the effector genes and 
that no selection is necessary to retain them.  Chromosomal insertion can be 
accomplished in a variety of ways.   
 
Perhaps the simplest way to insert genes into the chromosome is by transposition.   
Transposons mediate DNA breakage and joining of DNA sequences through a 
transposase protein that is contained within inverted terminal repeat (ITR) sequences that 
are specific to the given transposon.  Insertion of transposon DNA occurs at a transposon-
specific target site in the genome.  The target site can be at one specific site per genome 
(e.g., attTn7 for Tn7) or scattered throughout the genome in a way that is essentially 
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random (e.g., Tn5 or Himar1).  Transposons are almost always used in microbiology in a 
mini-transposon format where the transposase that mediates the movement of the DNA is 
separated from the ITRs.  Figure 5 shows pSC189, a typical embodiment of this kind of 
system for the Himar1 transposon (Chiang & Rubin, 2002).  The plasmid contains 
inverted terminal repeats that bound a kanamycin-resistance (kanR) gene to select for 
transposon insertions.  The kanR gene is itself inserted between two FRT sites for the 
FLP recombinase of yeast (see below).  The transposon also carries in it the plasmid 
origin of replication, in this case oriR6K which is conditional on the presence of the  
protein.  Without this protein, the plasmid will not replicate so it is only stably 
maintained as a plasmid in special strains of E. coli that have the  protein transduced 
into the chromosome.  This feature ensures that whatever kanamycin-resistant cells are 
recovered after movement of the plasmid into the paratransgenesis strain are due to 
transposition and not plasmid replication.  An 8 bp cutting AscI site is present near the 
end of the transposon for insertion of foreign DNA.  Outside the transposon in the 
backbone of the plasmid is a beta lactamase gene for selection of the entire plasmid, the 
transposase gene driven by a lac promoter, and an origin of transfer (oriT).  OriT enables 
the conjugation of this plasmid from E. coli strains carrying the conjugation machinery 
for oriT to essentially any other bacterial cell.  This feature is crucial in transferring 
plasmids to species where chemical or electrotransformation techniques work poorly and 
that will undoubtedly include many species contemplated for paratransgenesis.  While 
transposition can efficiently create stable insertions of effector genes into paratransgenic 
strains of bacteria it should be noted that the user has no control over the site of insertion 
so there may be fitness costs or other unintended effects on the strain and these will need 
to be measured under conditions that are likely to be encountered in the field. 
 
The second method to introduce effectors into the chromosome is recombination.  The 
most common kind of recombination occurs when a single cross-over event occurs 
between a plasmid carrying the effector construct and a homologous site on the 
chromosome.  This results in the integration of the entire plasmid into the chromosome 
and such events are common enough that they are easily produced and isolated. 
 
Ideally, only the effector gene and its promoter and terminator would be recombined into 
the chromosome.  This requires a double-cross over event which is much more rare.  
Such events can be increased in frequency by orders of magnitude by supplying enzymes 
that mediate recombination of foreign DNA into the chromosome.  The most highly 
developed of these is the Red recombination system derived from bacteriophage lambda 
(Datta et al., 2006; Thomason et al., 2007).  The use of Red recombination is developed 
in E. coli to such a degree that no drug marker is necessary to recover chromosomal 
recombination events (Sawitzke et al., 2007).  It is likely that this technique will work in 
many Gram negative bacteria and the recombination machinery for Red recombination 
has been placed on broad host range plasmids for just this use (Datta et al., 2006). 
 
Drug marker removal.   If drug markers are used to help select recombinants into the 
paratransgenic strain chromosome, either by transposition or recombination, they must be 
removed before the strain can be released into the field.  This is straightforward if the 
insertion was constructed properly beforehand.  For example, the kanR gene carried by 
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the Himar1 transposon on pSC189 in figure 5 is flanked by two FRT sites.  These sites 
are the recognition sites for the FLP recombinase from yeast.  When these sequences are 
in the same orientation around a central DNA sequence, recombination by FLP 
recombinase at the FRT sites results in the excision of the DNA between them leaving 
behind a single FRT site.  Many plasmids carrying FLP recombinase exist that can be 
transformed into strains carrying drug markers constructed this way.  Selection of cells 
that are kanamycin sensitive is a simple matter of patching cells onto media with and 
without the selective agent.  Once sensitive cells are recovered, the FLP plasmid can be 
eliminated by counter selection.  An excellent review of the use of this technique in 
bacteria can be found in Schweizer (2003). 
 
Standardization of parts.   As noted earlier, genetically engineering bacterial strains for 
paratransgenesis can be considered as a type of synthetic biology.  The synthetic biology 
community in beginning an effort to standardize the parts of synthetic constructs so that 
different modules can be interchanged easily.  One effort in this regard is the BioBricks 
Foundation (Smolke, 2009).  Another is the recently-published Standard European Vector 
Architecture (SEVA) (Silva-Rocha et al., 2013).  Each effort seeks to create a vector 
platform that is standardized and easy to use.  SEVA, in particular, stresses broad host 
range platforms that are most suitable to testing and creating paratransgenic bacterial 
strains from non-model system bacteria.  Origins of replication, drug markers, origins of 
transfer, promoters, and “cargo” are all modular and easily replaced or changed.  We 
strongly urge workers in the area of paratransgenesis to adopt the SEVA standards which 
should make paratransgenesis more straightforward and easier to adopt as this method 
spreads to different species and systems. 
 
6. Introducing and spreading bacterial strains for paratransgenesis.    
A critical step in the success of a paratransgenesis program is the introduction and spread 
of paratransgenic microorganisms within a vector population in nature.  Bacterial species 
that form an obligate association with vectors are ideal in this context since, once 
obtained by the vector, they will spread naturally via the biology of the vector itself.  As 
noted above, our current knowledge of mosquito microbiota suggests that such obligate 
associations do not exist, although some species are quite common.  Many common 
species of bacteria that live in adult mosquitoes, like Pantoea sp. and Asaia sp., are also 
found in floral nectar, suggesting that mosquitoes acquire these members of the 
microbiota from sugar meals.   
 
The use of bacterial strains that do not have inherent drive mechanisms (like Wolbachia, 
e.g.) or that do not form obligate associations with their vectors will require a careful 
choice of bacterial species and clever uses of vector behavior.  Asaia (reviewed in 
Chapter XXX) is a genus that has very attractive microbial ecology.  These species infect 
mosquito midguts, salivary glands, and ovaries, multiply with the blood meal, are spread 
from males to females during copulation, and are deposited on eggs by the female (Favia 
et al., 2007; Damiani et al., 2008; Crotti et al., 2009).  These properties suggest that 
paratransgenic Asaia strains might be easily spread in the field. 
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Spreading bacteria to mosquitoes in the field will also require taking advantage of 
mosquito behavior.  One suggestion has been to take advantage of the fact that the 
females of many mosquito species require sugar meals in addition to blood while males 
exclusively sugar feed.  It may be possible to spread paratransgenic strains by sugar 
meals supplemented with strong attractants (Muller et al., 2010; Beier et al., 2012).  No 
such field demonstration of the spread of paratransgenic strains exists, however, and this 
remains an area where much work is needed. 
 
Paratransgenesis of mosquitoes against malaria with genetically modified bacteria.   
Using the strategies outlined above, we successfully demonstrated paratransgenesis 
against malaria in the laboratory using transgenic strains of Pantoea agglomerans (Wang 
et al., 2012).  This species was isolated from a laboratory colony of Anopheles stephensi 
and was later selected to persist in the midgut of these flies for up to 14 days (Riehle et 
al., 2007).  P. agglomerans is a gammaproteobacterium in the Enterobacteriaceae, the 
same family to which E. coli belongs.  Strains expressing various anti-malarial peptides 
and proteins were able to reduce the prevalence of females carrying any oocysts from 
90?% to 18% after an infectious blood meal (Wang et al., 2012).  A reduction in 
prevalence was measured in both An. gambiae carrying P. falciparum and in An. 
stephensi carrying P. berghei, suggesting that these strains may work in any Anopheles 
vector species against multiple different species of Plasmodium.  This is an important 
consideration and a distinct advantage of paratransgenesis against malaria since there are 
five species of Plasmodium that cause malaria in humans vectored efficiently by at least 
40 species of Anopheles (Sinka et al., 2012). 
 
Paratransgenesis with naturally-occurring bacterial strains.  So far we have 
described strategies to genetically engineer bacteria with favorable microbial ecology into 
paratransgenesis strains.  Interestingly, some bacterial strains are naturally 
paratransgenic.  For example, Cirimotich et al. (2011) isolated 16 culturable bacterial 
species from the midguts of Anopheles gambiae collected in Zambia.  One of these 
strains belonged to the genus Enterobacter as determined by 16S sequencing.  This 
strain, Esp_Z, was capable of completely inhibiting P. falciparum development in the 
midgut of An. gambiae.  Additional experiments showed that the factor responsible for 
the inhibition was diffusible, heat insensitive, and was most likely some kind of reactive 
oxygen species since the effect could be eliminated through the presence of the 
antioxidant Vitamin C.  One hypothesis to account for the presence of this strain in An. 
gambiae is that it was selected for because it offers some kind of advantage to the 
mosquitoes that carry it by reducing the load of P. falciparum in the mosquitoes.  If this 
hypothesis were correct, we might expect to see Esp_Z widespread in African An. 
gambiae, but it is not.  An alternative hypothesis is that the anti-Plasmodium properties of 
Esp_Z are fortuitous and were selected for some other reason, most likely competition 
with other bacteria.  If this hypothesis is correct, many other naturally-occurring bacterial 
strains will prove to be anti-plasmodial.  Strains like these have the advantage of not 
having been genetically engineered, however they may lack the appropriate microbial 
ecology and their discovery requires the mass screening of culturable bacteria from wild 
mosquitoes. 
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Conclusion 
Reducing the ability of insects to vector disease through paratransgenesis offers a 
promising route to decrease the burden of many of the most important human diseases, 
like malaria and Dengue fever.  Although the creation of paratransgenic strains requires 
many facets, the genetic tools are available to modify nearly any bacterial species.  These 
include broad host range plasmids, constitutive promoters, broad host range transposons, 
an abundance of effectors, and simple genetic screens to isolate secretion signals and 
conditional promoters.  Many challenges remain, especially gaining an improved 
understanding of insect microbial ecology and methods to deliver and spread 
paratransgenic species in nature.  The use of metagenomics in different mosquito species 
will begin to clarify the nature of the mosquito microbiome and suggest bacterial species 
for which specialized culture techniques can be developed so that these species can be 
developed as paratransgenesis platforms.  An increasing understanding of the microbial 
ecology of mosquitoes will also suggest ways to deliver paratransgenic bacterial species 
in the field to ensure their spread throughout a vector population.  Finally, a systems 
biology approach to paratransgenesis and a standardization of vector construction will aid 
in the rapid development of paratransgenic strains for many mosquito species, as well as 
other important insect vectors. 
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Figure A.1.  Derivatives of antibodies useful in paratransgenesis.  Variable heavy and 
light chains of monoclonal antibodies are constructed into a single gene (scFvs, 
antimicrobial peptide fusion, and nanobody) or two genes that are coexpressed (diabody) 
that can reconstitute the binding properties of an immunoglobulin.  For details on each of 
these see the text or Kontermann (2010). 
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Figure A.2.  Secretion of effector proteins by bacteria using one of two different 
pathways.  The hemolysin autotransporter system is shown in part A.  The type II 
general secretory pathway is shown in part B.  Both are highly simplified.  Effector 
proteins destined for secretion carry either a ca. 50-amino acid C-terminal signal 
sequence for the HlyA pathway or a short N-terminal signal sequence for the Type II 
secretion pathway.  The signals differ in Type II depending on whether or not they will 
cross the inner membrane via either the twin-arginine pathway (Tat) or the general 
secretory pathway (Sec).  The hemolysin system consists of HlyB, HlyD, and a native 
TolC protein that assemble to create a pore that spans the inner and outer membranes.  
Proteins using this pathway are secreted directly into the extracellular space in one 
energy dependent step.  Effectors targeted to the Type II secretion system cross the inner 
membrane and spend time in the periplasm where the signal sequence is cleaved and they 
may undergo disulfide bond formation.  These proteins cross the outer membrane in 
many ways which are not completely understood.  For a fuller discussion see Korotkov et 
al. (2012). 
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Figure A.3.  A genetic screen to identify native secreted protein genes in bacteria 
using TnphoA.   The transposon Tn5 was modified to carry a kanamycin resistance gene 
and E. coli phoA without the leader sequence that normally targets it for secretion.  
TnphoA is introduced into the bacterial species in question where it randomly inserts into 
the bacterial chromosome.  A library of random insertions is then plated on medium 
containing kanamycin (to select for transposition events) and BCIP, which turns blue if 
TnphoA is fused to a bacterial gene that encodes a secreted protein.  For more details, see 
Manoil & Beckwith (1985). 
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Figure A.4. A differential fluorescence genetic screen in bacteria to identify 
conditional promoters activated in a blood meal.   A library of random chromosomal 
fragments from the bacterial species of interest is cloned upstream of a promoterless GFP 
gene in a broad host range plasmid.  This bacterial promoter trap library is then fed to 
adult female mosquitoes, which are then subsequently given a blood meal.  Promoters 
active in the blood meal can be separated from inactive ones by fluorescence activated 
cell sorting.    
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Figure A.5.  pSC189, a broad host range transposon insertion vector based on 
Himar1 
pSC189 is used to make random insertions into the chromosome of many bacterial 
species.  See text and Chiang & Rubin (2002) for details.  ApR = ampicillin resistance; 
KmR = kanamycin resistance; oriT = origin of transfer; Himar1 transposase=transposase 
gene; FRT=recombination sites of yeast FLP recombinase; AscI=insertion site for 
exogenous DNA; oriR6K=a conditional origin of replication; solid triangles indicated the 
transposon inverted terminal repeat sequences. 
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